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ABSTRACT 
Healthcare actuaries are increasingly responsible for advising their employers and 
clients in areas of managed care.  Managed care links traditional health actuarial 
financial work to areas of medical practice, to address the fundamental question: what 
works?  These relatively new responsibilities have required an expansion of actuarial 
techniques into non-traditional areas, and, in particular, epidemiology and biostatistics.  
This study is about a specific area of statistics, survival analysis, a topic of great 
potential application in non-traditional managed care actuarial practice.  Survival 
analysis is used frequently in biostatistics to evaluate the efficacy of treatments and to 
identify factors that contribute to patient survival.  In this study, we illustrate three 
applications of survival models to solve real-world problems in areas of health actuarial 
practice: the estimation of survival of permanently disabled workers receiving lifetime 
benefits for occupational illness and injury, the rate at which seriously ill hospice 
patients, at risk of polypharmacy, are weaned from non-life sustaining drugs, and the 
ability to predict, using a model incorporating drug dosage information and specifically 
changes in dosage, changes in expected future lifetimes of hospice patients.  
All three case studies are examples of practical models that can be applied 
within a business context.  The study will serve a more important purpose, if it shows 
health actuaries the potential value of the application of a non-traditional technique 
within their evolving practice.   
 
 
 
http://www.hw.ac.uk/registry/resources/abstractofthesis.doc.     
DEDICATION 
 
To my wife, Janet Duncan, FCAS FSA MAAA for her support while suffering patiently 
during this research.     
I also wish to express my thanks to my supervisors, Angus Macdonald PhD FFA FRSE 
and George Streftaris PhD for introducing me to the possibilities of survival modelling 
and guiding this research, and to Nhan Huynh MS for programming assistance.   
Thanks are also due to Andrew Horowitz, CEO and Greer Myers, EVP and the team at 
Enclara Pharmacia Inc. for their support and encouragement throughout this study, and 
particularly for the use of the hospice dataset in Chapters 5-8.   
  
DECLARATION STATEMENT 
 
 
Research Thesis Submission 
 
 
Name: Ian Gordon Duncan 
School: Mathematics & Computer Science 
Version:  (i.e. First, 
Resubmission, Final) 
First Degree Sought: PhD. 
 
 
Declaration  
 
In accordance with the appropriate regulations I hereby submit my thesis and I declare that: 
 
1. The thesis embodies the results of my own work and has been composed by myself 
2. Where appropriate, I have made acknowledgement of the work of others 
3. Where the thesis contains published outputs under Regulation 6 (9.1.2) these are 
accompanied by a critical review which accurately describes my contribution to the 
research and, for multi-author outputs, a signed declaration indicating the contribution of 
each author (complete Inclusion of Published Works Form – see below) 
4. The thesis is the correct version for submission and is the same version as any electronic 
versions submitted*.   
5. My thesis for the award referred to, deposited in the Heriot-Watt University Library, should 
be made available for loan or photocopying and be available via the Institutional 
Repository, subject to such conditions as the Librarian may require 
6. I understand that as a student of the University I am required to abide by the Regulations 
of the University and to conform to its discipline. 
7. Inclusion of published outputs under Regulation 6 (9.1.2) shall not constitute plagiarism.   
8. I confirm that the thesis has been verified against plagiarism via an approved plagiarism 
detection application e.g. Turnitin. 
 
* Please note that it is the responsibility of the candidate to ensure that the correct version 
of the thesis is submitted. 
 
Signature of 
Candidate: 
 
Date: 16th April 2020 
 
 
 
 Submission  
 
Submitted By (name in capitals): IAN GORDON DUNCAN 
 
Signature of Individual Submitting: 
 
 
Date Submitted: 
 
16th April 2020 
 
 
For Completion in the Student Service Centre (SSC) 
 
Received in the SSC by (name in 
capitals): 
 
1.1 Method of Submission  
(Handed in to SSC; posted through 
internal/external mail): 
 
 
1.2 E-thesis Submitted (mandatory 
for final theses) 
 
Signature: 
 
 Date:  
 
  
Inclusion of Published Works 
 
 
Declaration  
 
This thesis contains one or more multi-author published works. In accordance with Regulation 6 
(9.1.2) I hereby declare that the contributions of each author to these publications is as follows: 
 
Citation details Duncan I  Maxwell T  Dove H and Ahmed T.  
“Medicare Cost at End of Life.”  Am. J Hospice and 
Palliative Med.  36(8) August 2019.   
Doi: 10.1177/1049909119836204.  
 
Author 1 
 
Ian Duncan: conception; data acquisition; analysis 
design; paper drafting. 
Author 2 
 
Terri Maxwell: hospice and palliative care technical 
details 
Author 3 
 
Henry Dove:  literature review 
Author 4 
 
Tamim Ahmed: programming and analysis of the 
Medicare LDS file.  
Signature: 
 
 
Date: 
 
16th April 2020 
 
  
  
 
Citation details Duncan I. Huynh N. Molinari R. and Duncan J.  
“Using Survival Analysis to Predict Workers’ 
Compensation Termination.”  In Press.  Variance. 
https://www.variancejournal.org/articlespress/ 
 
Author 1 
 
Ian Duncan: Hypothesis, study design, data 
acquisition, summarization of results and paper 
authorship. 
Author 2 
 
Janet Duncan: Workers compensation technical 
input. 
Author 3 
 
Roberto Molinari: Review of statistical methods; 
MICE routine for estimation of missing data. 
Author 4 
 
Nhan Huynh: programming and modelling in R.  
Signature:  
 
Date: 
 
16th April 2020 
 
 
i 
 
TABLE OF CONTENTS 
 
CHAPTER 1 - INTRODUCTION ..................................................................................... 1 
CHAPTER 2 - STATISTICAL MODELLING OF SURVIVAL ........................................ 5 
2.1 Introduction .............................................................................................................. 5 
2.2 Survival Functions .................................................................................................... 6 
2.3 Estimating the Survival Function .............................................................................. 7 
2.3.1 Life table (actuarial) estimation .......................................................................... 7 
2.3.2 Kaplan-Meier estimation of the survival function ............................................... 8 
2.4 Semi-Parametric (Cox Proportional Hazards) Models ............................................. 11 
2.4.1 Proportional hazards model .............................................................................. 11 
2.5 Estimation of the Proportional Hazards Model ........................................................ 12 
2.5.1 Estimation of the baseline hazard function ....................................................... 14 
2.5.2 Stratified Cox Models ...................................................................................... 15 
2.6 Parametric Models .................................................................................................. 15 
2.6.1 Accelerated failure time models ....................................................................... 16 
2.6.2 Assumptions in the AFT model ........................................................................ 16 
2.6.3 Examples of parametric distributions................................................................ 17 
2.6.4 Prediction using AFT models ........................................................................... 22 
2.7 Survival Functions with Time-dependent covariates ............................................... 23 
2.7.1 Estimation ........................................................................................................ 24 
2.8 Assessing Model Validity ....................................................................................... 25 
2.8.1 Two types of test .............................................................................................. 25 
2.8.2  Overall fit for the Cox regression model .......................................................... 25 
2.8.3. Appropriateness of the proportional hazard assumption ................................... 27 
2.8.5 Overall fit for the log-normal accelerated failure time model ............................ 28 
2.9 Model Validation .................................................................................................... 28 
CHAPTER 3 - USING SURVIVAL ANALYSIS TO PREDICT WORKERS’ 
COMPENSATION TERMINATION .............................................................................. 30 
3.1 Workers Compensation: Background ...................................................................... 30 
3.2 Mortality of Disabled Lives .................................................................................... 32 
3.3 Workers Compensation Reserves ............................................................................ 33 
3.4 Author contributions to this paper ........................................................................... 33 
ii 
 
CHAPTER 4 - MEDICARE COST AT END-OF-LIFE ................................................... 64 
4.1 Health Coverage for the Elderly in the United States ............................................... 64 
4.2 End-of-Life Care in the United States ..................................................................... 65 
4.3 Hospice ................................................................................................................... 69 
4.4 End of Life Costs .................................................................................................... 73 
4.5 Author Contributions to this paper .......................................................................... 73 
CHAPTER 5 - HOSPICE DATA SET ............................................................................. 79 
5.1 Data Source ............................................................................................................ 79 
5.2 Data Source ............................................................................................................ 80 
5.3 Patient variables ...................................................................................................... 81 
5.4 Dataset .................................................................................................................... 81 
5.4.1 Demographic data ............................................................................................ 82 
5.4.2 Clinical data ..................................................................................................... 87 
5.4.3 Hospice drug coverage ..................................................................................... 97 
5.5 Summary ............................................................................................................... 116 
5.6 Appendix A: CMS’s Hierarchical Condition Categories (HCCs) ............................ 117 
5.7 Appendix B: Cancer diagnoses included in CMS’s Hierarchical Condition Categories
 .................................................................................................................................... 118 
CHAPTER 6 – POLYPHARMACY, MEDICATION POSSESSION AND 
DEPRESCRIBING OF PREVENTATIVE DRUGS IN HOSPICE PATIENTS .............. 119 
6.1 Background ........................................................................................................... 119 
6.1.1 Introduction .................................................................................................... 119 
6.2 Prior Studies .......................................................................................................... 120 
6.3 Methods ................................................................................................................. 121 
6.3.1 Design ............................................................................................................. 121 
6.3.2 Potentially ineffective drug classes .................................................................. 121 
6.4 Data ....................................................................................................................... 121 
6.5 Results ................................................................................................................... 129 
6.5.2 Cumulative Incidence Function analysis of termination rates........................... 131 
6.5.3  Prescription Durations: Medication Possession Ratios .................................... 134 
6.6 Discussion ............................................................................................................. 137 
6.7 Conclusion ............................................................................................................. 138 
6.7.1 Limitations ...................................................................................................... 138 
6.8 Appendix A: Condition Categorization .................................................................. 140 
iii 
 
CHAPTER 7 – WHAT IS KNOWN ABOUT SURVIVAL OF HOSPICE PATIENTS: 
REVIEW OF THE LITERATURE ................................................................................. 143 
7.1 Palliative Performance Scale to Estimate Length of Stay ........................................ 143 
7.2 Actuarial (Statistical) Studies Estimating Length of Stay ....................................... 145 
7.3 Prescription Drug Use and Survival ....................................................................... 146 
7.4 Studies of the Effect of Varying Dosage on Survival .............................................. 148 
CHAPTER 8 - RESULTS ............................................................................................... 149 
8.1 Exploratory Data Analysis:  Kaplan-Meier ............................................................. 149 
8.1.1 Kaplan-Meier estimation of survival by sex .................................................... 150 
8.1.2 Kaplan-Meier estimation of survival by site of care ......................................... 151 
8.1.3 Survival and cumulative hazard functions for key primary diagnoses .............. 152 
8.2 Cox Regression Models ......................................................................................... 154 
8.2.1 Cox regression models: results ........................................................................ 155 
8.3 Accelerated Failure Time Models .......................................................................... 160 
8.3.1 Checking the applicability of the log-normal AFT model ................................ 160 
8.3.2 AFT model residuals ....................................................................................... 161 
8.3.3 Results of the log-normal AFT model ............................................................. 162 
8.4 Prediction using the Log-normal Accelerated Failure Time Model ......................... 167 
8.4.1 Prediction and external validation using test set ............................................... 167 
8.5 Time Dependent Models ........................................................................................ 171 
8.5.1 Time-dependent Cox model ............................................................................ 171 
8.5.2 Time-dependent log-normal AFT model ......................................................... 172 
8.6 Prediction Using the Time-Dependent Log-Normal AFT Model ............................ 175 
8.7 Conclusion ............................................................................................................. 176 
8.8 Appendix A: Concurrence of Training and Test Datasets ....................................... 179 
8.9 Appendix B: Sample predictions using the log-normal AFT model ........................ 181 
CHAPTER 9 – CONCLUSION AND FUTURE WORK ................................................ 189 
  
 
 
 
 
 
 
iv 
 
 
 
LIST OF TABLES 
Table 4. 1 U.S. Mortality ................................................................................................. 66 
Table 4. 2 Cause of Death 2014 [31] ................................................................................ 67 
Table 5. 1 Patients in Hospice by Year of Admission ....................................................... 82 
Table 5. 2 Distribution of Patients by Care Setting ........................................................... 83 
Table 5. 3 Distribution of Age and Sex at Admission: 2015 Admissions .......................... 84 
Table 5. 4 Distribution of Age and Sex at Admission: 2016 Admissions .......................... 85 
Table 5. 5 Patients by Top 10 Primary Diagnosis in 2015 and 2016 ................................. 88 
Table 5. 6 Distribution of Major Diagnostic Categories by Sex, 2015 and 2016 ............... 89 
Table 5. 7 Diagnoses and Hierarchical Condition Categories (HCCs)............................... 89 
Table 5. 8 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Female) .......................................................................................................................... 90 
Table 5. 9 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Female) .......................................................................................................................... 91 
Table 5. 10 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Female) .......................................................................................................................... 92 
Table 5. 11 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Female) .......................................................................................................................... 93 
Table 5. 12 Distribution of Duration (days) from Hospice Admission  to Death in 2015 
(Male) .............................................................................................................................. 94 
Table 5. 13 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Male) .............................................................................................................................. 95 
Table 5. 14 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Male) .............................................................................................................................. 96 
Table 5. 15 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Male) .............................................................................................................................. 97 
Table 5. 16 Prevalence of Four (CMS) Drug Classes: 2015 Admissions ........................... 99 
Table 5. 17 Prevalence of Four (CMS) Drug Classes: 2016 Admissions ........................... 99 
Table 5. 18 Frequency of Drug Classes: 2015 Admissions .............................................. 101 
Table 5. 19 Frequency of Drug Classes: 2016 Admissions .............................................. 102 
Table 5. 20 Example of HIC Coding ............................................................................... 103 
Table 5. 21 Example of Drug Class Coding..................................................................... 104 
Table 5. 22 Example of Strength Coding – Analgesic drugs ............................................ 105 
v 
 
Table 5. 23 Patients with Prescriptions in Excess of the Recommended Maximum                   
Daily Dose of Opioids. ................................................................................................... 106 
Table 5. 24 Patients with Continuous Prescriptions in Excess of the Recommended 
Maximum Daily Dose of Opioids for Days until Death ................................................... 107 
Table 6. 1 Hospice Population by Age, Sex, Status, and Year of Admission .................... 121 
Table 6. 2 Distribution of Patients by Drug Class and Primary Condition (2015-2016) ... 123 
Table 6. 3 Distribution of Primary Condition within Drug Class (2015-2016) ................. 124 
Table 6. 4 Prevalence of Drug Classes by Primary Condition (2015-2016) ...................... 125 
Table 6. 5 Number and Percentage of Patients with Potentially Ineffective Drugs (2015) 126 
Table 6. 6 Number and Percentage of Patients with Potentially Ineffective Drugs (2016) 126 
Table 6. 7 Relationship between Primary Condition and Potentially Ineffective Drugs 
(2015) ............................................................................................................................. 127 
Table 6. 8 Relationship between Primary Condition and Potentially Ineffective Drugs 
(2016) ............................................................................................................................. 127 
Table 6. 9 Frequency of Potentially Ineffective Drugs by Patient and Primary Condition 
(2015) ............................................................................................................................. 128 
Table 6. 10 Frequency of Potentially Ineffective Drugs by Patient and Primary Condition 
(2016) ............................................................................................................................. 128 
Table 6. 11 Frequency of Potentially Ineffective Drugs Classes by Primary Condition 
(2015) ............................................................................................................................. 129 
Table 6. 12 Frequency of Potentially Ineffective Drugs Classes by Primary Condition 
(2016) ............................................................................................................................. 129 
Table 6. 13 Quantile Survival Time of Drug Classes in Days .......................................... 132 
Table 7. 1 Relationship Between PPS and Survival ......................................................... 144 
Table 8. 1 Kaplan-Meier Estimation of Survival ............................................................. 149 
Table 8. 2 Kaplan-Meier Estimation of Survival by Sex .................................................. 151 
Table 8. 3 K-M Estimation of Survival by Setting of Care .............................................. 152 
Table 8. 4 Kaplan-Meier estimate of Survival and Hazard Functions by Admitting 
Diagnosis ........................................................................................................................ 154 
Table 8. 5 Coefficients of the Cox PH Model .................................................................. 158 
Table 8. 6 Hypothesis Test for PH Assumption ............................................................... 160 
Table 8. 7 Coefficients of the Log-normal AFT Model with ˆ 1.4768   .......................... 165 
Table 8. 8 Summary Statistics for K-M Curves for Different Care Settings ..................... 166 
Table 8. 9 Summary Statistics for K-M Curves for Dementia (HCC 52) .......................... 167 
Table 8. 10 Sample Patient Characteristics for Newly Admitted Patient .......................... 168 
vi 
 
Table 8. 11 Error Groups ................................................................................................ 170 
Table 8. 12 Distribution of Errors by Group .................................................................... 170 
Table 8. 13 Time-Dependent Cox Model Coefficients ..................................................... 174 
Table 8. 14 Time-Dependent Log-Normal AFT Model Coefficients ................................ 174 
  
 
 
 
  
vii 
 
LIST OF FIGURES 
Figure 2. 1 Density of Length-of-Stay ................................................................................ 5 
Figure 2. 2 Construction of Intervals used in Kaplan Meier Estimation .............................. 9 
Figure 2. 3 Estimated Baseline Cumulative Hazard Function ........................................... 15 
Figure 2. 4 Example of Acceleration ................................................................................ 17 
Figure 2. 5 Exponential Distribution (Constant Mortality Hazard) .................................... 18 
Figure 2. 6 Gompertz Distribution.................................................................................... 19 
Figure 2. 7 (Gompertz) Makeham Distribution ................................................................. 19 
Figure 2. 8 Weibull Distribution with Increasing Mortality Hazard .................................. 20 
Figure 2. 9 Lognormal [N(0,1)] Distribution .................................................................... 21 
Figure 2. 10 Log-logistic Distribution with Unimodal Mortality Hazard .......................... 22 
Figure 2. 11 Cox-Snell Residuals ..................................................................................... 26 
Figure 4. 1 Cost by Place of Death and Type of Service for Patients in Last Three Months 
of Life .............................................................................................................................. 68 
Figure 4. 2 Cost by Place of Death and Type of Service for Patients in Last Six months of 
life ................................................................................................................................... 69 
Figure 4. 3 Growth in Hospice Utilization by Year.  Source: NHPCO [32].   Admissions in 
2016 are the most recently-available. ............................................................................... 72 
Figure 4. 4 Distribution of Hospice Stay Durations in 2016.  Source: NHCPO [32]. ......... 72 
Figure 5. 1 Age of Death: 2015 Admissions ..................................................................... 86 
Figure 5. 2 Age at Death: 2016 Admissions ..................................................................... 86 
Figure 5. 3 Treatment of ComfortPak Drugs ................................................................... 107 
Figure 5. 4 Cumulative Dosage of Analgesic Drugs at End of Life .................................. 109 
Figure 5. 5 Number of Laxative Prescriptions at End of Life ........................................... 109 
Figure 5. 6 Number of Anxiolytic Prescriptions at End of Life ........................................ 110 
Figure 5. 7 Number of Anti-Nausea Prescriptions at End of Life ..................................... 111 
Figure 5. 8 Cumulative Analgesic Dose at End of Life by Diagnostic Category .............. 112 
Figure 5. 9 Number of Laxative Prescriptions at End of Life by Diagnostic Category ..... 112 
Figure 5. 10 Number of Anxiolytic Prescriptions at End of Life by Diagnostic Category 113 
Figure 5. 11 Anti-nausea Prescriptions at End of Life by Diagnostic Category ................ 114 
Figure 5. 12 Decreasing Trend in Analgesic Dose as Age Increases ................................ 115 
Figure 5. 13 Males Have a Higher Analgesic Dose on Average Compared to Females .... 115 
Figure 5. 14 Home Care has Highest Analgesic Dose, on Average, Compared to Other 
Settings ........................................................................................................................... 116 
viii 
 
Figure 6. 1 Cumulative Incidence Function (CIF) Estimates of Termination of Preventive 
Drugs .............................................................................................................................. 133 
Figure 6. 2  Mean and variance of Medication Possession Ratios by drug class. .............. 135 
Figure 8. 1 Kaplan-Meier estimate of Survival and Hazard Functions (Full Population) .. 150 
Figure 8. 2 Kaplan-Meier Estimate of Survival and Hazard Functions by Sex ................. 150 
Figure 8. 3 Kaplan-Meier estimate of Survival and Cumulative Hazard Functions by Setting 
of Care (with confidence intervals) ................................................................................. 151 
Figure 8. 4 Kaplan-Meier estimate of Survival and Cumulative Hazard Functions by 
Admitting Diagnosis ....................................................................................................... 153 
Figure 8. 5 Cox-Snell Residuals for the Cox model ......................................................... 156 
Figure 8. 6 Log-Normal Probability Plot ......................................................................... 160 
Figure 8. 7 Assessment of Log-Normal Assumption for Care Setting and Sex ................. 161 
Figure 8. 8 Comparison Between K-M Survival and Log-Normal Residuals ................... 162 
Figure 8. 9 Cox-Snell Residuals, Log-normal AFT Model .............................................. 163 
Figure 8. 10 Stratified Kaplan-Meier Curves for Different Care Settings ......................... 165 
Figure 8. 11 Kaplan-Meier Curves for Patients with Dementia (HCC 52) ........................ 167 
Figure 8. 12 Survival Curve for a Newly Admitted Patient .............................................. 168 
Figure 8. 13 Frequency Distribution of Differences between Actual and Predicted Lengths 
of Stay ............................................................................................................................ 169 
Figure 8. 14 Distribution of Mean Errors at Different Times ........................................... 176 
Figure 8. 15 Comparison of Expected and Actual Survival times for patients surviving 
different durations ........................................................................................................... 178 
 
 
 
  
ix 
 
LIST OF PUBLICATIONS BY THE CANDIDATE 
1. Glantz NM Morales JM Bevier WM Larez A Hoppe CB Duncan IG  Mackenzie AJ and 
David Kerr MD: “Insurance status and biological and psychosocial determinants of 
cardio-metabolic risk among Mexican-origin U.S. Hispanic/Latino adults with type 2 
diabetes.”  Health Equity Forthcoming 2020.  
2. Morales J Glantz N Larez A Bevier W Conneely M Fan L Reed B Alatorre C 
Paczkowski R Ahmed T Mackenzie A Duncan I and Kerr D: “Understanding the 
impact of five major determinants of health (genetics, biology, behavior, psychology, 
society/ environment) on type 2 diabetes in U.S. Hispanic/Latino families: Mil Familias 
- A cohort study.”  BMC Endocrine Disorders.  Forthcoming.  
3. Duncan I, Herndon W. and Liao X.:  “Health Benefits Associated with an Employer-
sponsored Health Promotion Program with Device-reported Activity.”  Journal of 
Wellness 1(1) October 2019.   
4. Glantz N Kerr D Duncan I et al.  “Racial and Ethnic Disparities in the Burden and Cost 
of Diabetes for US Medicare Beneficiaries" Health Equity 3(1) May 2019 211-8     
DOI: 10.1089/heq.2019.0004.   
5. Liao X Kerr D Duncan I and Morales J.  “Application of Machine Learning to Identify 
Clustering of Cardio-Metabolic Risk Factors in US Adults.”  Diabetes Technology and 
Therapeutics 21(5) April 2019 1-9. 
6. Yosick L Crook RE Gatto M Maxwell TL Duncan I Ahmed T and Mackenzie AJ 
“Effect of a Population Health Community-based Palliative Care Program on Cost and 
Utilization.”  Journal of Palliative Medicine.  Published online April 2019.                
DOI 10.1089/jpm.2018.0489.   
7. Duncan I  Maxwell T  Dove H and Ahmed T.  “Medicare Cost at End of Life.”  Am. J 
Hospice and Palliative Med.  36(8) August 2019  Doi: 10.1177/1049909119836204.  
8. Gaba P Pegus C Duncan I Ahmed T Leon M Horne A and Alu M.  “Access to 
Transcatheter Aortic Valve Replacement (TAVR): A Growing Issue?” Circulation 138 
A15030 November 2018.   
9. Cheryl Pegus MD MPH Ian Duncan FSA FIA FCIA FCA CSPA MAAA Judy Greener 
PhD MA Juan F. Granada MD and Tamim Ahmed PhD MBA: “Normalizing Cardiac 
Care.”  Health Equity. 2018; 2(1): 404–411.  
10. Duncan I. Huynh N. Molinari R. and Duncan J.  “Using Survival Analysis to Predict 
Workers’ Compensation Termination.”  In Press.  Variance. 
11. Duncan I. and Huynh N.  “A Predictive Model for re-admissions among Medicare 
Patients in a California Hospital.” Population Health Management, 2018 Aug; 
21(4):317-322. doi: 10.1089/pop.2017.0150. 
12. Fitzner K, Handmaker K.E. and Duncan I.  “Augmented Intelligence: Enhancing the 
Roles of Health Actuaries and Health Economists for Population Health Management,"  
Population Health Management, September 2017 
https://doi.org/10.1089/pop.2017.0146 
13. Ian Duncan FSA FIA FCIA FCA MAAA and Ryung Suh MD: Massachusetts Health 
Insurance Reform: Promise and Results.  Impact on Insurance Markets, Pricing, and 
Profitability.  A study sponsored by the Commonwealth Fund and Society of Actuaries.   
Schaumburg, IL.  Society of Actuaries.  2016.   
https://www.soa.org/resources/research-reports/2016/2016-ma-health-insurance/ 
x 
 
14. Ian Duncan and Stephane Guerrier: “Member Plan Choice and Migration in Response 
to Changes in Member Premiums after Massachusetts Health Reform.”   North 
American Actuarial Journal, 2016 20(4), 404-419. 
15. Adam Long, Ian Duncan and Roger Reed: “Outcomes across the value chain for a 
comprehensive employee health and wellness intervention: A cohort study by degrees 
of health engagement.”  Journal of Occupational and Environmental Medicine.  July 
2016 Vol. 58 - Issue 7: p 696–706.   
16. Duncan Ian. “An Elephant—But Not Just in the Emergency Room.”   Population 
Health Management. April 2016, 19(2): 77-77. doi:10.1089/pop.2016.0002. 
17. Ian Duncan, Stephane Guerrier and David Kerr:  “Use of a publicly available database 
to determine the impact of diabetes on length of hospital stay for elective orthopedic 
procedures in California.” Population Health Management.  Dec 2016, 19(6): 439-444.   
18. Duncan, I, Clark, K.L. and Wang, S.  “Cost and Utilization of Retail Clinics vs. Other 
Providers for Treatment of Pediatric Acute Otitis Media” Population Health 
Management 2016 Oct;19(5):341-8. doi: 10.1089/pop.2015.0051.  
19. Duncan, I, Loginov, M and Ludkovski, M: “Predictive Modeling of Healthcare Costs 
using Hierarchical Regression”   North American Actuarial Journal 20(1):1-23  January 
2016.   
Winner of the Brockett-Shapiro Actuarial Journal Award of the American Risk & 
Insurance Association, 2018.   
20. Janeen DuChane, PhD; Bobby Clark, PhD; Francis Staskon, PhD; Rick Miller, RPh, 
MBA; Kathleen Love, RN; Ian Duncan, FSA, FIA, FCIA, MAAA.    “Impact of 
Managed Therapy on Adherence to Medications Used to Treat Multiple Sclerosis and 
Related Comorbid Conditions.”  International Journal of MS Care: March/April 2015, 
Vol. 17, No. 2, pp. 57-64. 
21. B.L. Clark et al.  “Evaluation of a Retrospective Drug Utilization Review Program for 
the treatment of Plaque Psoriasis: A Pilot Study.”   J. Pharma. Care Health Sys.  2015 
2: 126.   
22. Duncan, I and H. E. Frech III: “Measuring Healthcare Efficiency.”   North American 
Actuarial Journal      18(4) 443-4. 
23. Janeen DuChane; Bobby Clark; John Hou; Karen Fitzner; Glen Pietrandoni; Ian 
Duncan  “Impact of HIV-specialized pharmacies on adherence to medications for 
comorbid conditions” J Am Pharm Assoc. (2003) 2014;54:493-501. 
doi:10.1331/JAPhA.2014.13165 
24. Kirkham, H. S., Clark, B. L., Bolas, C., Lewis G.H., Jackson A., Fisher D.  “Which 
modifiable health risks are associated with changes in productivity costs?”  Population 
Health Management,  2015 Feb;18(1):30-8.  
25. Kirkham, H. S., Clark, B. L., Paynter, J., Lewis, G. H., & Duncan, I. (2014). “The effect 
of a collaborative pharmacist–hospital care transition program on the likelihood of 30-
day readmission” American Journal of Health-System Pharmacy, 71(9), 739-745. doi: 
10.2146/ajhp130457 
26. Bobby Clark, Karen Fitzner, Julia Zhu, Michael Einodshofer, Suann Stone, Janeen 
DuChane, Ian Duncan “Site of Care Optimization for Infusion Therapy” Am. J. Mgd. 
Care.  
27. Kessler, R, Shahly V. and Duncan I.   “Worksite Primary Care Clinics: A Systematic 
Review” Population Health Management, 2014 Oct;17(5):306-15.   
28. Clark, B, DuChane J, Hou, J., Rubinstein, E, McMurray, J and Duncan I.  “Evaluation 
of Increased Adherence and Cost Savings of an Employer Value Based Benefits 
xi 
 
Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications”   J. 
Mgd. Care Pharmacy. 2014;20(2):141-50 
29. Lewis, GL, Kirkham, HS, Duncan, I and Rhema Vaithianathan: “How Health Systems 
Could Avert 'Triple Fail' Events That Are Harmful, Are Costly, And Result In Poor 
Patient Satisfaction.” Health Affairs, 32, no.4 (2013):669-676 
30. Irizarry L, Li QE, Duncan I, Thurston AL, Fitzner KA, Edwards BJ, McKoy-Bent JM, 
Tulas KM, McKoy JM.  “Effects of Cancer Comorbidity on Disease Management: 
Making the Case for Diabetes Education (A Report from the SOAR Program).” Pop. 
Health Manag. 2013 Feb;16(1):53-7.   
31. Taitel MS, Duncan IG, "Medication days’ supply, adherence, wastage, and cost among 
chronic patients in Medicaid.”   Medicare and Medicaid Research Review 2012 2 
(3).    E1-E13.   
32. Duncan IG, Taitel MS, Zhang J, Kirkham HS: “Planning influenza vaccination 
programs: a cost benefit model.” Cost Effectiveness and Resource Allocation 2012 July 
26, 10 (1):10.   
33. Khandelwal, N, Duncan, I, Rubinstein, E, Ahmed, T and Pegus, C. “Community 
Pharmacy and Mail Order Cost and Utilization for 90-Day Maintenance Medication 
Prescriptions”.  Journal of Managed Care Pharmacy.   2012 Apr;18(3):247-55. 
34. Hou, J, Murphy, P, Tang, A, Khandelwal, N, Duncan, I and Pegus, C. “Impact of an 
Online Prescription Management Account on Medication Adherence”  American 
Journal of Managed Care 2012;18(3):e86-e90). 
35. Taitel M, Cohen, E, Duncan, I, Pegus, C. “Pharmacists as providers: Targeting 
pneumococcal vaccinations to high risk populations.” Vaccine. 2011 Oct 
19;29(45):8073-6.  
36. Khandelwal, N, Duncan, I, Rubinstein, E, Ahmed, T and Pegus, C. “Community 
Pharmacy and Mail Order Cost and Utilization for 90-Day Maintenance Medication 
Prescriptions”.  Journal of Managed Care Pharmacy.  2012 Apr;18 (3):247-55. 
37. Taitel M, Terranova B, Baloun L, Kirkham H, Duncan I, Pegus C. “Pharmacists as 
Immunization Providers: Patient Attitudes and Perceptions.” Pharmacy Times. 2011.  
http://www.pharmacytimes.com/publications/issue/2011/September2011/  
38. Khandelwal N, Duncan I, Rubinstein E, Ahmed T, Pegus C, Murphy P, Kudrak KE. 
“Medication adherence for 90-day quantities of medication dispensed through retail and 
mail order pharmacies.” Am J Manag Care. 2011 Nov 1;17(11):e427-34. 
39. Vortherms, J., PharmD, Leonard Fensterheim, MPH, Michael Taitel, PhD, Heather 
Kirkham, PhD, MPH, Mahesh Raju, PharmD, MPH, Joanna Lalich, PharmD, Ian 
Duncan, FSA, FIA, FCIA, MAAA. “A Community Pharmacy Diabetes Management 
Program to Improve Biometric and Cardiac Risk Factors” Poster Presentation at 
American College of Clinical Pharmacy 2011 Annual Meeting. 
40. Patwardhan, A, Duncan, I, Murphy, P, Pegus, C.  The Expanded Role and Value of 
Pharmacists in Health Care.  Population Health Management.  June 2012, 15(3): 157-
162. doi:10.1089/pop.2011.0030. 
41. Khandelwal N, Duncan I, Ahmed T et al. Oral Chemotherapy Program Improves 
Adherence and Reduces Wastage and Hospital Admissions. Journal of National 
Comprehensive Cancer Network.  2012;10:618-625. 
42. Ian Duncan, FSA FIA FCIA MAAA, et al.  "Assessing the Value of the Diabetes 
Educator” The Diabetes Educator 37(5) September-October 2011 638-657.  
xii 
 
43. Khandelwal, N, Duncan I, et al “Medication Adherence for 90-day Quantities of 
Medication dispensed through Retail and Mail-order pharmacies.”  Am J Manag Care. 
2011; 17 (5 Spec No.):e169-e173.  
44. Day, Brian, Ed. D., Ian Duncan, FSA FIA FCIA MAAA, and Brian Beatty, MS “A 
Risk-Based Evaluation Methodology for Cost Effectiveness of Chronic Condition 
Health Management Programs”   North American Actuarial Journal 2011 15 (1) 
https://doi.org/10.1080/10920277.2011.10597606 
45. Khandelwal N, Duncan I, Ahmed T et al. “Impact of Clinical Oral Chemotherapy 
Program on Wastage and Hospitalizations.”  Am J Manag Care. 2011; 17 (5 Spec 
No.):e169-e173  
46. Khandelwal N, Duncan I, Ahmed T et al "Impact of Clinical Oral Chemotherapy 
Program on Wastage and Hospitalizations." Journal of Oncology Practice. 2011; 7 
(3S):e25s-e29s  
47. Taitel M, Duncan I, Meaux N, Pegus C, Valerian C, Kirkham H. “Place of death among 
terminal heart failure patients in a continuous inotropic infusion program.” American 
Journal of Hospice and Palliative Medicine. 2012 Jun; 29(4):249-53.     
doi: 10.1177/1049909111418638. Epub 2011 Aug 11. 
48. Mason, M, Poole-Yeager, A, Lucas B, Krueger, C, Ahmed T, Duncan I.  "Effects of a 
Pregnancy Management Program On Birth Outcomes in Managed Medicaid"   
Managed Care 2011 Apr; 20(4):39-46. 
49. Rosenberg, M, Johnson, P.H. Jr.  and Duncan, I “Exploring Stakeholder Perspectives on 
What Is Affordable Health Care” Risk Management and Insurance Review 13(2) 251-
63 Fall 2010 doi.org/10.1111/j.1540-6296.2009.01174.x. 
50. Ian Duncan, FSA FIA FCIA MAAA, et al.   “Assessing the Value of Diabetes 
Education” The Diabetes Educator 35(5) September-October 2009 752-760.   
51. Birkmeyer, C and Duncan I:  “Health plans tackle DM. Software innovations enable 
health plans to structure results-driven disease-management programs and demonstrate 
true ROI.” Health Management Technology.  2009 Jun;30 (6): 22-4. 
52. Messer, T, Farah, J.R., Duncan I, Kamali, K, Harner, J.  “Random Fluctuations and 
Validity in Measuring Disease Management Effectiveness for Small Populations” 
Population Health Management Dec;11(6):307-16. doi: 10.1089/pop.2007.0024. 
53. Duncan I, Lodh, M, Berg, G, and Mattingly, D “Understanding Patient Risk and its 
Impact on Chronic and Non-Chronic Member Trends.”  Population Health 
Management, October 2008.  11(5):261-7. doi: 10.1089/pop.2007.0015. 
54. Duncan I, Bachler R and Juster I. “A Comparative Analysis of Chronic and Non-
Chronic Insured Commercial Member Cost Trends”  North American Actuarial Journal 
10 (4) October 2006.     
Winner of the DMAA prize for best published article in 2006.     
55. Duncan I.  "Care And Disease Management: An Actuarial Response".   Benefits & 
Compensation Digest, 42 (8) August 2005. 
56. Duncan I.  “Accuracy in the assessment of return on investment of defined population 
interventions.” Joint Commission Journal on Quality and Patient Safety     Joint 
Commission Resources.2005 Jun;31(6): 357; author reply 358. 
57. Duncan I. "Measurement of ROI/Effectiveness of Medical Management Processes". 
Record, Society of Actuaries, Volume 30, (1). http://library.soa.org/library-
pdf/rsa04v30n1111of.pdf 
58. Duncan I.  “Its time for the industry to move on from ROI”, Disease Management, 
(Vol. 7 (3) October, 2004).   
xiii 
 
59. Duncan I. “New Strategies in Disease and Utilization Management: Substituting Facts 
for Assumptions” Record, Society of Actuaries, 29(2) June 2003. 
60. Duncan I, Dove H and Robb, A. “A prediction model for targeting low-cost, high-risk 
members of managed care organizations" Am. J. Mgd. Care, May 2003.   (Winner of 
the DMAA Prize for the best published article in 2003).    
 
Books and Book Chapters 
1. Duncan I. Healthcare Risk Adjustment and Predictive Modelling.  Actex Publications, 
Winsted CT.  2nd edition 2018.   
2. Camilli S.J., Duncan I. and London R.L.  Chapter 17: Profit Analysis in: Models for 
Quantifying Risk 6th ed. 2014: Actex Publications, Winsted CT.  
3. Duncan I.  Managing and Evaluating Healthcare Intervention Programs. Actex 
Publications, Winsted CT.  January 2014. 
4. Duncan I.  “Mining Health Claims Data for Assessing Patient Risk” In “Data Mining: 
Foundations and Intelligent Paradigms” Volume 3: Medical, Health, Social, Biological 
and other Applications. D.E. Holmes and L. Jain (eds.), Springer Verlag 2012.   
5. Duncan I.  "Managing and Measuring Care Management Intervention Programs" in J. 
Rosenbloom (ed).   Handbook of Employee Benefits (7th ed).  McGraw-Hill (2011).   
6. Duncan I, Healthcare Predictive Modeling and Risk Adjustment Actex Publications 
Winsted CT. (2011).    
7. Duncan I. Managing and Evaluating Healthcare Intervention Programs.  Actex 
Publications, Winsted CT.  2008.   
8. Duncan I (Editor): Dictionary of Disease Management Terminology: A comprehensive 
guide to the processes, definitions, and terminology used in this area of Managed Care.  
Washington D.C.  Disease Management Association of America.  Second edition 2006 
9. Duncan I (Editor): Dictionary of Disease Management Terminology: A comprehensive 
guide to the processes, definitions, and terminology used in this area of Managed Care.  
Washington D.C.  Disease Management Association of America.  2004.     
10. Duncan I. and Robb A. "Population Risk Management:  Reducing Costs and Managing 
Risk in Health Insurance."  in Arnold Shapiro, ed : Intelligent and other Computational 
Techniques in the Insurance Industry. (World Scientific, December 2003).   
11. Duncan I and Crane J. “Measuring the Total Cost of Lost Time” in Janet R. Douglas: 
Managing Workers’ Compensation. John Wiley, 1996.  
12. Duncan I.  "Benchmarking and Cost Control" in Janet R. Douglas: Managing Workers' 
Compensation. John Wiley, 1994.  
  
Other 
1. Society of Actuaries Part 8 Examination Study Note on Care Management evaluation.  
2. "Evaluating the Results of Care Management Interventions: Comparative Analysis of 
Different Outcomes Measures" by Henry Dove, Ph.D. and Ian Duncan, FSA, MAAA.  
Research sponsored by the Society of Actuaries Health Section.  Available at : 
http://www.soa.org/ccm/content/?categoryID=327001 
3. Duncan I. “Population Risk Management”, Health Section News, Society of Actuaries. 
June, 2002.   
 
 
1 
 
CHAPTER 1 - INTRODUCTION 
Actuaries and Statisticians have studied and modelled survival for centuries.  Early 
actuaries studied graveyards and parish records to derive the data from which to build 
mortality tables.  Actuaries, such as Benjamin Gompertz (1779-1865) and William 
Makeham (1826-91), developed parametric models to predict human mortality.  While 
there is a significant amount of literature in both mortality modelling and the application of 
survival analysis in medical research, survival models are not as well represented in health 
actuarial practice.  Actuaries traditionally applied complicated exposed-to-risk techniques 
to estimate mortality rates; it was not until the ground-breaking work of the Scandinavian 
actuary Jan Hoem [1] (1984) that statistical approaches to mortality modelling began to 
enter the actuarial syllabus.   
 David Collett [2] defines survival analysis as “the analysis of data in the form of 
times from a well-defined time origin until the occurrence of a particular event or end-
point.”  Macdonald, Richards, and Currie [3] note that “survival modelling is a well-
established field of statistics and offers much for actuarial work.”  It is ironic that these 
authors have to make this claim in the 21st Century, but the claim is indicative of the lack of 
interest that exists in much of the actuarial profession.  Like much actuarial work, however, 
Macdonald and colleagues’ book is devoted to the study of mortality.  Actuarial students 
are introduced to survival models early in their course of study, in the context of mortality 
projections.  However, most actuaries will not encounter survival models again in practice.  
 Health actuaries (a small profession outside the United States, but a large one inside 
North America) have traditionally been responsible for pricing, reserving and risk 
management of health insurance coverages.  Traditionally, financial risk was the province 
of insurers and health actuaries, while clinical risk was the responsibility of doctors and 
hospitals.  With the widespread penetration of managed care in health insurance in the 
United States since the 1980s, financial risk has increasingly been shifted to providers 
(hospitals, physicians, pharmaceutical companies, and other providers of health-related 
services) and away from payers (employers, insurers, and the government).  With the 
increasing prevalence of managed care, health actuaries have had to become more involved 
in the provision and assessment of medical care and clinical services.  The health actuary is 
increasingly called on to advise employers and clients on “what works,” not clinically, but 
from a financial perspective, as evidenced by readings from Duncan [4] in the Society of 
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Actuaries’ health fellowship track examinations.  This new responsibility has required 
training in topics and areas unfamiliar to actuaries, such as epidemiology and biostatistics.  
Professionals trained in these subjects use survival models routinely, and as actuaries 
become more responsible for evaluating the underlying delivery of care, survival models 
will become more important to health actuaries.  While survival analysis has a part to play 
in the new and expanded field of managed care actuarial work, health actuaries will need to 
increase their awareness of the value that survival models can bring to their work.  This 
thesis  is intended to provide examples of actuarial applications of survival modelling in 
healthcare.  This study covers three applications in health care: 
1. Terminations (largely, but not solely, due to death) of permanently disabled claimants 
eligible for lifetime medical coverage under U.S. workers compensation law 
(occupationally disabled claimants).  Reserves for workers compensation claims have 
traditionally been set by claims adjusters examining each claimant’s individual 
circumstances, with the addition of a bulk adjustment for a block of claimant reserves 
using a Chain-ladder or similar method.  To the extent that survival of a claimant is 
taken into account, it is through the professional judgement of the claims adjuster.  Our 
first example applies survival modelling techniques to the estimation of life expectancy 
of these claimants.  We find that studying the actual experience of a population, using 
survival methods, allows us both to construct a model that more accurately represents 
the experience of the population, but also incorporates covariates and other information 
that is potentially useful to the insurer for claim management purposes.   
2. Our second and third examples both apply to patients admitted to hospice at the end of 
life.  In the United States, patients are admitted to hospice and the Medicare program 
pays for their care, if two physicians certify that the patient has a life expectancy of six 
months or less.  One requirement of hospice is that therapeutic (curative) care be 
discontinued and palliative care provided instead.  As a result, therapeutic medications, 
except those required to maintain life, are gradually discontinued (deprescribed) and 
only palliative medications prescribed.  The severe nature of illnesses for these patients 
often results in a multitude of prescriptions (polypharmacy) with many attendant 
problems.  There are relatively few studies about deprescribing for patients at end of 
life.  What studies there are conclude that therapeutic medications are withdrawn 
slowly.  We study the rate at which different medications are deprescribed for patients 
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with different conditions.  To our knowledge, our study is the first to apply survival 
modelling techniques within a substantial database of hospice patients and their 
medications to model the length of time and proportion of a hospice stay that a patient 
has prescriptions for potentially inappropriate medications.   
3. Our third example, also from hospice, uses survival models to predict life expectancy of 
patients in hospice.  The literature on this topic indicates that estimates (made by 
physicians) are not particularly accurate.  Empirically, prescriptions and, particularly, 
dosage of opioids increase during the patient’s stay in hospice.  Our hypothesis is that 
by incorporating information about changes in a patient’s drug regimen during the stay, 
it is possible both to estimate dynamically future life expectancy and to do so more 
accurately than professional judgement alone.  A more accurate estimate of life 
expectancy allows hospice management to tailor services to patient needs, more 
effectively schedule on-call staff, and reduce the supplies of drugs to avoid wastage at 
end of life.   
The remainder of this study proceeds as follows: In Chapter 2, a review of the 
theoretical and statistical background to survival analysis and the models used in this study 
is presented.  Chapter 3 consists of a study of survival of permanently disabled claimants 
under a workers’ compensation program.  This study was published as “Using Survival 
Analysis to Predict Workers’ Compensation Termination” in Variance.1  Chapter 4 consists 
of a paper entitled “Medicare Cost at End of Life” and covers the cost of death and dying in 
the United States, particularly the frequency and cost of end of life services.  These 
patients’ costs are covered by the Medicare system in the United States; although the 
number of Medicare patients dying annually is less than 5%, their cost amounts to between 
20% and 25% of total spending by Medicare.  This paper was published in the American 
Journal of Hospice and Palliative Medicine.  We focus specifically on variables that affect 
patient life expectancy: age, sex, diagnosis, facility, and most importantly, the drugs that 
patients are prescribed during stays in hospice.  The remainder of Chapter 4 explores the 
hospice movement and contains a summary of the hospice prescription database on which 
the hospice study is based.  Our database contains very detailed prescription records, 
including covariates that change over time, such as specific drugs and their dosage, leading, 
                                                           
1 Journal of the U.S. Casualty Actuarial Society.  
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in turn, to time-dependent survival models.  Because of the multiplicity of different drugs, 
strengths, and forms (liquid, pills, etc.), Chapter 5 contains an in-depth discussion of the 
hospice drug database and the process of mapping the data in a manner that allows us to 
compare the dosage of analgesic drugs prescribed to patients, and the way that this dosage 
changes during a hospice stay.  Chapter 6 is a study of the rate of deprescribing, or 
termination of therapeutic (curative) drugs administered to patients in hospice.  Chapter 7 is 
a literature review, looking at prior publications on estimation of life expectancy of patients 
admitted to hospice and reveals that, generally, these estimates are not particularly accurate.  
We also review prior literature exploring the relationship between analgesic prescriptions 
and mortality.  The literature is inconclusive regarding whether these drugs hasten or slow 
the passing of a terminal patient.  Finally, in Chapter 8 we apply several survival models, 
including standard Kaplan-Meier and Cox proportional hazards models, as well as time-
dependent Cox proportional hazards, log-normal, accelerated failure time (AFT), and time-
dependent log-normal AFT models, to the data to estimate both survival curves and life 
expectancy of terminal patients.  Finally, the findings from the different examples are 
discussed and areas for future study are suggested, particularly the application of stochastic 
process models.   
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CHAPTER 2 - STATISTICAL MODELLING OF SURVIVAL 
2.1 Introduction  
Survival analysis describes the process of statistical modelling of a specific form of data, 
data that have a beginning and an end-point in time.  We are frequently interested in the 
duration from beginning to end, as, for example, with life-span.  Shorter durational studies, 
such as medical research, could involve time from treatment to either failure or survival of 
a patient.  Actuaries have typically studied survival over lifetimes (or conversely, mortality, 
or the time to death).   
Survival data are inherently different to other types of data, requiring their own set 
of analytical techniques.  Specifically, the data are frequently left-truncated (the subject is 
not observed at time 0) and right-censored (the end-point of interest is not observed).  
Survival times, as figure 2.1 shows, are also highly skewed, with more observations at the 
beginning of the distribution and survival times showing a long tail.  As an example, figure 
2.1, which is a representation of the probability density of duration (time-to-death) of 
patients admitted to hospice, illustrates the extreme right-skewed tail of the distribution.  
 
 
Figure 2. 1 Density of Length-of-Stay 
 
A second issue with survival data is that censoring and truncation occur frequently.  
“Survival time for that individual is said to be censored when the end-point of interest has 
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not been observed for that individual” ([2], p.2).    Censoring occurs when an individual is 
still alive at the time of the last observation.  In some cases, an individual’s final status 
could be unknown, as when the individual is “lost to follow-up.”  In this case, the 
individual is censored at the last observation.   
The response variable T, in a survival study, is the time from the origin (either the 
start of the study or the beginning of the observation period of the patient) to a defined end 
point.  A patient enters the study at time 0t  and dies (or otherwise terminates) at time 
0t T , or is still alive at the end of the study.  The individual who is still alive is “right-
censored,” because he is still alive at the observation date.  Other types of censoring occur, 
for example, left-censoring occurs when individuals enter a study after the triggering event 
of interest, and interval censoring occurs when the precise date of the triggering event is 
unknown, but is believed to be between two observations.  In this study we will be 
concerned with right-censoring, but not the other two types, because our subject 
populations consist either of permanently disabled employees (Chapter 3) or patients 
admitted to hospice care (chapters 4-8), both with a precisely recorded beginning point.  
Our interest is in modelling T as a function of explanatory variables.   
2.2 Survival Functions 
In describing survival data there are two functions of interest: the survival function and the 
hazard function or, as denoted by actuaries, the force of mortality.  The variable 
representing survival time T is a non-negative random variable.  T can take different values 
and, thus, represents observations from an underlying probability distribution.  The 
probability density function for this distribution is represented by f(t) and the cumulative 
distribution by F(t).  The distribution function of T is given by 
0
( ) Pr  ( ) ( ) 
t
F t T t f u du     
and represents the probability that survival time is less than or equal to t.  The 
corresponding survival function, S(t), gives the probability that the survival time is greater 
than, or equal to, t; hence,  ( ) Pr  ( ) 1  ( )S t T t F t    , or the probability that the 
individual survives to a point beyond t. 
In actuarial applications, particularly mortality studies, a subscript x is added to 
indicate that the applicable function is measured from age x forward.  In this study, x is a 
covariate, but we are primarily interested in survival time T and, therefore, will omit x , 
unless it is specifically required.  Similarly, we will use the more general terminology for 
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the instantaneous rate of change of the survival function, the hazard rate, rather than the 
actuarial terminology, force of mortality that is specific to mortality.  We will use the 
symbol for hazard rate h(t), defined as: 
Pr( |
( ) lim
t
t T t t T t
h t
t


      
 
, which is the 
probability that an individual dies in the interval ( , )t t t , given that the individual has 
survived to time t.  The cumulative hazard function, H(t), is defined as: 
0
( ) ( )
t
H t h u du  .   
A number of relationships may be derived from the definition of survival and 
hazard functions, as is done, for example, in [5] and [3].  Applying Bayes’s theorem 
Pr( ) ( ) ( )
Pr  ( | )
Pr( ) ( )
t T t t F t t F t
t T t t T t
T t S t
 

    
     

                                             (2.1) 
Re-writing the earlier result,
( ) ( )
( ) lim
 ( )t
F t t F t
h t
t S t


  
  
 
, and because 
( ) ( )
lim
t
F t t F t
t


  
 
 
is the derivative of F(t), f(t) we have the result 
( )
( )
( )
f t
h t
S t
  , 
implying that 
d
( ) (ln ( ))
d
h t S t
t
   and 
0
( ) exp ( ) )
t
S t h u du
 
  
 
 . Finally, from the survival 
function S(t), we can calculate a life expectancy at age x for an individual (which we shall 
need later) as 
0
 ( ) dtx xe t f t

 ɺ  or 
0
( ) dtx xe S t

 ɺ .             (2.2) 
2.3 Estimating the Survival Function 
We can estimate the survival function S(t) empirically by 
No. individuals with survival time ˆ ˆ( ) 1 ( )  
Total no. individuals
t
S t F t

       
No. individuals dead at time ˆwhere ( )
Total no. individuals
t
F t                                                                      (2.3) 
There are a number of different ways to estimate the survival function; in what follows, we 
will discuss the life table (actuarial) approach, Kaplan-Meier estimation, Cox proportional 
hazards, and other semi-parametric and parametric approaches. 
2.3.1 Life table (actuarial) estimation 
The life table is a summary of survival data grouped into convenient intervals.  In actuarial 
(life table) estimation data are collected in grouped form.  In order to estimate the survival 
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function, using the life table or actuarial approach, we first divide our observation period 
into a series of time intervals.  In mortality studies, these tend to be years, quinquennial, or 
decennial intervals.  In our hospice dataset, analysed later, we are fortunate in having a 
large population whose drug use is observed (essentially) daily.  Generally, however, we 
define j  periods, 1,2,...j m .  The j th  period extends from 1 to j jt t 
' '
.   and j jd c  
denote the number of deaths and censored individuals in period j .  jn  denotes the number 
of individuals alive and at risk of death at the beginning of period j .  Typically, actuaries 
have assumed that censoring occurs uniformly throughout the j th  period.  On average, 
the number of individuals at risk of death during the interval is  =  2j j jn n c
' / .  The length 
of the interval is defined as  j , implying that the average time survived in this interval is
'( / 2) j j jn d  . 
In this interval, the probability of death can be estimated as  j jd n
'/  and 
corresponding survival probability as 
' '( ) /j j jn d n .  This value is an estimate of the 
probability of surviving during the j th  period; cumulatively, the estimated probability of 
surviving t years is 
'
*
'
1
( )
k
j j
j j
n d
S t
n
 
   
 
    for ' ' 1< , 1,2,...k kt t t k m  . The corresponding 
hazard function, *( )h t , is estimated as *
'
( )
(  /2)
j
j j j
d
h t
n d 


  . The asymptotic standard error of 
this estimate has been shown by Gehan [6] to be 
* * 2
*
( ) {1 ( ( ) / 2) }
s.e.  { ( )}
j
j
h t h t
h t
d

   
and the standard error of the survival function is 
1/2
* *
' '
1
s.e.  { ( )} ( ) , 0
( )
k
j
j j j j
d
S t S t t
n n d
  
  
  
   . 
2.3.2 Kaplan-Meier estimation of the survival function 
In the case of data that are collected individually and not grouped (as in the case of the data 
in this study), it is possible to obtain more accurate survival estimates.  The most basic 
survival function is that of Kaplan and Meier [7]. To obtain the Kaplan-Meier estimate, a 
series of time intervals is constructed (as with the life table estimate), but designed to 
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include at least one death per interval.  Death is assumed to occur at the start of the interval.  
Following the example of Collett [2], let there be three time points 1 2 3, ,t t t  1 2 3, ,t t t , such 
that 1 2 3t t t  .  One or more deaths (D) occur at each of these points; in addition, some 
subjects are censored (C).  Collett’s [2] figure 2.2 shows the incidence of deaths and 
censored lives. 
 
 
 
Figure 2. 2 Construction of Intervals used in Kaplan Meier Estimation 
 
In this example, two individuals die at time one, one at time two, and three at time 
three; one individual is censored between observation points.  In general, there are n
individuals with survival times 1 2, ..... nt t t .  As in the figure, more than one individual may 
have the same survival time.  We observe r  deaths among the individuals, and arranging 
the death times in ascending order, the j th  death occurs at time , 1, 2...,.jt j s .  jd
denotes the number of individuals dying at time ,  and jj n is the number of individuals alive 
immediately before time jt .  The estimated probability of dying at time jt  is /j jd n  and 
the estimated probability of surviving through interval jt  to 1jt   is ( ) /j j jn d n .  The 
Kaplan-Meier estimate of the survival function is then 
1
ˆ( ) ,  0
k
j j
j j
n d
S t t
n
 
   
 
 , for 
( ) ( 1) ,  1, 2,....k kt t t k r    and (1) (2) ( ), .... rt t t  are r  ordered death times.   
As with the life table estimate, the Kaplan-Meier estimate is the product of a series 
of estimated probabilities.  The Kaplan-Meier estimate is the limiting value of the life table 
estimate above, as the number of intervals tends to increase and the width of the interval 
trends to zero.  The variance of the Kaplan-Meier estimate may be found in different ways.  
10 
 
Defining 
ˆ ˆ(1 )
ˆ ˆ,  ( )
j j j
j j
j j
d
Var
n n
 
 

  .                               (2.4) 
  
 
Variance estimate 
Method 1 Delta method:  ˆ(ln(1 ))
( )
j
j
j j j
d
Var
n n d
 

               (2.5)       
Method 2 Greenwood’s formula: 
 
The standard error of the Kaplan-Meier function is  
1/2
1
ˆ ˆs.e.  { ( )} ( )
( )
k
j
j j j j
d
S t S t
n n d
  
  
  
   (Greenwood’s formula).                               (2.6)  
 
Confidence Intervals for the Survival Function 
Original scale:  1 /2
ˆ ˆ( ) ( ( )) CI S t Z se S t .  Because the CI may lie outside [0,1] we may 
use a log transformed confidence interval. 
If: /2 /2
ˆ( ( ))
ˆ ˆ ˆ ( )( ( )) ln(( ( )) ln(( ( )) 
 

j
j
t t j j j
dz se S t z
U
n n dS t S t S t
    then the log-transformed CI is: 
exp( ) exp( )ˆ ˆ( ) , ( )U US t S t    
Sometimes we need Confidence Bands, [ ( ), ( )]L t U t  such that  
Pr( ( ) ( ) ( ) for all ) 1     L UL t S t U t t t t  .  
 the smallest observed event time, and largest event time. L Ut t   
Equal Probability bands for Survival Function 
(Log scale): 1/ˆ ˆ( ) ( ) , ( ) ( ) L t S t U t S t   where ˆ ˆexp( ( , ) ( ) / ln( ( )) L Uc a a S t S t   
2 2
2 2
( ) ( )
,
1 ( ) 1 ( )
 
 
S L S U
L U
S L S U
n a n a
a a
n a n a
 
 
 , 

2
ˆ( ( ))
( )
ˆ( ( ))
S
Var S t
t
S t
   
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Hall-Wellner Bands for Survival Functions  
(Log scale): 1/ˆ ˆ( ) ( ) , ( ) ( ) L t S t U t S t    
Where 
2
1/2
( , )(1 ( ))
exp
ˆln( ( ))
 
  
 
L U Sk a a n t
n S t
    
 
2.4 Semi-Parametric (Cox Proportional Hazards) Models 
The methods discussed above (life table and Kaplan-Meier) are non-parametric.  Although 
explanatory variables may exist in the data, they do not form part of the modelling.  
Instead, the data (and modelling) would need to be stratified according to the variable of 
interest, a cumbersome and ultimately unhelpful method.  A modelling approach that 
includes explanatory variables allows us to determine how the experience of subjects 
depends on the values of explanatory variables.   
Modelling survival data allows us to determine the effect of the explanatory 
variables (or combinations thereof) on the hazard function and to obtain an estimate of the 
hazard function.  From the hazard function, an estimate of the survival function can be 
obtained.  The survival function, in turn, allows the estimation of statistics, such as median 
survival time and life expectancy (complete expectation of life, in actuarial terms).  
The most common model in survival analysis is the Cox proportional hazards model 
[8-10].  The model is semi-parametric because there is no underlying functional form (such 
as Poisson, negative binomial, Weibull, etc.) but it, nevertheless, incorporates covariates, 
allowing an assessment of the relative effect of different explanatory variables.   
2.4.1 Proportional hazards model 
The general form of the proportional hazards model posits explanatory variables 
1, 2,.... pX X X .  The p explanatory variables take values 1 , 2 , . . . . . px x x  at the 
commencement of the study (or at entry into the study, if an individual is recruited later).  
We will later introduce time-dependent variables.  The values 1, 2,..... px x x are represented by 
the vector X .  Let 0 ( ),  0h t t  be the hazard function for an individual when 0X , i.e. 
when the explanatory variable values are all zeroes.  0 ( )h t is the baseline hazard function, 
and the hazard function for the i th  individual is 0( ) ( ) ( )ih t h t ix , where ( ) ix  is a 
function of the values of the explanatory variables at time t for individual i.  The function 
12 
 
( )
i
x  is the hazard at time t for individual i, relative to the hazard for an individual with 
X = 0 .  If we define ( ) ix  as exp( )i , where 1 1 2 2 ...i i i p pix x x       then the general 
proportional hazards model is 1 1 2 2 0( ) exp( ... ) ( )i i i p pih t x x x h t     , which implies, in 
turn, that 1 1 2 2
0
( )
ln ...
( )
i
i i p pi
h t
x x x
h t
  
 
   
 
.        
        (2.7) 
The variables 1, 2,.... pX X X may be variables or factors.  Variables are continuous 
(for example, age), while factors are categorical.  Depending on the software used, we may 
need to define factors as a series of indicator variables with values (0,1) to accommodate 
the factor level [2]. For example, in our study of survival of hospice patients, care setting is 
treated as a categorical variable with four levels: homecare, long-term care, hospital 
inpatient unit, and assisted living.  If homecare is the baseline level, we have three different 
indicator functions as follows: 
 
1,   if   patient is in long-term care
0,  otherwiseicare long term
I
i th
 



             (2.8a) 
 
1,   if   patient is in an inpatient facility
0,  otherwiseicare inpatient
i t
I
h




           (2.8b) 
  
1,   if   patient is in  an assisted-living facility
0,  otherwiseicare assisted living
I
i th


 

           (2.8c) 
If all three indicator functions are 0, we have a patient in the homecare setting.  
2.5 Estimation of the Proportional Hazards Model 
The proportional hazards model requires estimates of both the coefficients of the 
explanatory variables and the baseline hazard function, in the case of a fully-parametric 
function (e.g. Weibull).  The former may be estimated first, and the latter function 
estimated when estimates of the coefficients have been found.   In the case of the Cox 
regression model, a semi-parametric function, the β coefficients are found by the method of 
maximum likelihood.  Given that data are available for n  individuals, of whom r  have 
died and n r are right censored, and, for simplicity, that there are no ties in the data 
(more than one individual dying at the same time) we order the r  death times as 
(1) (2) ( )..... rt t t   and ( )jt is the j th  ordered death time.  The set of individuals alive, at 
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risk, and uncensored at time j  is ( )( )jR t .  The partial likelihood function for the 
proportional hazards model is 
( )
1 ( )
exp( )
( )
exp( ) 




'
'
j
j
r
j tt R t
x
L
x
, where jx  is the vector of covariates for the individual who 
dies at the j th  ordered time jt .  
( )( )
exp( )
 
'
j
tt R t
x is a summation over all individuals 
who are at risk at time jt .  Individuals who are censored do not contribute to the numerator 
of the likelihood function but they do contribute to the denominator up to the time of 
censoring.     
To incorporate the censored observations into the data we assume n  survival times
1 2, ,..... nt t t .  We also introduce an event indicator, t  which takes a value of 1 when the 
individual dies at time t and 0 if the individual’s observation is (right-) censored.  When the 
subject is censored at iT : 
0
( ) Pr(subject  survives beyond   ) = ( ) exp ( )
iT
i i i iL i T S T h s ds
 
    
 
 .  
When the subject is not censored at iT , iT  is the failure time ( 1)i   then: 
0
( )= ( ) ( )  ( )exp ( )
iT
i i i i i i i
L S T h T h T h s ds
 
   
 
 .  Full likelihood is then: 
1 0
( ) ( ) exp ( )
i
i
Tn
i i i
i
L h T h s ds

 
   
 
  .  Re-writing: 
 
( )1 0
( )
( )
( ) ( ) exp ( )
( )
i
i
i
i
i
Tn
i i
j i i
j R Ti j i
j R T
h T
L h T h s ds
h T





 
   
      
    
 
 
.   If we focus on the first term, then 
under the proportional hazards assumption,   
1
( )
( )
( )
( )
i
i
n
i i
i i i
j R T
h T
L
h T




 
 
  
 
 
 
      
 
 
and defining Zi as a vector of co-variates,                      
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0
1 1 0
( ) ( )
( ) ( )exp( )
( ) ( )exp( )
i i
i i
n n
i i i i
i ij j i j
j R T j R T
h T h T Z
h T h T Z
 

 
 
   
   
   
   
   
   1
( )
exp( )
exp( )
i
i
n
i
i j
j R T
Z
Z




 
 
 
 
 
 
,                           (2.9) 
which is the partial likelihood function 
1 ( )
exp( )
( )
exp( )
j
r
j tt R t
x
L
x 




'
'
j
                          (2.10) 
   
The full likelihood function has been factored into two parts: the first term which 
involves 0 ( ) and h t   and the second term the partial likelihood, which involves β only.   
The first term contains information about contains information about 0 ( )h t  while the 
second term contains information about  .  By discarding the first term and using only the 
partial likelihood, some information about β is discarded.  The resulting estimate is not 
fully efficient; standard errors are larger than they would be if full likelihood were used.  In 
most cases, Efron [11] showed that the loss of efficiency was small.   
In order to accommodate tied observations, this likelihood function needs to be 
modified.  The simplest approximation to the likelihood function when ties are present is 
that of Breslow [12] 
1
( )
exp( )
( )
{ exp( )} j
j
r
j
d
j tt R t
s
L
x 
 



'
'                                                (2.11) 
               
Where jd are deaths at time j and js  is the sum of the p covariates for the individuals who 
die at time j.  There are other approximations, due to Efron [11], and Cox [8].   
2.5.1 Estimation of the baseline hazard function 
If the shape of the baseline hazard follows a recognizable form, we could consider a 
parametric version of the survival model.  For example, if the empirical baseline hazard is a 
horizontal line, the underlying failure time follows an exponential distribution.  If the 
baseline hazard is concave and increasing, it is possible that the failure time follows a 
gamma distribution or Weibull distribution.  The R function (basehaz) allows us visually to 
discern the shape of the cumulative baseline function.  We will explore these possible 
functions later when we fit models.   
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Figure 2. 3 Estimated Baseline Cumulative Hazard Function 
2.5.2 Stratified Cox Models 
When the proportional hazards assumption is violated hazards will not be proportional on 
an overall basis but will be proportional in subgroups.  In our study of workers’ 
compensation terminations, the proportional hazards assumption is shown to be violated for 
the covariate “entity group” (essentially the employer or department for which the disabled 
employee worked). For situations such as this, we assume that subjects have different 
baseline hazard functions for each of the strata to which the covariate levels map.  Now, 
instead of the Cox proportional hazards model above ( 0( ) ( ) ( )ih t h t ix ) we have instead a 
stratified model 
'
0 0( ) ( ) ( ) exp( ) ( )ij j jh t h t h tij ijx x    where ijx is the vector of explanatory 
variables 1,... pX X  , excluding kX that violates the PH assumption and {1,2,... }j g  which 
indicates the categorical level in kX . 
 
2.6 Parametric Models 
A parametric model is one in which survival time is assumed to follow a known 
distribution.  The Cox proportional hazards model has the advantage of being semi-
parametric, which makes it flexible.  While the regression parameters are known, the 
baseline survival is not specified in the Cox model, so the distribution of the outcome 
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remains unknown.  The definition of a specific functional form for the parametric model 
has the advantage of more precise inferences and smaller standard errors.   
2.6.1 Accelerated failure time models 
Although we are concerned with the estimation of survival in the population, because the 
outcome is mortality, we are also interested in estimating life expectancy for individuals 
based on their specific circumstances (co-variates).  Ultimately, we need a method to 
develop life expectancy for the population.  Time-dependent models (which we will discuss 
shortly), such as the time-dependent Cox model are not ideal for this purpose because the 
future pathway of the time-dependent variable is not determined at any point in time; in 
fact, the pathway unfolds in a stochastic fashion.  One way to estimate life expectancy 
would be to impute a future pathway to the patient.  Other alternatives are to fit parametric 
models or to apply accelerated failure time (AFT) models.  Unlike the semi-parametric Cox 
model, the AFT model has a completely specified form for the hazard function h(t) and the 
survival function S(t).  The AFT model is a statistical approach to the study of survival, 
rather than through the hazard function.   
In the previous section, the key assumption for the survival model was the 
proportional hazard (PH) assumption.  Many parametric models are accelerated failure time 
(AFT) models rather than PH models.  Interpretation of coefficients also differs between 
AFT and PH models.  The coefficients ( s ) in PH models affect the hazard rates, while the 
coefficients in AFT models affect the survival time.  AFT models are consistent with 
theoretical survival models, while at the same time robust (in the sense that the model does 
not need to satisfy a proportional hazards assumption) with respect to departure from the 
proportional hazards assumptions.  We can use the complete specified form of the survival 
function to predict the future survival curve for any patient using the time-quantile function.   
2.6.2 Assumptions in the AFT model 
AFT models assume that the effect of the predictors is to accelerate or decelerate the 
survival function by a constant.  The example in Kleinbaum and Klein [10], although 
somewhat trivial, illustrates the point.  Kleinbaum and Klein [8] posit two survival 
functions: ( )DS t  for dogs and ( )HS t for humans.  They observe that dogs are often believed 
to age at seven times the rate of humans.  The probability of a dog living past 10 years old 
is (in this model) equal to the probability of a human living beyond age 70.  We can 
therefore write ( ) (7 )D HS t S t .  In this model, dogs are viewed as “accelerating” through 
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their lifetimes at seven times the rate of humans; conversely, human survival is decelerated 
by a factor of seven, compared with that of dogs [8].   
More generally, ( ) ( )A BS t S t , where   is the acceleration factor and the rate of 
aging for population B is   times that of population A.  In terms of survival time, random 
variables  = A BT T .  The following summarizes the role of  :  
1    the effect of the predictor variables increases survival  
1    the effect of the predictor variables decreases survival . 
In Figure 2.4, the acceleration factor is 
2
 constant
1
D
D
   .   
 
 
Figure 2. 4 Example of Acceleration 
 
2.6.3 Examples of parametric distributions 
A number of different distributions can be used.  In this section, we will discuss the 
exponential, Weibull, lognormal, and log-logistic distributions.   
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2.6.3.1 Exponential distribution 
The simplest model for the hazard function is the exponential distribution (see figure 2.5).  
In this model, the hazard is constant over time, implying that the risk of death is the same 
irrespective of the elapsed time since entry to the study.  Under this model, h(t) = λ for  0 ≤ 
t < ∞ (λ is replaced by μ in actuarial studies of mortality).  The survival function is 
0
( ) exp ,  0
t
tS t du e t 
 
    
 
 .  The exponential distribution is not particularly realistic 
and is not much used in practice.   
 
 
 
Figure 2. 5 Exponential Distribution (Constant Mortality Hazard) 
 
2.6.3.2 Gompertz distribution 
The Gompertz distribution (see figure 2.6) is an early example of an exponential 
distribution and has particular application in early actuarial mortality modelling, being 
introduced by Benjamin Gompertz in 1825.  The hazard function of the Gompertz 
distribution is ( ) th t e .  When β = 0, the model defaults to the exponential distribution.  
The corresponding survival function is ( ) exp (1 ) ,  0
tS t e t


 
   
 
. When multiple 
explanatory variables are introduced 1... pX X  with values 1 ....i pix x  for the i th  individual
1, 2...i n , the Gompertz proportional hazards model becomes
1 1( ) exp( ... ) 
t
i i p pih t x x e
     .  The coefficients 1  are log-hazard ratios.  
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Figure 2. 6 Gompertz Distribution 
 
2.6.3.3 Makeham distribution  
The Makeham distribution, sometimes called the Gompertz-Makeham distribution, adds a 
constant to the Gompertz function (see figure 2.7).  It is of the form ( ) th t e   .   
The Makeham survival function is: 
0 0
( ) exp ( ). exp exp( ). ,  t>0
t t
S t h s ds s ds  
   
       
   
 
 0exp exp | exp 1t ts s t e    
   
         
   
                                                              (2.12) 
 
 
  
Figure 2. 7 (Gompertz) Makeham Distribution 
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2.6.3.4 Weibull distribution 
A more general form of the hazard function than the Gompertz model is 
1 ( ) ,  0h t t t   .  When 1   the model defaults to the exponential distribution.  The 
hazard function increases or decreases monotonically depending on values of  .  Figure 2.8 
illustrates a Weibull distribution with increasing hazard function, a distribution that may be 
suited to our population that faces increased mortality hazard as duration in hospice 
increases.  The Weibull survival function is 1
0
( ) exp ,  0
t
tS t u du e t
   
 
    
 
            
and 
1( ) tf t t e
    . 
 
 
 
 
Figure 2. 8 Weibull Distribution with Increasing Mortality Hazard 
 
2.6.3.5 Lognormal distribution 
Under the lognormal distribution the form of the hazard function is:  
ln
l
1
( )
(
)n
)
(
t
h t
t
t






 
 
 
  



        and the Survival function:  
)ln
1 ,  0) ,
(
( 0
t
S t t


   




, 
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Where   is the cumulative unit normal distribution and  the unit normal density.  The 
survival and hazard functions are illustrated in figure 2.9. 
 
 
 
Figure 2. 9 Lognormal [N(0,1)] Distribution 
 
2.6.3.6 Log-logistic distribution 
The final parametric function to be considered is the log-logistic.  A limitation of the 
Weibull function is that it is a monotonic function of time.  While we would a priori expect 
this to be an appropriate model for the survival of patients in hospice, it is possible that 
their mortality hazard both decreases and increases (or vice-versa) over time.  It is possible, 
for example, that the addition or change in the strength of a drug could have this effect on 
survival.  The unimodal form of the function in which hazard first increases and then 
decreases over time is particularly worth considering (see figure 2.10).  The hazard function 
is
1 
( ) ,  0 ,  0 .
1
p
p
e p t
h t t p
e t



  

  If p ≤ 1 the hazard decreases with time.  If p > 1 the 
hazard first increases and then decreases (unimodal).  The corresponding survival function 
is
1
( ) ,  0.
1 p
S t p
e t
 

. 
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Figure 2. 10 Log-logistic Distribution with Unimodal Mortality Hazard 
 
2.6.4 Prediction using AFT models 
Some of the models discussed above (e.g. Weibull, log-normal) are appropriate for 
modelling AFT survival curves.  Below, predicting the survival curve for future 
observations are discussed. 
 
2.6.4.1 Weibull  
Assume T ~ Weibull (λ, p) and hazard function 1 ( ) ph t pt  .  For the AFT model we re-
parameterize λ as a linear combination of the predictors, such that 0exp  ( )i iX    . 
The corresponding survival function is 
1/
1/
1
( )    ln( ( ))  ( ln( ( ))) ,  0, 0.
pt p p
p
S t e S t t t S t t p 

                             (2.13) 
0
1/
1
i iX
p
e
 

 then   
 0
1/  
1/
( ln( ( )))
i i
p
p
X
S t
t
e
 



 .                     (2.14) 
2.6.4.2 Log-normal 
Assume T ~ LN (μ, σ); μ is a linear combination of predictors, 0 i iX    . 
The hazard function is:   
  
ln
ln
1
( )
( ) .
( )
t
h t
t
t









 
 
 
                                                                                                (2.15) 
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and the Survival function: 
1( )( ) ln( )  (1 ( )),  0,1 0
ln
t
t
S t S t t

 



       
 

                              (2.16)                               
We will use expression 2.16 later in predictions.  
Solving for t in terms of predictors:  
1
0ln( ) ( )  (1 ( ))i it X S t  
                                                                         (2.17)
We will return to these distributions when we perform modelling in Chapter 8.   
2.7 Survival Functions with Time-dependent covariates 
In studies where individuals are monitored continuously or periodically, values of observed 
data are generated at different time points.  Incorporation of changing values of explanatory 
variables can result in a more accurate model.  Time-dependent variables are those 
variables whose values change with time.  There are two types: internal (endogenous) and 
external (exogenous).  Internal variables relate to an individual in a study and result from 
repeated observations made on the individual over time.  They are often measures of 
clinical function.  External variables are measures of factors that are not dependent on the 
patient, such as temperature.  In Chapter 8, we apply time-dependent models to survival of 
patients in hospice.  For these patients, fixed covariates include age and sex at admission, as 
well as admitting diagnosis and co-morbidities.  Additionally, we have considerable 
volumes of drug dispensing data that are time-dependent, including drug name, strength, 
form, and dosage.  These co-variates are patient-specific and time-dependent, and indicate 
changes in medication triggered by changes in patients’ conditions. 
A distinction needs to be drawn between time-dependent coefficients and time-
dependent covariates.  In the Cox proportional hazards model, the hazard of death at time t 
for individual ,  {1,.. }i i n    is of the form 0
1
( ) exp ( )
p
i j ji
j
h t x h t

 
  
 
   , where 
,  1,2...jX j p are explanatory variables and 0 ( )h t is the baseline hazard function.  The Cox 
regression model with time-dependent variables is 0
1
( ) exp ( ) ( )
p
i j ji
j
h t x t h t

 
  
 
 .     
In this model, the term 0 ( )h t  is interpreted as the baseline hazard function for an 
individual whose variables have a value of zero at inception of the study and remain at zero 
throughout.  Values of variables  ( )j ix t  depend on time t, meaning that 0( ) / ( )ih t h t   is time 
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dependent, that is, dependent on the value of variables at time .t   Conversely in a model 
with time-dependent coefficients, 0
1
( ) exp ( ) ( )
p
i j ji
j
h t t x h t

 
  
 
  the value of the 
coefficients changes with time.  For the remainder of this thesis we will be concerned with 
time-dependent covariates.   
  With time-dependent covariates, the hazard of death at time t is no longer 
proportional to the baseline hazard and the model is no longer a proportional hazard model.   
Looking at the ratio of two individuals, r and s,
1 1 1( ) / ( ) exp([ ( ( ) ( ))... ( ( ) ( ))]r s r s p rp sph t h t x t x t x t x t      the coefficient j can be 
interpreted as the log-hazard ratio for two individuals whose value of variable j  differs by 
one unit at time t, holding all other variables constant.   
2.7.1 Estimation 
The log-likelihood function for the Cox regression model is 
 
1 1 ( ) 1
( ) ln exp ( )
i
p pn
i j ji i j jl l
t t l R t j
x t x t  
   
   
  
   
     , where ( )iR t is the risk set at time  and  1i it     
(when the individual has died) and = 0 when the individual is censored.  To maximize this 
expression to obtain values of j we require values of time-dependent variables, ( )ijX t  at 
the death of the i th  individual.  Certain variables are measured, however, at intervals 
that do not coincide with death.  In these cases, a problem can arise because the exact value 
is not recorded at death, and there are established procedures to deal with this issue (for 
example, using the last value, interpolating between two values, or developing a model to 
predict the value at a point in time).  In our case, this will not be an issue because key 
variables, such as drug dispensing data, are recorded at intervals, but represent continuous 
therapy, adjusted on a periodic basis.   
According to the nature of the time-dependent Cox model, it is not correct to 
incorporate endogenous variables into the model.  In order to obtain an unbiased estimate 
of the effect of a covariate on an outcome variable using standard survival analysis 
methods, it is necessary that the covariate be measured at all times and without error [13].  
Specifically, the value of a time-dependent covariate in the Cox model is changed at the 
follow-up time point, but must remain constant until the next follow up.  This assumption is 
valid in the case of an exogenous variable, but it is not necessarily true in the case of an 
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endogenous variable.  Said differently, time-dependent covariates are the result of a 
“stochastic process generated by the subject” [14].  Theoretically, drug strength values 
could change continuously between two measurement points.  That they do not is a 
function of drug prescribing; patients either receive 28-day supplies of their prescription 
drugs, using them until the drugs are exhausted or a new (possibly stronger) prescription is 
filled.  Arguably, the nature of prescription drugs suggest that the endogenous variable 
(drug strength) meets the requirements necessary to obtain an unbiased measurement of the 
effect of this covariate, and, for this reason, we considered developing an extended Cox 
regression model.  However, there is still endogeneity between the patient and the 
prescription strength, with the result that this method tends to underestimate both the effect 
and the standard errors of the examined endogenous variable (drug strength).  In this case, 
one solution is to perform joint modelling of the path of the endogenous variable (repeated 
measures) and the survival model can be an alternative method for consideration.   
The functional form of the joint model is as follows: 
      Χ α0|Μ , ,  0
T
i im t
i i i
h t t X h t e t
   , where  Μi t  denotes the history of the true 
unobserved longitudinal process up to time point t and  im t  denotes the true and 
unobserved value of the longitudinal outcome at time t.  Keep in mind that  im t is not the 
same as  i t , as it is measured with error.  In addition, we apply an appropriate mixed-
effects model to estimate  im t  and reconstruct the complete history  Μi t .  However, 
ultimately, it was decided to fit a parametric function and to estimate survival this way.   
 
2.8 Assessing Model Validity 
2.8.1 Two types of test 
To assess the validity of a particular Cox regression model we need to perform tests of 
overall fit as well as the proportional hazards assumption.   
 
2.8.2  Overall fit for the Cox regression model 
There are several different tests of fit of the Cox regression model: 
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Method Primary Use 
1. Cox-Snell residuals Overall Fit 
2. Martingale residuals Form of covariates (should covariates be 
transformed?) 
3. Deviance residuals Outliers 
4. Schoenfeld residuals Proportional Hazards assumption 
5. Score residuals Influential points 
 
1. Cox-Snell residuals [15] are defined as 
ˆ
0
ˆ ( ) ixi ir H T  e
 , which can be used to assess 
the overall fit of a Cox proportional hazards model.  If the model is correct, the 
estimated cumulative hazard for each observation at the time of death or censoring 
should be like a censored sample from a unit exponential distribution. Thus a plot of 
the Cox-Snell residuals versus the estimated cumulative hazard rates 0
ˆ ( )iH T  should 
follow a straight line through the origin, given that the Cox model provides a good 
fit of the data. In figure 2.11, we see the estimated cumulative hazard is close to the 
diagonal line for all but large values of Cox-Snell residuals.  
2. The Martingale residual for the i th subject is i i iM r   where ir is the Cox-Snell 
residual and iM is the difference between the observed number of deaths, ( 0,1i  ) 
and the expected number of deaths for subject i between time 0 and iT .  A plot of 
Martingale residuals vs. covariates indicates whether a transformation of the 
covariate is appropriate.  
 
 
Figure 2. 11 Cox-Snell Residuals 
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3. Deviance residuals are defined as  
1/2
sign ( ) 2 ln( )j j j j jM M M       which is 
less skewed and more symmetrical compared to the distribution of Martingale 
residuals. A large value of the deviance residual implies a possible outlier.  
4. Schoenfeld residuals.   Schoenfeld residuals were proposed by Schoenfeld (1982, 
[16]). Unlike residuals discussed above, there is not a single residual value for each 
individual but a set of values, one for each explanatory value in the fitted Cox 
model.  The i th  residual for  the jX j th  explanatory variable is 
{ }
ji j ji ji
r x x   , where jix  is the value of the j th  explanatory variable, and jir  
represents the difference between the observed covariate and its average over the 
risk set at time iT .    
5. Score residuals.  Score residuals are a modification of Schoenfeld residuals.  The 
score residual is not a single value for each observation but a set of values, one for 
each covariate in the fitted Cox model.  A large value of the score residual implies 
large influence of the i th subject on the estimate of j .   
 
2.8.3. Appropriateness of the proportional hazard assumption 
The departure from proportionality could lead to an incorrect model.  The PH assumption 
may be tested in two ways: 1) by plotting the Schoenfeld residuals [16] and 2) performing a 
formal hypothesis test for correlation between Schoenfeld residuals and time. 
If the PH assumption is true, the trend of   versus time is expected to be a horizontal line 
for each covariate.  A more formal test of the PH assumption was proposed by Grambsch 
and Therneau [17]. Each parameter in the model is allowed to depend on time 
    ( )j i j jt t g t    .  If the correlation parameter 0j  ,  we would reject the 
hypothesis that parameters are time-dependent. 
 
2.8.4 Model Selection with fully-parametric models 
 
Comparisons between a number of different models (varying, for example by 
inclusion of more covariates or interaction terms) can be made on the basis of the AIC 
28 
 
statistic.  Akaike’s information criterion (AIC) is applied to compare the goodness-of-fit 
between fully-parametric AFT models.  By definition,  
2 ( ) 2( )AIC Log likelihood p k    , where p is the number of parameters, and k = 1 for 
the exponential model and k = 2 for the Weibull, log-logistic, and log-normal models.  The 
Log-likelihood is a measure of goodness-of-fit, where the higher the number the better the 
model fits the data, but penalizes the model for inclusion of additional variables.   The AIC 
statistic is, however, only useable to compare parametric models: “This classic question 
(comparison of non-parametric and parametric models) cannot be answered by AIC or BIC 
since a non-parametric model has no likelihood.”  [18].  To compare semi-parametric 
models (e.g. Cox regression) and parametric models we need other techniques, which are 
not well developed.   
 
2.8.5 Overall fit for the log-normal accelerated failure time model 
The final log-normal AFT model is assessed using AIC and goodness-of-fit tests.  We 
further assess the overall goodness-of-fit using the Cox-Snell residuals for the log-normal 
AFT model.  For the AFT model, the Cox-Snell residual for the thi   observation is 
defined as 
ˆ( )
ˆ
n
ln
l
1
ˆ
i
ir
t 

 

 



 


 
 ,                                    
(2.14) 
where   is the cumulative distribution function of the standard normal distribution.  If the 
model is correctly specified, the set ˆ( , ) , 1 , 2 , . . .i ir i n   behaves similarly to a 
censored sample of unit exponentially distributed variables.  A drawback of Cox-Snell 
residuals is that they do not provide insights into the reasons for a model’s failure to fit the 
data.   
2.9 Model Validation 
The use of the concordance statistic for Cox models was popularized by Harrell et al [19] 
and is now the most used measure of goodness-of-fit of survival models (Therneau and 
Atkinson, [17, 20].  If  and i iy x are observed and predicted data values, Concordance is 
defined as Pr( | )i j i jx x y y  , the probability that the prediction x is in the same direction 
as the actual data .y  A pair of observations ,x y is considered concordant if the prediction 
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and data go in the same direction; the concordance statistic is the fraction of concordant 
pairs.   
We validate the model by applying the derived model estimates to a hold-out dataset. The 
metrics for validation are Somers’ xyD  correlation index [21] and Harrell’s concordance 
index [19], both of which are used to assess the predictive value of a right-censored 
survival model.  Somers’ xyD is a measure of ordinal association between two possibly 
dependent random variables X and Y.  Somers’ xyD  takes values between  when all pairs of 
the variables disagree and when all pairs of the variables agree.  
( 1) / 2
c d
xy
n n
D
n n



,  where 
cn  is the number of pairs that are concordant (i.e. rank orders of predicted and actual pairs 
are the same, or i jy y  and ˆ ˆi jy y ). 
d
n  is the number of pairs that are disconcordant (i.e. rank orders of predicted and 
actual pairs are the different, or ˆ ˆ  but  i j i jy y y y  ).  ( 1) / 2n n   is the number of of all 
possible pairs of observations in the data.  A number close to 1 implies a model that 
generates high concordance, and Harrell’s concordance or c-index is defined as 
1
2
xyD
c

  .   
A value of c > 0.5 implies that predictions are better than random.   
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CHAPTER 3 - USING SURVIVAL ANALYSIS TO PREDICT 
WORKERS’ COMPENSATION TERMINATION 
This chapter consists of a study of termination rates of permanently disabled workers 
eligible for lifetime workers’ compensation medical benefits in the State of California.    
3.1 Workers Compensation: Background 
Workers Compensation (WC) is a compulsory, no-fault insurance system in the United 
States.  The fragmentation of the provision of medical and income benefits between 
multiple private payers and providers, in the absence of a national system (such as in the 
United Kingdom), requires oversight and regulation of private providers.  The workers 
compensation system addresses occupational illness and injury and operates in parallel 
with the medical and non-occupational disability income systems.  Workers compensation 
regulation requires employers to purchase insurance to compensate employees for lost 
wages and medical expenses in the event of occupational injuries and illness.  Under this 
system, the employer is deemed to be absolutely liable for occupational injuries and illness, 
regardless of responsibility.  Coverage is compulsory for all U.S. employers, with some 
exceptions, e.g., employers with fewer than five employees, farm labour, domestic servants, 
and longshoremen.  Employers can purchase private insurance, self-insure and purchase 
excess (WC) insurance, or use state workers compensation funds – some of which are 
monopolistic and some of which compete with private insurers.   
The United States constitution reserves to the states responsibilities that are not 
explicitly assigned to the Federal Government.  Workers compensation is one such activity 
whose regulation is the responsibility of the states and benefits are defined by each 
individual state.  Typical benefits are as follows: 
 Unlimited medical benefits 
 Disability benefits for lost wages.  Disability benefits are typically limited to two thirds 
of a state’s average weekly wage (subject to minimums and maximums), so there is an 
incentive for workers to return to work.  WC return-to-work programs are important in 
controlling costs.  Disability income benefits under the workers compensation system 
are usually classified as: 
o Temporary Total (TT) – Injury is deemed short-term; however, the employee is 
unable to work while in an injured condition, for example, with broken bones in 
traction. 
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o Permanent Total (PT) – Injury is deemed permanent and the employee cannot return 
to employment, for example, with paralysis or a coma.  PT injuries typically result 
in lifetime disability benefits.   
o Temporary Partial (TP) – Injury is deemed short-term and the employee can do 
some work while injured, for example, having one broken arm. 
o Permanent Partial (PP) – Injury is deemed permanent; however, the employee can 
still work (sometimes with re-training for a different job), for example, the loss of 
one limb or the loss of sight in one eye. 
 Death benefits – for burial. 
 Rehabilitation benefits – vocational evaluation and re-training. 
PT injuries are the least frequent, but most severe, causing medical benefits for PT 
injuries to be the most difficult to estimate.  Due to the infrequent nature of the claims and 
their duration (to end of life), as well as medical trend (inflation), a traditional chain ladder 
(triangle) approach to reserving does not usually work very well for estimating the liability 
for future medical costs.  Tail data is often thin, volatile, and out-dated.  The medical 
condition and treatment of PT workers can and does change over time.  Changes in medical 
technology and medication can cause significant changes in medical cost.  End of life costs 
(e.g., nursing homes) can also cause spikes in benefits.  The best way to estimate medical 
reserves (unpaid claims) for these lifetime cases is often to estimate case reserves2 and to 
rely less on bulk IBNR3 estimates from triangle methods.  In order to estimate reliable case 
reserves, it is important to reflect accurate information about each case.  One important 
factor in these estimates is the duration of claim benefits to the injured employee 
(claimant), which is the future lifetime of the employee.  
The duration of PT benefits, at the case level, is often dependent on mortality tables.  
However, it is important to use the correct mortality table for the injury.  The severity of PT 
injuries often means that the expected mortality of the claimant is compromised.  Hence, a 
standard mortality may not be appropriate.  However, states may regulate the estimation of 
case reserves by formula, including the use of a standard mortality table.  When an 
                                                           
2 Case Reserves are estimated at the individual level by claims adjusters.  
3 IBNR estimates are bulk estimates for Incurred but Not Reported claims, including development on known 
claims, claims not yet reported (small in workers’ compensation) and re-opened claims.   
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inappropriate mortality table is used, this can result in inaccurate case reserves and 
increased reliance on less-reliable bulk IBNR methods.   
Although, historically, wage replacement (called “indemnity” in workers 
compensation contracts) was the larger of the two liabilities, the continual inflation in 
medical costs has resulted in a shift so that medical benefits now represent over 55% of the 
total employer liability.   
3.2 Mortality of Disabled Lives 
Although general insurance companies use mortality tables for workers’ compensation case 
reserving, there are no published tables of disabled life mortality and few comparisons of 
standard and non-standard mortality.  The few studies comparing standard and non-
standard mortality suggest that mortality of younger disabled workers is higher than that of 
a standard population, while older disabled worker mortality does not differ significantly 
from that of the standard population.  The Casualty Actuarial Society has, in the past, 
published studies of disabled worker mortality.  Venter et al. [22], p.117, in a study of 
mortality of disabled lives, found that: “injured worker mortality after some years comes 
close to standard mortality, and after some age may actually be lower. Because of this, not 
much credit can be taken on pension case reserves, even though for younger workers initial 
mortality is much higher than standard.”  Gillam [23] tested the hypothesis that the 
mortality of pensioned (disabled) workers differs significantly from that of the general 
population.  It does appear that, at least for ages below 60, the reported injured worker 
mortality rate is higher than standard U.S. Life.  Between age 60 and 74 the injured worker 
mortality rate does not differ appreciably from U.S. Life.  The differences in mortality, 
even if accepted, do not imply significant redundancy or inadequacy of tabular reserves. 
The data for our study comes from one such excess insurance pool, operated by an 
entity called California State Association of Counties Excess Insurance Authority (CSAC-
EIA).  CSAC-EIA is the excess insurer (similar to a reinsurer) for many self-insured 
California government agencies and bodies, such as municipalities, police forces, fire 
departments, school boards, etc.  The conclusion of our study is that the mortality of 
disabled lives in the study population is higher than that of the U.S. Life table (the standard 
table required by the California regulator).  The difference between our conclusion and the 
CAS studies referenced may be due to population differences (including more recent data) 
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or because we focus only on permanently disabled workers, rather than all disabled 
workers.   
3.3 Workers Compensation Reserves 
In California, the state regulator requires that case reserves for medical losses be calculated 
as the product of an estimate of future life expectancy of the claimant (based on a standard 
population mortality table) and the average of past costs.  Our hypothesis for the published 
study was that the use of a standard population mortality table (as required by the 
California regulator) over-estimates the life expectancy of disabled workers, and, thus, the 
case reserves for future medical payments.   
3.4 Author contributions to this paper 
Ian Duncan: Hypothesis, study design, data acquisition, summarization of results and paper 
authorship. 
Janet Duncan: Workers compensation technical input. 
Roberto Molinari: Review of statistical methods; MICE routine for estimation of missing 
data. 
Nhan Huynh: programming and modelling in R.  
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Chapter 3: Addendum 
 
This addendum is intended to supplement the published work in the main part of Chapter 3.    
A.1  Missing Data 
 
A problem in any study is that of missing data.  Several methods exist to address missing 
data; because the sample in this case was relatively small and the missing values for gender 
were a non-trivial percentage of all observations, we did not remove observations.  
Methods for addressing missing data when observations are not removed include 
replacement by the mean, median or mode, or imputation with the last (or next) value of 
the missing variable.  For this study we focus on values of one missing variable, gender, 
and apply an imputation method.  
 
Multiple imputation has become increasingly popular for handling missing data in 
epidemiologic analysis.  Initially, statistical models are used to obtain plausible substitutes 
for missing values, with the imputation process being repeated several times to allow for 
the uncertainty in the missing values. Analytic results are then obtained by combining the 
results of standard complete-data analyses across the multiple completed data sets in an 
appropriate manner (Lee and Carlin, [24]).  Missing values are imputed based on observed 
values for an individual and relations observed in other data for other participants. (Azur et 
al. [25]).  Multiple imputation involves creating multiple predictions for each missing value 
on a variable-by-variable basis using logistic models for each variable and assuming that 
the gender values are MCAR (missing completely at random).  The R package used for this 
analysis performs five iterations of the routine [26]and combines estimates using Rubin’s 
rules [27].  Table AA3.1 shows a comparison of gender distribution before and after 
imputation.   
 
 Missing Values Females Males 
Without imputation 19% 32% 49% 
With imputation  59% 41% 
 
Table AA 3.1  Gender Distribution Before and After Imputation 
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A.2  Data 
 
Imputation has led to a higher number of female claimants than males; with imputation, 
females are now 60% of the group.  This change in gender distribution as a result of 
imputation helps to explain the differences between Cox regression models applied to the 
non-imputed and imputed datasets.   
 
At the suggestion of a reviewer Table 3.3 (Grouping of entity variables) has been re-sorted 
according to median survival time.  There is some similarity between entities at different 
levels: for example level 4 (longest median survival time) consists of a number of heavy 
manual occupations (fire, emergency, construction).  These entities have the longest median 
survival time, possibly because they claim at an earlier age.   
Original levels 
Median 
survival 
time using 
KM 
Updated 
levels 
using KM 
(6)    Fire and emergency services 5.279 4 
(4)    Construction and building services 4.559 4 
(5)    Education 4.507 4 
(9)    Police, corrections, and security 4.425 4 
(7)    General government 4.348 3 
(11)  Sanitation and waste collection 4.332 3 
(8)    Health and medical services 4.205 3 
(3)    Community services 4.107 3 
(10)  Recreation and resource protection 3.800 2 
(12)  Transportation and transit 3.797 2 
(1)    Agriculture and farming 3.564 2 
(15)   Water and water conservation 3.512 1 
(14)   Utilities and power 3.479 1 
(2)    Animal and vector control 3.351 1 
(13)  Unknown/Other group 2.830 1 
 
 Table AA3.2: Grouping of Entity Variables 
Grouping of Cause of Loss 
There does not appear to be a natural grouping of causes of loss.  Therefore in table AA3.3 
we group cause of loss by median survival time.   
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Original level  
Median survival 
time using KM 
Group 
(6)      CL6: Explosion or flare back 5.178 4 
(2)      CL2: Animal or insect 4.893 4 
(16)    CL16: Strain 4.474 4 
(17)    CL17: Strike 4.356 4 
(7)      CL7: Fall 4.274 4 
(13)    CL13: Person in act of a crime 4.274 4 
(1)      CL1: Absorption, ingestion, or inhalation 4.211 3 
(3)      CL3: Burn 4.192 3 
(9)      CL9: Machine or tool 4.181 3 
(10)    CL10: Miscellaneous 4.090 2 
(11)   CL11: Motor vehicle 3.978 2 
(8)      CL8: Fellow worker, patient, or other person 3.597 2 
(4)      CL4: Caught 3.493 2 
(5)      CL5: Cut 3.455 1 
(15)    CL15: Slipped 3.332 1 
(14)    CL14: Rubbed 2.745 1 
(12)    CL12: Natural disasters 1.268 1 
 
Table AA3.3: Grouping of Cause of Loss 
 
Grouping of body parts 
There are different ways to group body parts; they can be grouped by body system (e.g. 
body parts involving the head and neck could be clustered).  However, inspection of the 
median survival time by body part indicates different survival times for related body parts, 
and similar survival time for disparate parts.  We therefore elected to group by median 
survival time.   
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Original level (description with numeric code) 
Median 
survival 
time using 
KM 
Grouping 
(11)    facial bones -19 9.266 4 
(37)     heart -49 8.932 4 
(35)     spinal cord -47 6.888 4 
(50)     lumbar and/or sacral vertebrae -63 5.638 4 
(47)     lung -60 5.501 4 
(14)     disk (neck) -22 5.458 4 
(10)     other facial soft tissue -18 5.405 4 
(7)       nose -15 5.267 4 
(31)     disc trunk -43 5.266 4 
(54)     multiple body parts -90 5.227 4 
(29)     upper back area -41 5.219 4 
(5)       ear(s) -13 5.132 4 
(2)       multiple head injury -10 5.063 4 
(17)     soft tissue neck -25 5.044 4 
(39)     hip -51 4.932 3 
(30)     lower back area -42 4.877 3 
(36)     internal organs -48 4.753 3 
(12)     multiple neck injury -20 4.668 3 
(55)     body system and multi. body systems -91 4.611 3 
(13)     vertebrae -21 4.600 3 
(28)     multiple trunk -40 4.532 3 
(15)     spinal cord -23 4.429 3 
(18)     multiple upper extremities -30 4.375 3 
(33)      sacrum and coccyx -45 4.359 3 
(38)      multiple lower extremities -50 4.348 3 
(22)      wrist -34 4.274 3 
(45)      toe(s) -57 4.258 3 
(41)      knee -53 4.249 3 
(27)      wrist(s) and hand(s) -39 4.195 2 
(52)      insufficient info to identify/unclass -65 4.085 2 
(23)      hand -35 4.06 2 
(26)      shoulder(s) -38 3.929 2 
(34)      pelvis -46 3.868 2 
(9)        mouth -17 3.83 2 
(3)        skull -11 3.816 2 
(44)      foot -56 3.674 2 
(21)      lower arm -33 3.658 2 
(19)      upper arm incl. clavicle and scapula -31 3.644 2 
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(32)      chest -44 3.534 2 
(43)      ankle -55 3.501 2 
(20)      elbow -32 3.438 2 
(48)      abdomen incl. groin -61 3.321 2 
(25)      thumb -37 3.096 1 
(1)        other -9 3.074 1 
(40)      upper hip -52 3.066 1 
(49)      buttocks -62 2.992 1 
(56)      whole body -99 2.978 1 
(6)        eye(s) -14 2.964 1 
(42)      lower hip -54 2.921 1 
(24)      finger(s) -36 2.803 1 
(4)        brain -12 2.773 1 
(53)      no physical injury -66 2.721 1 
(51)      artificial appliances (braces, etc.) -64 2.452 1 
(8)        teeth -16 1.996 1 
(16)      larynx -24 1.956 1 
(46)      great toe -58 1.508 1 
 
Table AA3.5: New Grouping of Body Parts in Imputed Data 
 
Final Model Selection 
 
ANOVA tables are provided to display the sequential analysis of the deviance of our final 
models.  That is, we test the significance of the reduction in the model log-likelihood when 
the covariates are added sequentially to the model.  The likelihood ratio test is employed as 
the models are nested. Note that the NULL covariates within a model mean that that model 
does not have covariates and that the predicted values are simply the average within the 
data.  
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Covariates Log-
likelihood 
Chi-squared 
Statistics 
Degrees of 
freedom 
p-value 
Null -73030    
Age at Date of Loss -73011 38.2591 1 0.000 
Body -72736 548.0979 3 0.000 
Cause of Loss -72727 18.5789 1 0.000 
Severity -72635 177.6585 1 0.000 
Sex -72635 7.3075 1 0.007 
Years employed -72616 38.2910 1 0.000 
Age at DOL: Sex -72604 23.4909 1 0.000 
Body: Cause of Loss -72595 18.2113 9 0.033 
 
Table AA 3.6: ANOVA for the final model with imputed data 
 
Covariates Log-
likelihood 
Chi-squared 
Statistics 
Degrees of 
freedom 
p-value 
Null -75694    
Entity 75631 -127.1092 3 0.000 
Age at Date of Loss -75610 40.7316 1 0.000 
Body -75373 474.8634 3 0.000 
Cause of Loss -75296 10.7016 3 0.000 
Severity -75296 143.1253 1 0.000 
Sex -75292 7.3213 1 0.007 
Years employed -75280 23.7520 1 0.000 
Severity: Sex -75267 27.7000 1 0.000 
Entity: Sex -75259 14.0961 3 0.003 
Body: Cause of Loss -75249 21.6641 9 0.010 
 
Table AA 3.7  ANOVA for the final model without imputed data 
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A.3  Model Interpretation 
 
 
 
 
 
 
 
 
 
 
Figure AA 3.1  Effect of the Interaction Terms in the Final Model with Imputed Data 
 
We provide examples to understand the effect on the hazard rates of interaction terms 
between covariates.  
 
Example 1:  Interpret the interaction between Age at DOL and Sex (continuous vs. 
categorical).  We fix the value for Years Employed (0.9), Severity (17.46), Entity group (3)  
Cause of Loss (4), Body Part (2) while letting Age at DOL vary between 40 and 60.  
Furthermore we compute  (
	)separately for Males and Females.  The interaction 
between Age at DOL and Sex suggests that the effect of Age at DOL on the hazards 
depends on the status of Sex.  Figure AA 3.1 shows that as we increase values of Age at 
DOL hazard decreases for Males but increases for Females.   
Example 2:  Interpret the interaction between Body Part and Cause of Loss (categorical vs. 
categorical).  Similar to Example 1, we fix the value for Years Employed (0.9), Severity 
(17.46), Entity Group (3), Age at DOL (28), Sex (Female) while computing (
	)   for 
each level of Body Part and Cause of Loss.  The second figure in AA 3.1 confirms that the 
effect of each level of Body Part on the hazard rate depends on which category of Cause of 
Loss  to which the claim  belongs.                                                                                              
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CHAPTER 4 - MEDICARE COST AT END-OF-LIFE 
4.1 Health Coverage for the Elderly in the United States 
This chapter serves as an introduction to the hospice setting of care, the experience of 
patients at end of life, and the cost of such patients to the healthcare system.  We are 
concerned with the cost of patients at the end of life, as paid by the United States (U.S.) 
Medicare system.  Elderly patients, 65 and older, are the responsibility, financially, of the 
Medicare system, administered by the U.S. Centers for Medicare and Medicaid Services 
(CMS).4  Although CMS is responsible for payment, care is actually delivered by private 
providers (doctors, hospitals, pharmacies, hospices etc.).  Medicare members may choose, 
on an annual basis, to be covered by traditional Medicare, which consists of Parts A 
(hospital), B (outpatient and professional), and D (prescription drugs), or by a managed 
care plan under Medicare Part C (Medicare Advantage).  Approximately one-third of 
Medicare-eligible persons elect Medicare Advantage coverage.  Traditional Medicare 
allows choice of provider, and providers are reimbursed on a fee-for-service basis.  
Medicare Part C consists of contracting Health Maintenance Organizations (HMOs), 
insurers that are reimbursed on the basis of a risk-adjusted premium per member per month.  
Risk adjustment results in modified payments, according to the expected costs of a patient’s 
long-term conditions.  Because the HMO takes risk for all services for its members, choice 
of providers is limited and often additional steps are required before medical services are 
obtained (a referral from a gate-keeping provider, for example).  For more information, see, 
for example, Kaiser Family Foundation [28].   
 The dataset on which the analysis in the accompanying paper is based is known as 
the Medicare 5% Limited Data Set (LDS) Analytical File or the “Medicare 5% file,” 
because it consists of a sample of 5% of all of Medicare’s reimbursed claims.  Researchers 
may purchase annual LDS files; patients are included, longitudinally, in the samples, so that 
patient experience may be followed over time.  Despite its name, the 5% LDS “file” 
actually consists of eight separate files: a denominator file that contains eligibility and 
demographic data and seven claims files, together with files for services performed in 
different facilities, reported separately (inpatient hospital, outpatient, skilled-nursing 
                                                           
4 In addition certain persons under age 65 who are deemed permanently disabled in terms of the Social 
Security Act are also eligible for Medicare coverage.  
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facility (SNF), home health, and hospice).  Finally, one file contains professional claims.  
The claim files consist of the clinical files (containing for example diagnoses and procedure 
codes) and revenue files, containing cost of care information.  We have integrated all files 
into an analysis dataset.  In addition, there is an eligibility file (the “denominator” file), 
containing information on eligibility dates and demographics of sample members.    
Our available data consists of samples for 2015 and 2016.  Total Medicare 
enrolment in these two years was 55.3 million and 57.1 million, respectively [29].   Our 
analytical dataset consists of a random sample of Medicare’s claims for the two years, 
containing experience of approximately 2.9 million patients for each year, or approximately 
5% of Medicare’s total enrolment.  Approximately 30% of these patients are enrolled in 
managed care plans (Medicare Advantage Health Maintenance Organizations (HMOs, or 
pre-paid, capitated health insurance) and Preferred Provider Organizations, (PPOs, or 
groups of providers paid on a discounted fee-for-service basis)), leaving approximately 2.1 
million beneficiaries enrolled in “traditional Medicare5” and available for analysis.  We 
exclude members who have less than six months of eligibility in any year.  Our sample 
shows that 259,000 of the 5.8 million total patients (including Medicare Advantage 
patients) died in 2015-6, or 4.47%, a rate that is consistent with the Krumholz study [30] 
and Medicare’s published rate.    
4.2 End-of-Life Care in the United States 
The topic of care at the end of life is not a happy one.  It is too often expensive, painful, and 
fraught with complications involving medical practitioners, patients, their families, and 
caregivers.  In addition, in the United States, because patients are invariably elderly and 
covered by the Medicare system, these decisions affect the cost and financing of care.  
Table 4.1 shows the number of deaths in the U.S. in 2013, with the distribution by age.  The 
total budget for Medicare, net of premiums, and other expenses paid by beneficiaries in 
2016 was $685 billion U.S.6  The cost of care provided by Medicare for medical services of 
                                                           
5 Unlike Medicare Managed Care plans which impose varying degrees of managed care techniques such as 
pre-authorization, restricted networks, etc., patients in traditional Medicare are free to seek care from any 
willing provider, who is then reimbursed on a fee-for-service basis.  
6 https://www.hhs.gov/about/budget/budget-in-brief/cms/medicare/index.html#overview; accessed March 
2017.  
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patients in the last six months of life is believed to account for 25% to 30% of Medicare’s 
total spending.7 
 
 
Total no. deaths (US) 2013 2.6 million 
Deaths over 65 1.9 million 
Number of deaths in hospice8, 2013 1.1 million (42%) 
Deaths per 100,000 of population by age group  
65-74 1,802.1 
75-84 4,648.1 
85 and over 13,660.4 
 
Table 4. 1 U.S. Mortality 
 
With mortality heavily skewed toward elderly patients, and given the increased 
prevalence of different medical conditions as patients age, cost of care is likely to increase 
with increased age, and with increased proportions of “old-old” seniors in the population.  
Table 4.2 shows the cause of death for patients dying in the U.S. in 2013.  Slightly fewer 
than one-quarter of patients die from diseases of the heart and malignant neoplasms, both of 
which are conditions that can be chronic and require expensive treatment over time.  
As noted in the attached paper, the last six months of care for patients that die accounts for 
approximately 25% of Medicare’s expense in the last year of life.  Interestingly, these 
patients account for 13% of cost in the year prior to the last year of life, indicating that 
patients nearing the end of life account for a significant portion of Medicare’s total 
expense, particularly when we consider that fewer than 5% of Medicare members die 
annually.  According to Krumholz [30], the mortality rate of Medicare members was 4.45% 
in 2013.  In the attached paper, we report the mortality rate of the Medicare sample 
database.   
 
                                                           
7 Our paper, reproduced in this chapter, examines this belief and finds that it is an over-estimate of actual cost.  
8 In the United States “hospice” refers both to a type of service and a place of service.  As we discuss in 
Chapter 5, approximately two-thirds of patients receive hospice benefits in their own homes.   
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Rank Cause of death (based on ICD-10) Number Percent 
of total 
deaths 
2014 
crude 
death 
rate 
 All causes 2,626,418 100.0 823.7 
1 Disease of heart ……………………………...(ǀ00-ǀ09,ǀ11,ǀ13,ǀ20-ǀ51) 614,348 23.4 192.7 
2 Malignant neoplasms……………………...........................(C00-C97) 591,699 22.5 185.6 
3 Chronic lower respiratory diseases…………………………(J40-J47) 147,101 5.6 46.1 
4 Accidents (unintentional injuries)……………...(V01-X59,Y85-Y86) 136,053 5.2 42.7 
5 Cerebrovascular diseases…………………………………….(ǀ60-ǀ69) 133,103 5.1 41.7 
6 Alzheimer’s disease…………………………………………….(G30) 93,541 3.6 29.3 
7 Diabetes mellitus…………………………………………..(E10-E14) 76,488 2.9 24.0 
8 Influenza and pneumonia…………………………………...(J09-J18) 55,227 2.1 17.3 
9 Nephritis, nephrotic syndrome, and nephrosis…………….(N00-N07,            
N17-N19,N25-N27 
48,146 1.8 15.1 
10 Intentional self-harm (suicide)…………........(*U03,X60-X84,Y87.0) 42,773 1.6 13.4 
11 Septicaemia……………………………………………...(A40-A41) 38,940 1.5 12.2 
12 Chronic liver disease and cirrhosis………………......(K70,K73-K74) 38,170 1.5 12.0 
13 Essential hypertension and hypertensive renal disease…..(ǀ10,ǀ12,ǀ15) 30,221 1.2 9.5 
14 Parkinson’s disease………………………………………..(G20-G21) 26,150 1.0 8.2 
15 Pneumonitis due to solids and liquids…………………………...(J69) 18,792 0.7 5.9 
 All other causes……………………………………………..(residual) 535,666 20.4 168.0 
 
Table 4. 2 Cause of Death 2014 [31] 
 
It is usual, in the United States, to report medical costs on the basis of net paid 
claims cost per member, per month (abbreviated to PMPM).9  Each patient (“member”) in 
the dataset has a record of the beginning and end of the member’s exposure during the year.  
These dates could be the first of the year and the last day of the year for those members 
who were enrolled prior to the start of the year and did not leave during the year.  All 
exposure is incremented in months (because eligibility at the start of the month entitles the 
member to a full month of coverage).  For those members who “exit” the exposure is 
slightly over-stated.10  The numerator of the calculation is the total costs incurred by the 
members during the period (usually a year).   
Table 3, in the attached paper, contains the cost, per member, per month, of 
different types of medical service, incurred and reimbursed by Medicare, in the last three 
                                                           
9 In Medicare, as in other forms of U.S. insurance, all services that are to be reimbursed require the 
submission and adjudication of a claim. “Net Paid Claims” represent the portion of the approved claim that is 
the responsibility of the payer (in this case, Medicare), after exclusion of any ineligible services and deduction 
of patient responsibility (deductible and coinsurance).   
10 Exits during the year, other than by death are relatively infrequent.  Members may change between 
traditional Medicare and Medicare Advantage, but except in rare circumstances (such as a geographical 
move) this occurs at the start of the year.  A small fraction of members may leave the United States or 
otherwise lose their coverage during the year.  
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and six months of life.  The paper reports numbers only.  Figures 4.1 and 4.2 report costs, 
per member, per month, by place of death and by type of service.  Patients dying in an 
inpatient setting, unsurprisingly, incur the highest costs, while hospital costs are the most 
significant component of overall costs, even among patients who die in settings other than 
hospital.  
  
 
 
Figure 4. 1 Cost by Place of Death and Type of Service for Patients in Last Three Months 
of Life 
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Figure 4. 2 Cost by Place of Death and Type of Service for Patients in Last Six months of 
life 
4.3 Hospice 
As we saw above, about 40% of all deaths of Medicare-age persons in the United States 
take place in hospice.  In this section, we discuss the purpose and some of the benefits of 
hospice.  Beginning with the work of Dame Cecily Saunders in London, hospice is 
considered the model for compassionate care for people facing a life-limiting illness.  
Hospice provides palliative medical care, pain management, and emotional and spiritual 
support, tailored to the patient’s needs and wishes, as well as support to the patient’s 
family.  Hospice focuses on palliative, rather than curative care.  In most cases (about 
60%), care is provided in the patient’s home, but may also be provided in freestanding 
hospices, inpatient hospitals, nursing homes, and other long-term care facilities.  Hospice 
services are available to patients with any terminal illness, although the most frequent 
diagnoses are cancer and heart disease.  
One important feature of hospice care is that it is palliative, rather than curative.  
The hospice team develops a care plan that meets each patient’s individual needs for pain 
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management and symptom control.  This interdisciplinary team usually consists of the 
patient’s personal physician, hospice physician, or medical director, nurses, hospice aides, 
social workers, bereavement counsellors, clergy, or other spiritual counsellors, trained 
volunteers, and speech, physical, and occupational therapists, if needed.  In the United 
States in 2014, an estimated 1.6 to 1.7 million patients received services from hospice.  As 
shown in Figure 4.1, the number of patients and families served by hospice has steadily 
increased over the past several years.  The National Hospice and Palliative Care 
Organization (NHPCO) estimates that approximately 1,200,000 deaths occurred in the U.S. 
while under the care of hospice, or approximately 46% of all U.S. deaths.   
 The total number of days that a hospice patient receives care is referred to as the 
length of stay or length of service.  Length of stay can be influenced by a number of factors, 
including disease course, timing of referral, and access to care.  According to NHCPO, the 
median (50th percentile) length of stay in 2014 was 17.4 days.  This means that about half 
of hospice patients received care for fewer than 17 days and half received care for more 
than 17 days.  Because of long stays among a minority of patients, average length of stay 
was 71.3 days in 2014.  In 2014, 35.5% died or were discharged within seven days of 
admission, while 10.3% of patients had a length of stay of 180 days or more.  
 A goal of caregivers and, to some degree, CMS, (the payer for much of the care 
delivered in hospice for patients 65 and older) is to encourage earlier admission to hospice, 
because this reduces potentially futile care in inpatient and outpatient settings for patients 
who, otherwise, are at risk of early death.  At the same time, CMS has strict eligibility 
requirements for admission to hospice (see Appendix 4.1).  About 35% of patients are only 
in hospice less than one week, and, often, while the patient is actively dying and the family 
is in crisis.  Earlier encouragement of admission would result in longer median and average 
lengths of stay in hospice.  For hospice providers, more accurate estimates of life 
expectancy, for newly admitted patients, would allow the hospice to better plan for staffing, 
medication, and other needs of patients.  The prediction of life expectancy of hospice 
patients and, in particular, how their changing prescription drug use is a predictor of 
termination is one of the purposes of this study and is covered in Chapter 8.   
The hospice movement provides quality compassionate care at the end of life.  Hospice 
services consist of: 
 Pain and symptom management 
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 Maintenance of quality of life. 
 Emotional, psychosocial, and spiritual support. 
 Maintenance drugs, medical supplies, and equipment for palliation, but not acute 
drugs or equipment necessary to prolong life.  
 Speech or physical therapy, if needed. 
 Short-term inpatient care available, if needed (patient can be transferred back to the 
inpatient setting when acute services are required). 
 Instruction for the family on how to care for the patient.  
 Bereavement care and counselling 
There are generally four levels of hospice care: 
 Home-based care (“hospice at home”). 
o Routine home care: patient receives care at the patient’s home. 
o Continuous home care: care consisting predominantly of licensed nursing 
care on a continuous basis at home.  This is only for brief periods of crisis 
and only as necessary. 
 Inpatient care 
o General inpatient care: patient receives care in an inpatient facility for pain 
or acute/complex symptom control that cannot be managed in the home or 
nursing home setting. 
o Inpatient respite care: patient receives care in an approved facility on a short-
term basis in order to give respite to the caregiver. 
Hospice utilization in the U.S. is growing at a rate of about 5%, annually.  Figure 4.3 shows 
the growth in the number of patients served, by year, since 2009.   
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Figure 4. 3 Growth in Hospice Utilization by Year.  Source: NHPCO [32].   Admissions in 
2016 are the most recently-available.  
The length of stay in hospice is also highly skewed, with the median length of stay 
equal to 17.4 days in 2014.  The mean length of stay is 71.3 days, indicating the effect of 
outliers.  Over one-third of patients stay for less than seven days.  Figure 4.4 shows the 
distribution of hospice stay duration. 
 
 
 
Figure 4. 4 Distribution of Hospice Stay Durations in 2016.  Source: NHCPO [32]. 
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In summary, hospice provides palliative care for patients near the end of life.  
Patients who would do well in hospice tend to receive acute and invasive care, rather than 
palliative care.  How to provide education for patients and their families about the benefits 
of hospice remains a significant issue within a system in which patients are accustomed to 
receiving unlimited access to world-class care.   
4.4 End of Life Costs 
As we discuss in the following paper, care delivered to patients at end of life is often costly 
(particularly when delivered in an inpatient setting) and frequently futile.  Our analysis of 
the Medicare LDS data shows that patients who die in hospital cost on average nearly 
$6,000 per day, compared with $231 per day, if the patient were to die in hospice (paper, 
Table 5).  Encouraging greater use of hospice would result in better-quality care for the 
patient and reduced costs for Medicare.  
4.5 Author Contributions to this paper 
Ian Duncan: conception; data acquisition; analysis design; paper drafting. 
Terri Maxwell: hospice and palliative care technical details 
Henry Dove:  literature review 
Tamim Ahmed: programming and analysis of the Medicare LDS file.  
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CHAPTER 5 - HOSPICE DATA SET 
This chapter covers the hospice dataset on which the modelling, in this part of the thesis, is 
based.  Our objective, in this part of the thesis, is two-fold: to model the rate at which drugs 
are deprescribed (patient weaning) and to predict expected future length of stay (or 
expected future lifetime) of patients admitted to hospice, as a function of admitting 
diagnosis, co-morbidities, drug regimens, and changes in regimen (drug/dosage/drug form).   
These problems are appropriate for survival modelling, as discussed, in theory, in Chapter 
2. 
The source of the data is Enclara Pharmacia Inc. a large national hospice pharmacy 
benefit manager (PBM).  In the United States, because there is neither a national 
formulary11, nor regulated drug prices, PBMs play an intermediary role between payers 
(insurers, employers or, in this case, Medicare) providers, and patients.  PBMs define 
formularies for payers and negotiate pricing with drug companies.  They will often supply 
the drugs as well, through a mail-order facility.  The PBM is also the intermediary through 
which all drug-related financial transactions flow, resulting in a unique database of 
complete prescription records for hospice patient drugs.  
5.1 Data Source 
Data used for this study come from a single-source clinical and administrative database, 
provided by Enclara Pharmacia Inc. (EP) that contains information about clinical outcomes 
and medical resource use for persons who receive hospice care.  EP is a Philadelphia, 
Pennsylvania-based company that provides telephonic support and pharmacy services to 
hospice patients.  EP currently provides service to over 800 hospices in 49 states, 
overseeing medication therapy for more than 85,000 patients daily.  EP maintains a 
comprehensive and continuously updated administrative database for all patients.  Data are 
routinely collected as part of the pharmacy care process, including demographic variables, 
drug prescription information, and characteristics of hospice programs rendering services.  
Permission to use the EP data for this study was given by the Executive Vice President and 
                                                           
11 A formulary is a listing of approved drugs; in the U.S. PBMs construct different formularies. While the 
inclusion of a drug on the formulary means that the drug will be reimbursed by insurance, formularies also 
have different “tiers” that determine the level of patient cost-sharing for each drug.  
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Chief Development officer of EP.  Ethics approval for this study was given by Heriot-
Watt’s Ethics committee.   
5.2 Data Source 
A nurse, or hospice representative, records the data, including all medication information, 
in a patient profile in EP’s computer system.  This study includes patient demographic data 
recorded during telephone calls, such as date of birth, sex, race, diagnosis, select 
medication information, and discharge status.  Data are collected for all patients during 
each telephone encounter between pharmacists and nurses, including all patient 
demographic information, any changes in medication or care setting, clinical assessment 
information, and discharge status, beginning with the hospice admission and continuing 
until the patient is either discharged from hospice or dies.  In general, a hospice nurse visits 
the patient every few days, or more often, as the patient’s condition warrants.  
Validation of the dataset has been demonstrated in published studies [33, 34].  
These studies of patients in the EP dataset (N = 356,760), between February 1, 2000 and 
July 26, 2004, found a high level of accuracy in the data: 0.1% of patients were listed with 
a negative age on admission, 0.2% with a discharge date before admission date, 0.2% 
missing an admission date, and 0.1% with a negative length of stay.  Because patient 
records are matched to billing data, variables such as admission date, discharge status (died 
vs. discharged and associated dates), hospice affiliation, and hospice location (state and zip 
code) are reliable.  Internal quality checks at EP have found medication-related information 
to be very reliable; however, these data are dependent upon the nurse communicating a 
complete medication profile for each patient, otherwise drug use could be underestimated.  
If the hospice nurse fails to provide a complete list of medications to the EP pharmacist, 
medications will be missing from the patient profile, which is a potential limitation of the 
study.  Raw data files were provided by EP in MS Excel.  Analysis was performed in Excel 
and R.  After being reformatted, the data were checked by performing descriptive and 
summary statistics, such as ranges, means, and frequency distributions, to identify outliers, 
such as negative age, age > 110, negative length of stay, and duplicate identifiers.
 Representatives of EP also assisted with data validation, interpretation, and 
mapping of drug classes.  The comparability of the EP dataset to other national estimates 
from the National Home and Hospice Care Survey (NHCCS) and the National Hospice and 
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Palliative Care Organization (NHPCO), indicates that this dataset is a generally 
representative sample of persons who receive hospice care.   
5.3 Patient variables 
The patient’s age was calculated from the date of birth at the time of admission.  Sex was 
recorded as either male or female and was provided by the hospice staff at the time of 
admission to hospice.  The patient’s diagnosis was the medical diagnosis responsible for 
the admission of the patient on hospice, recorded as ICD-9 or ICD-10 codes, depending 
whether date of admission was prior to, or after, October 1st 201512.  There is no missing 
demographic data, although it is possible that there is missing drug data (for example, for 
any prescription medications in possession of the patient at the time of admission).  
Prescriptions ordered and filled after admission must be recorded as a requirement of 
patient care.    
 Patient status was indicated as “active” at the time of admission and remained active 
until the patient was reported as “discharged” or “deceased,” and recorded accordingly.  
Hospice length of stay described the total number of continuous days of service from 
admission to discharge, including both the admission and discharge days.  The length of 
hospice stay was calculated as the number of days from when the patient was accepted for 
coverage by the hospice organization (start coverage date) to the date when the hospice 
organization was no longer responsible for the patient services (stop coverage date).  
Length of stay was calculated as a continuous variable.   
 The patient profile contained a list of all medications, regardless of whether or not 
EP supplied them; therefore, drugs from other sources (such as a local pharmacy), outside 
of EP were included.   
5.4 Dataset 
Our dataset consists of three main categories of data: demographic, clinical, and drug data.   
Demographic data includes age and sex, as well as date of admission to hospice and date of 
death.  Clinical data includes admitting diagnosis and co-morbidities.  Finally, the drug data 
includes all prescriptions with drug name, dose, days’ supply, and average wholesale price 
of the drug.   
                                                           
12 The U.S. adopted the ICD-10 classification system with effect from October 1, 2015.  
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5.4.1 Demographic data 
Data were available from 2014 to 2017, inclusive of 499,277 participants.  Table 5.1 shows 
the distribution of members, by year of admission, together with numbers of patients alive 
and deceased.  Designation of “active” status (alive) is made at May 5, 2018.  All members 
are recorded at first admission to hospice, so there is no issue with left truncation of the 
observations.  Some right censoring of observations occurs; of the 499,264 admitted 
patients, 26,463 remain alive at the extract date of the data (May 2018).    
 
 
Year Female Male Total  Subtotal by 
Year Active13 Deceased Active Deceased Active Deceased 
2014 40 39,671 19 27,582 59 67,253 67,312 
2015 140 42,730 55 31,350 195 74,080 74,275 
2016 3,041 63,949 1,149 44,490 4,109 108,439 112,629 
2017 14,957 124,848 7,062 98,181 22,019 223,029 245,048 
Subtotal 
by Year, 
Sex, and 
Status 
18,178 271,198 8,285 201,603 26,463 472,801 499,264 
 
Table 5. 1 Patients in Hospice by Year of Admission 
 
Patients in table 5.1 represent those 499,264 patients for whom we have 
demographic data, as well as drug data, in their records.  In the data summary, in table 5.1, 
years prior to 2016 have relatively few surviving patients, as of May 2018.  The fact that 
2015-6 admission years still have patients who are alive is somewhat problematic, although 
it is not uncommon for hospice patients to survive more than six months, despite the 
expectation of a stay of 180 days or fewer in hospice.  Patients with hospice benefits are 
confined in different settings (home, nursing home, assisted living facility (ALF), and 
hospital inpatient).  Table 5.2 shows the number and distribution of patients by setting of 
care.    
 
 
 
                                                           
13 Still alive at May 5th, 2018.  
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Year 
Assisted 
Living 
Homecare Inpatient 
Long-Term 
Care14 
Total 
2014 429 47,956 2,133 16,777 67,295 
2015 354 53,352 2,238 18,317 74,261 
2016 3,129 72,865 3,344 33,282 112,620 
2017 8,696 153,648 7,597 75,109 245,050 
Total 12,608 327,821 15,312 143,485 499,226 
Year 
Assisted 
Living 
Homecare Inpatient 
Long-Term 
Care 
Total 
2014 0.6% 71.3% 3.2% 24.9% 100.0% 
2015 0.5% 71.8% 3.0% 24.7% 100.0% 
2016 2.8% 64.7% 3.0% 29.6% 100.0% 
2017 3.5% 62.7% 3.1% 30.7% 100.0% 
Total 2.5% 65.7% 3.1% 28.7% 100.0% 
 
Table 5. 2 Distribution of Patients by Care Setting 
 
The majority of patients receive hospice care, either in their own home or in a 
nursing home (care home, or other long-term care facility).  Only a very small proportion of 
all hospice patients receive benefits while in an inpatient hospital or assisted-living facility.  
The small number of patients receiving hospice care in the inpatient setting may appear 
contradictory with the literature that shows the scope of futile care delivered in the inpatient 
setting.  However, it should be remembered that patients receiving inpatient critical care are 
almost invariably covered by traditional Medicare (even if the care represents services at 
end of life).  It is very rare for a patient who has been accepted for Medicare hospice 
benefits to be re-admitted to an acute inpatient setting.   
5.4.1.1 Patient age   
Patient age at admission is, as one would expect, heavily skewed to older ages.  Table 5.3 
shows the distribution of age at admission for 2015 admissions.   
                                                           
14 Long-term Care settings are care homes that include assisted-living and nursing care.  Assisted living 
facilities are generally step-down facilities where ambient patients receive assistance with daily activities.  
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Age at 
Admission 
Female Male Total Total 
Active Deceased Active Deceased Active Deceased  
Age < 5 0 66 0 66 0 132 132 
6 < Age < 21 1 71 0 115 1 186 187 
22 < Age < 34 1 130 0 148 1 278 279 
35 < Age < 50 2 1,100 2 906 4 2,006 2,010 
51 < Age < 64 9 4,670 9 4,986 18 9,656 9,674 
65 < Age < 74 14 6,874 18 6,774 32 13,648 13,680 
75 < Age < 79 17 4,530 9 4,007 26 8,537 8,563 
80 < Age < 84 23 5,950 4 4,659 27 10,609 10,636 
85 < Age < 89 31 7,797 8 4,968 39 12,765 12,804 
Age > 89 42 11,542 5 4,721 47 16,263 16,310 
Subtotal by 
Age and Sex 
140 42,730 55 31,350 195 74,080 74,275 
Age at 
Admission 
Female Male Total Total 
Active Deceased Active Deceased Active Deceased  
Age < 5 0.0% 0.1% 0.0% 0.1% 0.0% 0.2% 0.2% 
6 < Age < 21 0.0% 0.1% 0.0% 0.2% 0.0% 0.3% 0.3% 
22 < Age < 34 0.0% 0.2% 0.0% 0.2% 0.0% 0.4% 0.4% 
35 < Age < 50 0.0% 1.5% 0.0% 1.2% 0.0% 2.7% 2.7% 
51 < Age < 64 0.0% 6.3% 0.0% 6.7% 0.0% 13.0% 13.0% 
65 < Age < 74 0.0% 9.3% 0.0% 9.1% 0.0% 18.4% 18.4% 
75 < Age < 79 0.0% 6.1% 0.0% 5.4% 0.0% 11.5% 11.5% 
80 < Age < 84 0.0% 8.0% 0.0% 6.3% 0.0% 14.3% 14.3% 
85 < Age < 89 0.0% 10.5% 0.0% 6.7% 0.1% 17.2% 17.2% 
Age > 89 0.1% 15.5% 0.0% 6.4% 0.1% 21.9% 22.0% 
Subtotal by 
Age and Sex 
0.2% 57.5% 0.1% 42.2% 0.3% 99.7% 100.0% 
 
Table 5. 3 Distribution of Age and Sex at Admission: 2015 Admissions 
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Age at 
Admission 
Female Male Total Total 
Active Deceased Active Deceased Active Deceased  
Age < 5 6 64 6 72 12 136 148 
6 < Age < 21 7 77 6 118 13 195 208 
22 < Age < 34 6 150 7 156 13 306 319 
35 < Age < 50 23 1,168 21 956 44 2,124 2,168 
51 < Age < 64 127 5,710 114 5,933 241 11,643 11,884 
65 < Age < 74 248 8,732 208 9,046 456 17,778 18,234 
75 < Age < 79 285 6,439 137 5,686 422 12,125 12,547 
80 < Age < 84 459 8,889 189 6,870 648 15,759 16,407 
85 < Age < 89 699 12,093 223 7,621 922 19,714 20,636 
Age > 89 1,181 20,627 238 8,032 1,419 28,659 30,078 
Subtotal by 
Age and Sex 
3,041 63,949 1,149 44,490 4,190 108,439 112,629 
Age at 
Admission 
Female Male Total Total 
Active Deceased Active Deceased Active Deceased  
Age < 5 0.0% 0.1% 0.0% 0.1% 0.0% 0.1% 0.1% 
6 < Age < 21 0.0% 0.1% 0.0% 0.1% 0.0% 0.2% 0.2% 
22 < Age < 34 0.0% 0.1% 0.0% 0.1% 0.0% 0.3% 0.3% 
35 < Age < 50 0.0% 1.0% 0.0% 0.8% 0.0% 1.9% 1.9% 
51 < Age < 64 0.1% 5.1% 0.1% 5.3% 0.2% 10.3% 10.6% 
65 < Age < 74 0.2% 7.8% 0.2% 8.0% 0.4% 15.8% 16.2% 
75 < Age < 79 0.3% 5.7% 0.1% 5.0% 0.4% 10.8% 11.1% 
80 < Age < 84 0.4% 7.9% 0.2% 6.1% 0.6% 14.0% 14.6% 
85 < Age < 89 0.6% 10.7% 0.2% 6.8% 0.8% 17.5% 18.3% 
Age > 89 1.0% 18.3% 0.2% 7.1% 1.3% 25.4% 26.7% 
Subtotal by 
Age and Sex 
2.7% 56.8% 1.0% 39.5% 3.7% 96.3% 100.0% 
 
Table 5. 4 Distribution of Age and Sex at Admission: 2016 Admissions 
 
5.4.1.2 Age at death  
Consistent with age at admission and length of stay, age at death is also heavily skewed to 
older ages.  Figures 5.1 and 5.2 show age at death for 2015-2016 admissions. 
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Figure 5. 1 Age of Death: 2015 Admissions 
 
 
 
Figure 5. 2 Age at Death: 2016 Admissions 
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5.4.2 Clinical data 
5.4.2.1 Cause of admission  
Approximately 74% of patients are admitted with a primary diagnosis of one of ten 
conditions, primarily dementia, cancer, and heart disease.  Stroke, COPD, and Parkinson’s 
diseases are also prevalent.  Table 5.5 shows the distribution of the ten most common 
admitting conditions.  Diagnoses, both admitting (primary) diagnoses and co-morbidities, 
are recorded as part of the hospice patient record.  Diagnoses are coded using the ICD-9 
system (until September 30, 2015) and ICD-10 system (October 1, 2015 and later).  We 
address the large number of diagnosis codes (approximately 15,000 in the ICD-9 system 
and 80,000 in the ICD-10 system) by grouping conditions into diagnostic categories, called 
hierarchical condition categories (HCCs).  The HCC system15 was developed for CMS and 
is used by CMS, and most commercial health plans, for (among other purposes) 
reimbursement in a risk adjusted revenue transfer system.  For a detailed discussion about 
the development, structure, and use of the HCC system, see Duncan [35].  In total, there is 
provision for 189 HCCs (although CMS only uses 86 of these) and the system provides a 
simple way of aggregating and displaying patient records, according to their primary 
diagnoses, without having to create and maintain algorithms to group multiple diagnosis 
codes.  In addition to grouping by HCCs we also group HCCs into “super” condition 
categories for some analyses; the HCC mapping into these categories is described in 
Appendix 6.8.   
 
 
 
  
                                                           
15 See Appendix 5.6 for a detailed discussion of CMS’s HCC grouper model. 
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 2015 2016 
Diagnosis Female Male Total Female Male Total 
Lung and Other Severe Cancers16 6,881 6,779 13,660 8,712 9,222 17,934 
Dementia without Complication 5,878 2,306 8,184 12,631 4,608 17,239 
Congestive Heart Failure 4,030 2,948 6,978 7,615 5,447 13,062 
Breast, Prostate, and Other Cancers 
and Tumours 
3,609 2,438 6,047 4,309 3,241 7,550 
Colorectal, Bladder, and Other 
Cancers 
2,282 2,419 4,701 3,519 3,678 7,197 
COPD 3,002 2,017 5,019 4,493 3,038 7,531 
Cerebrovascular Disease 1,578 744 2,322 4,999 1,908 6,907 
Lymphoma and Other Cancers 1,778 967 2,745 2,855 1,764 4,619 
Ischaemic and Unspecified Stroke 1,580 772 2,352 2,585 1,298 3,883 
Heart Disease 1,094 720 1,814 1,570 1,098 2,668 
Subtotal by condition 31,712 22,110 53,822 53,288 35,302 88,590 
Total (all conditions) 42,870 31,405 74,275 66,990 45,639 112,629 
Top 10 Dx as % of all patients 74.0% 70.4% 72.5% 79.5% 77.4% 78.7% 
 2015 2016 
Diagnosis Female Male Total Female Male Total 
Lung and Other Severe Cancers 16.1% 21.6% 18.4% 13.0% 20.2% 15.9% 
Dementia without Complication 13.7% 7.3% 11.0% 18.9% 10.1% 15.3% 
Congestive Heart Failure 9.4% 9.4% 9.4% 11.4% 11.9% 11.6% 
Breast, Prostate, and Other Cancers 
and Tumours 
8.4% 7.8% 8.1% 6.4% 7.1% 6.7% 
Colorectal, Bladder, and Other 
Cancers 
5.3% 7.7% 6.3% 5.3% 8.1% 6.4% 
COPD 7.0% 6.4% 6.8% 6.7% 6.7% 6.7% 
Cerebrovascular Disease 3.7% 2.4% 3.1% 7.5% 4.2% 6.1% 
Lymphoma and Other Cancers 4.1% 3.1% 3.7% 4.3% 3.9% 4.1% 
Ischaemic and Unspecified Stroke 3.7% 2.5% 3.2% 3.9% 2.8% 3.4% 
Heart Disease 2.6% 2.3% 2.4% 2.3% 2.4% 2.4% 
Subtotal by condition 74.0% 70.4% 72.5% 79.5% 77.4% 78.7% 
Total (all conditions) 42,870 31,405 74,275 66,990 45,639 112,629 
 
Table 5. 5 Patients by Top 10 Primary Diagnosis in 2015 and 2016 
 
For some later analysis, the relative distribution of primary diagnosis, by sex, will 
be important.  Table 5.6 shows the distribution of some major diagnostic categories, by sex.  
                                                           
16 “Other Cancers” is a collective term used by the developer of the HCCs (CMS) because of the number of 
different diagnoses included.  More detail is provided in Appendix B.   
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A key implication of these tables is that males are more likely to suffer from cancers and 
less likely to suffer from stroke or dementia than females.   
 
 Female  Male  Total  Total 
Condition Active Deceased Active Deceased Active Deceased  
Cancers 13.8% 46.0% 36.6% 57.0% 20.0% 50.5% 50.4% 
Dementia 63.3% 18.4% 26.8% 10.4% 53.3% 15.1% 15.2% 
Cardiac 8.3% 16.2% 22.0% 16.6% 12.0% 16.3% 16.3% 
Lung 5.5% 9.5% 9.8% 9.1% 6.7% 9.3% 9.3% 
Cerebrovascular and Stroke 9.2% 10.0% 4.9% 6.9% 8.0% 8.7% 8.7% 
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 Female  Male  Total   
Condition Active Deceased Active Deceased Active Deceased Total 
Cancers 9.6% 37.7% 23.4% 51.4% 13.2% 43.2% 42.1% 
Dementia 35.7% 23.1% 19.5% 12.9% 31.4% 19.0% 19.5% 
Cardiac 15.9% 17.3% 22.0% 18.5% 17.5% 17.8% 17.8% 
Lung 7.9% 8.5% 12.1% 8.5% 9.0% 8.5% 8.5% 
Cerebrovascular and Stroke 31.0% 13.4% 23.0% 8.7% 28.9% 11.5% 12.2% 
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Table 5. 6 Distribution of Major Diagnostic Categories by Sex, 2015 and 2016 
 
Condition 
Category 
Diagnosis(es) 
HCC52 Dementia Without Complication 
HCC85 Congestive Heart Failure 
HCC111 Chronic Obstructive Pulmonary Disease 
HCC9 Lung and Other Severe Cancers 
HCC8 Metastatic Cancer and Acute Leukaemia 
HCC96 Specified Heart Arrhythmias 
HCC19 Diabetes without Complication 
HCC100 Ischemic or Unspecified Stroke 
HCC12 Breast, Prostate, and Other Cancers and Tumours 
HCC11 Colorectal, Bladder, and Other Cancers 
HCC10 Lymphoma and Other Cancers 
HCC78 Parkinson’s and Huntington’s Diseases 
HCC21 Protein-Calorie Malnutrition 
HCC48 Coagulation Defects and Other Specified Haematological Disorders 
HCC141 Nephritis 
HCC108 Vascular Disease 
HCC79 Seizure Disorders and Convulsions 
HCC28 Cirrhosis of Liver 
HCC2 Septicaemia, Sepsis, Systemic Inflammatory Response Syndrome/Shock 
HCC18 Diabetes with Chronic Complications 
 
Table 5. 7 Diagnoses and Hierarchical Condition Categories (HCCs) 
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Tables 5.8 through 5.11 show distributions, by sex, and admitting diagnosis of 
frequencies of duration, from admission to death. 
 
 Female 
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 
90-
179 
≥ 180 Total 
Dementia Without Complication 243 544 755 842 891 546 834 1,223 5,878 
Lung and Other Severe Cancers 391 880 1,161 1,512 1,422 652 607 256 6,881 
Congestive Heart Failure 286 489 570 672 688 334 523 468 4,030 
Breast, Prostate, and Other Cancers 
and Tumours 
216 445 606 743 689 335 372 203 3,609 
COPD 240 360 384 438 500 276 428 376 3,002 
Cerebrovascular Disease 59 159 246 256 261 149 240 208 1,578 
Colorectal, Bladder, and Other 
Cancers 
122 244 359 483 499 200 248 127 2,282 
Lymphoma and Other Cancers 97 192 307 391 364 168 170 89 1,778 
Ischemic or Unspecified Stroke 123 256 267 248 217 101 190 178 1,580 
Heart Disease 74 110 148 174 167 103 150 168 1,094 
Protein-Calorie Malnutrition 21 61 97 93 85 51 70 54 532 
Parkinson's and Huntington's 
Diseases 
8 20 23 47 45 19 40 51 253 
Metastatic Cancer and Acute 
Leukaemia 
39 59 84 83 83 28 37 18 431 
Cirrhosis of Liver 20 52 85 65 58 34 29 19 362 
Unspecified Renal Failure 44 89 87 59 48 20 22 26 395 
Chronic Kidney Disease 6 13 9 8 7 1 5 9 58 
Lung Disease 37 41 37 36 19 17 12 17 216 
Neoplasm 15 27 44 72 80 33 36 9 316 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
42 39 36 29 22 15 7 12 202 
Fibrosis of Lung and Other Chronic 
Lung Disorders 
21 35 33 41 39 37 40 42 288 
Subtotal by Condition 2,669 5,219 6,624 7,721 7,542 3,778 4,979 4,338 42,870 
Discrete Mortality Frequency 6.2% 12.2% 15.5% 18.0% 17.6% 8.8% 11.6% 10.1% 100% 
Cumulative Mortality Frequency 6.2% 18.4% 33.9% 51.9% 69.5% 78.3% 89.9% 100% 100% 
 
Table 5. 8 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Female) 
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Condition Categories 
Female 
0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥ 180 Total 
Dementia Without Complication 432 836 1,069 1,362 1,488 1,026 2,006 4,412 12,631 
Lung and Other Severe Cancers 545 1,077 1,424 1,718 1,663 795 876 614 8,712 
Congestive Heart Failure 447 775 934 1,046 1,112 640 1,083 1,578 7,615 
Breast, Prostate, and Other Cancers and Tumours 247 503 722 798 762 392 470 415 4,309 
COPD 268 425 461 556 639 403 697 1,044 4,493 
Cerebrovascular Disease 120 282 350 486 509 350 776 2,126 4,999 
Colorectal, Bladder, and Other Cancers 188 407 550 688 654 322 397 313 3,519 
Lymphoma and Other Cancers 136 321 508 569 538 250 285 248 2,855 
Ischemic or Unspecified Stroke 178 378 351 308 282 180 337 571 2,585 
Heart Disease 57 113 166 181 200 124 236 493 1,570 
Protein-Calorie Malnutrition 36 75 126 176 166 96 208 310 1,193 
Parkinson's and Huntington's Diseases 34 83 93 155 181 128 252 552 1,478 
Metastatic Cancer and Acute Leukaemia 67 102 129 153 110 54 51 56 722 
Cirrhosis of Liver 41 66 57 71 70 28 29 23 385 
Unspecified Renal Failure 54 68 83 74 58 36 36 40 449 
Chronic Kidney Disease 13 24 39 44 30 15 23 36 224 
Lung Disease 11 14 16 16 20 12 13 19 121 
Neoplasm 21 55 70 103 76 46 57 43 471 
Septicaemia, Sepsis, Systemic Inflammatory Response 
Syndrome/Shock 
55 65 63 57 42 20 29 28 359 
Fibrosis of Lung and Other Chronic Lung Disorders 30 37 44 58 59 37 66 88 419 
Subtotal by Condition 3,592 6,669 8,255 9,770 9,718 5,540 8,858 14,588 66,990 
Discrete Mortality Frequency 5.4% 10.0% 12.3% 14.6% 14.5% 8.3% 13.2% 21.8% 100.0% 
Cumulative Mortality Frequency 5.4% 15.3% 27.6% 42.2% 56.7% 65.0% 78.2% 100.0% 100.0% 
 
Table 5. 9 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Female)  
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 Female 
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥ 180 Total 
Dementia Without Complication 4.1% 9.3% 12.8% 14.3% 15.2% 9.3% 14.2% 20.8% 100% 
Lung and Other Severe Cancers 5.7% 12.8% 16.9% 22.0% 20.7% 9.5% 8.8% 3.7% 100% 
Congestive Heart Failure 7.1% 12.1% 14.1% 16.7% 17.1% 8.3% 13.0% 11.6% 100% 
Breast, Prostate, and Other 
Cancers and Tumours 
6.0% 12.3% 16.8% 20.6% 19.1% 9.3% 10.3% 5.6% 100% 
COPD 8.0% 12.0% 12.8% 14.6% 16.7% 9.2% 14.3% 12.5% 100% 
Cerebrovascular Disease 3.7% 10.1% 15.6% 16.2% 16.5% 9.4% 15.2% 13.2% 100% 
Colorectal, Bladder, and Other 
Cancers 
5.3% 10.7% 15.7% 21.2% 21.9% 8.8% 10.9% 5.6% 100% 
Lymphoma and Other Cancers 5.5% 10.8% 17.3% 22.0% 20.5% 9.4% 9.6% 5.0% 100% 
Ischemic or Unspecified Stroke 7.8% 16.2% 16.9% 15.7% 13.7% 6.4% 12.0% 11.3% 100% 
Heart Disease 6.8% 10.1% 13.5% 15.9% 15.3% 9.4% 13.7% 15.4% 100% 
Protein-Calorie Malnutrition 3.9% 11.5% 18.2% 17.5% 16.0% 9.6% 13.2% 10.2% 100% 
Parkinson's and Huntington's 
Disease 
3.2% 7.9% 9.1% 18.6% 17.8% 7.5% 15.8% 20.2% 100% 
Metastatic Cancer and Acute 
Leukaemia 
9.0% 13.7% 19.5% 19.3% 19.3% 6.5% 8.6% 4.2% 100% 
Cirrhosis of Liver 5.5% 14.4% 23.5% 18.0% 16.0% 9.4% 8.0% 5.2% 100% 
Unspecified Renal Failure 11.1% 22.5% 22.0% 14.9% 12.2% 5.1% 5.6% 6.6% 100% 
Chronic Kidney Disease 10.3% 22.4% 15.5% 13.8% 12.1% 1.7% 8.6% 15.5% 100% 
Lung Disease 17.1% 19.0% 17.1% 16.7% 8.8% 7.9% 5.6% 7.9% 100% 
Neoplasm 4.7% 8.5% 13.9% 22.8% 25.3% 10.4% 11.4% 2.8% 100% 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
 
20.8% 19.3% 17.8% 14.4% 10.9% 7.4% 3.5% 5.9% 100% 
Fibrosis of Lung and Other 
Chronic Lung Disorders 
7.3% 12.2% 11.5% 14.2% 13.5% 12.8% 13.9% 14.6% 100% 
 
Table 5. 10 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Female)  
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 Female         
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥180 Total 
Dementia without Complication 3.4% 6.6% 8.5% 10.8% 11.8% 8.1% 15.9% 34.9% 100% 
Lung and Other Severe Cancers 6.3% 12.4% 16.3% 19.7% 19.1% 9.1% 10.1% 7.0% 100% 
Congestive Heart Failure 5.9% 10.2% 12.3% 13.7% 14.6% 8.4% 14.2% 20.7% 100% 
Breast, Prostate, and Other 
Cancers and Tumours 
5.7% 11.7% 16.8% 18.5% 17.7% 9.1% 10.9% 9.6% 100% 
COPD 6.0% 9.5% 10.3% 12.4% 14.2% 9.0% 15.5% 23.2% 100% 
Cerebrovascular Disease 2.4% 5.6% 7.0% 9.7% 10.2% 7.0% 15.5% 42.5% 100% 
Colorectal, Bladder, and Other 
Cancers 
5.3% 11.6% 15.6% 19.6% 18.6% 9.2% 11.3% 8.9% 100% 
Lymphoma and Other Cancers 4.8% 11.2% 17.8% 19.9% 18.8% 8.8% 10.0% 8.7% 100% 
Ischemic or Unspecified Stroke 6.9% 14.6% 13.6% 11.9% 10.9% 7.0% 13.0% 22.1% 100% 
Heart Disease 3.6% 7.2% 10.6% 11.5% 12.7% 7.9% 15.0% 31.4% 100% 
Protein-Calorie Malnutrition 3..0% 6.3% 10.6% 14.8% 13.9% 8.0% 17.4% 26.0% 100% 
Parkinson’s and Huntington’s 
Disease 
2.3% 5.6% 6.3% 10.5% 12.2% 8.7% 17.1% 37.3% 100% 
Metastatic Cancer and Acute 
Leukaemia 
9.3% 14.1% 17.9% 21.2% 15.2% 7.5% 7.1% 7.8% 100% 
Cirrhosis of Liver 10.6% 17.1% 14.8 18.4% 18.2% 7.3% 7.5% 6.0% 100% 
Unspecified Renal Failure 12.0% 15.1% 18.5% 16.5% 12.9% 8.0% 8.0% 8.9% 100% 
Chronic Kidney Disease 5.8% 10.7% 17.4% 19.6% 13.4% 6.7% 10.3% 16.1% 100% 
Lung Disease 9.1% 11.6% 13.2% 13.2% 16.5% 9.9% 10.7% 15.7% 100% 
Neoplasm 4.5% 11.7% 14.9% 21.9% 16.1% 9.8% 12.1% 9.1% 100% 
Septicamia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
15.3% 18.1% 17.5% 15.9% 11.7% 5.6% 8.1% 7.8% 100% 
Fibrosis of Lung and Other Chronic 
Lung Disorders 
7.2% 8.8% 10.5% 13.8% 14.1% 8.8% 15.8% 21.0% 100% 
 
Table 5. 11 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Female)
94 
 
 
 Male 
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥ 180 Total 
Dementia Without 
Complication 
125 244 341 368 353 207 327 341 2,306 
Lung and Other Severe 
Cancers 
481 955 1,314 1,505 1,278 527 496 223 6,779 
Congestive Heart Failure 233 426 413 508 500 280 320 268 2,948 
Breast, Prostate, and Other 
Cancers and Tumours 
152 295 385 483 535 218 248 122 2,438 
COPD 159 249 288 296 312 173 287 253 2,017 
Cerebrovascular Disease 31 85 112 131 121 72 110 82 744 
Colorectal, Bladder, and 
Other Cancers 
134 306 409 544 501 197 228 100 2,419 
Lymphoma and Other 
Cancers 
55 114 170 235 197 78 82 36 967 
Ischemic or Unspecified 
Stroke 
69 109 135 114 100 58 94 93 772 
Heart Disease 55 74 93 110 124 63 102 99 720 
Protein-Calorie Malnutrition 9 27 34 31 43 16 26 16 202 
Parkinson's and Huntington's 
Diseases 
19 31 47 59 64 33 53 34 340 
Metastatic Cancer and Acute 
Leukaemia 
36 66 61 79 59 25 34 10 370 
Cirrhosis of Liver 49 101 87 73 77 33 38 24 482 
Unspecified Renal Failure 56 75 92 50 32 20 24 14 363 
Chronic Kidney Disease 4 4 5 6 8 2 3 2 34 
Lung Disease 31 32 18 16 20 15 13 8 153 
Neoplasm 15 27 44 57 62 30 15 12 262 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
18 35 29 26 18 7 6 7 146 
Fibrosis of Lung and Other 
Chronic Lung Disorders 
18 29 32 49 53 35 39 25 280 
Subtotal by Condition 2,302 4,288 5,261 5,902 5,520 2,579 3,248 2,305 31,405 
Discrete Mortality Frequency 7.3% 13.7% 16.8% 18.8% 17.6% 8.2% 10.3% 7.3% 100.0% 
Cumulative Mortality 
Frequency 
7.3% 21.0% 37.7% 56.5% 74.1% 82.3% 92.7% 100.0% 100.0% 
 
Table 5. 12 Distribution of Duration (days) from Hospice Admission  to Death in 2015 
(Male) 
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 Male 
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥ 180 Subtotal 
Dementia Without Complication 217 410 527 566 593 389 734 1,172 4,608 
Lung and Other Severe Cancers 770 1,366 1,564 1,906 1,656 693 777 490 9,222 
Congestive Heart Failure 405 682 723 842 759 412 691 933 5,447 
Breast, Prostate, and Other 
Cancers and Tumours 
172 412 488 595 614 291 396 273 3,241 
COPD 220 322 337 392 424 278 441 624 3,038 
Cerebrovascular Disease 57 149 191 205 204 152 310 640 1,908 
Colorectal, Bladder, and Other 
Cancers 
240 486 626 723 625 331 390 257 3,678 
Lymphoma and Other Cancers 116 228 302 373 298 149 175 123 1,764 
Ischemic or Unspecified Stroke 95 173 169 173 146 86 173 283 1,298 
Heart Disease 49 103 144 139 168 89 148 258 1,098 
Protein-Calorie Malnutrition 26 50 56 76 65 59 75 88 495 
Parkinson's and Huntington's 
Disease 
64 123 173 210 223 132 304 462 1,691 
Metastatic Cancer and Acute 
Leukaemia 
73 114 139 139 104 32 40 39 680 
Cirrhosis of Liver 48 85 99 94 89 32 45 42 534 
Unspecified Renal Failure 49 95 67 52 42 12 35 34 386 
Chronic Kidney Disease 16 29 25 30 21 17 23 17 178 
Lung Disease 8 14 16 9 11 9 6 12 85 
Neoplasm 28 49 65 77 62 35 37 38 391 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
44 59 50 32 30 12 15 18 260 
Fibrosis of Lung and Other 
Chronic Lung Disorders 
28 34 34 51 61 46 62 65 381 
Subtotal by Condition 3,230 5,749 6,535 7,432 6,848 3,670 5,444 6,731 45,639 
Discrete Mortality Frequency 7.1% 12.6% 14.3% 16.3% 15.0% 8.0% 11.9% 14.7% 100.0% 
Cumulative Mortality Frequency 7.1% 19.7% 34.0% 50.3% 65.3% 73.3% 85.3% 100.0% 100.0% 
 
Table 5. 13 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Male) 
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 Male 
Condition Categories 0-3 4-7 8-14 15-29 30-59 60-89 90-179 ≥ 180 Subtotal 
Dementia Without 
Complication 
5.4% 10.6% 14.8% 16.0% 15.3% 9.0% 14.2% 14.8% 100.0% 
Lung and Other Severe 
Cancers 
7.1% 14.1% 19.4% 22.2% 18.9% 7.8% 7.3% 3.3% 100.0% 
Congestive Heart Failure 7.9% 14.5% 14.0% 17.2% 17.0% 9.5% 10.9% 9.1% 100.0% 
Breast, Prostate, and Other 
Cancers and Tumours 
6.2% 12.1% 15.8% 19.8% 21.9% 8.9% 10.2% 5.0% 100.0% 
COPD 7.9% 12.3% 14.3% 14.7% 15.5% 8.6% 14.2% 12.5% 100.0% 
Cerebrovascular Disease 4.2% 11.4% 15.1% 17.6% 16.3% 9.7% 14.8% 11.0% 100.0% 
Colorectal, Bladder, and 
Other Cancers 
5.5% 12.6% 16.9% 22.5% 20.7% 8.1% 9.4% 4.1% 100.0% 
Lymphoma and Other 
Cancers 
5.7% 11.8% 17.6% 24.3% 20.4% 8.1% 8.5% 3.7% 100.0% 
Ischemic or Unspecified 
Stroke 
8.9% 14.1% 17.5% 14.8% 13.0% 7.5% 12.2% 12.0% 100.0% 
Heart Disease 7.6% 10.3% 12.9% 15.3% 17.2% 8.8% 14.2% 13.8% 100.0% 
Protein-Calorie Malnutrition 4.5% 13.4% 16.8% 15.3% 21.3% 7.9% 12.9% 7.9% 100.0% 
Parkinson's and 
Huntington's Disease 
5.6% 9.1% 13.8% 17.4% 18.8% 9.7% 15.6% 10.0% 100.0% 
Metastatic Cancer and Acute 
Leukaemia 
9.7% 17.8% 16.5% 21.4% 15.9% 6.8% 9.2% 2.7% 100.0% 
Cirrhosis of Liver 10.2% 21.0% 18.0% 15.1% 16.0% 6.8% 7.9% 5.0% 100.0% 
Unspecified Renal Failure 15.4% 20.7% 25.3% 13.8% 8.8% 5.5% 6.6% 3.9% 100.0% 
Chronic Kidney Disease 11.8% 11.8% 14.7% 17.6% 23.5% 5.9% 8.8% 5.9% 100.0% 
Lung Disease 20.3% 20.9% 11.8% 10.5% 13.1% 9.8% 8.5% 5.2% 100.0% 
Neoplasm 5.7% 10.3% 16.8% 21.8% 23.7% 11.5% 5.7% 4.6% 100.0% 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
12.3% 24.0% 19.9% 17.8% 12.3% 4.8% 4.1% 4.8% 100.0% 
Fibrosis of Lung and Other 
Chronic Lung Disorders 
6.4% 10.4% 11.4% 17.5% 18.9% 12.5% 13.9% 8.9% 100.0% 
 
 
Table 5. 14 Distribution of Duration (days) from Hospice Admission to Death in 2015 
(Male) 
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 Male 
Condition Categories 0-3 04-07 08-14 15-29 30-59 60-89 90-179 ≥ 180 Subtotal 
Dementia Without Complication 4.7% 8.9% 11.4% 12.3% 12.9% 8.4% 15.9% 25.4% 100.0% 
Lung and Other Severe Cancers 8.3% 14.8% 17.0% 20.7% 18.0% 7.5% 8.4% 5.3% 100.0% 
Congestive Heart Failure 7.4% 12.5% 13.3% 15.5% 13.9% 7.6% 12.7% 17.1% 100.0% 
Breast, Prostate, and Other 
Cancers and Tumours 
5.3% 12.7% 15.1% 18.4% 18.9% 9.0% 12.2% 8.4% 100.0% 
COPD 7.2% 10.6% 11.1% 12.9% 14.0% 9.2% 14.5% 20.5% 100.0% 
Cerebrovascular Disease 3.0% 7.8% 10.0% 10.7% 10.7% 8.0% 16.2% 33.5% 100.0% 
Colorectal, Bladder, and Other 
Cancers 
6.5% 13.2% 17.0% 19.7% 17.0% 9.0% 10.6% 7.0% 100.0% 
Lymphoma and Other Cancers 6.6% 12.9% 17.1% 21.1% 16.9% 8.4% 9.9% 7.0% 100.0% 
Ischemic or Unspecified Stroke 7.3% 13.3% 13.0% 13.3% 11.2% 6.6% 13.3% 21.8% 100.0% 
Heart Disease 4.5% 9.4% 13.1% 12.7% 15.3% 8.1% 13.5% 23.5% 100.0% 
Protein-Calorie Malnutrition 5.3% 10.1% 11.3% 15.4% 13.1% 11.9% 15.2% 17.8% 100.0% 
Parkinson's and Huntington's 
Disease 
3.8% 7.3% 10.2% 12.4% 13.2% 7.8% 18.0% 27.3% 100.0% 
Metastatic Cancer and Acute 
Leukaemia 
10.7% 16.8% 20.4% 20.4% 15.3% 4.7% 5.9% 5.7% 100.0% 
Cirrhosis of Liver 9.0% 15.9% 18.5% 17.6% 16.7% 6.0% 8.4% 7.9% 100.0% 
Unspecified Renal Failure 12.7% 24.6% 17.4% 13.5% 10.9% 3.1% 9.1% 8.8% 100.0% 
Chronic Kidney Disease 9.0% 16.3% 14.0% 16.9% 11.8% 9.6% 12.9% 9.6% 100.0% 
Lung Disease 9.4% 16.5% 18.8% 10.6% 12.9% 10.6% 7.1% 14.1% 100.0% 
Neoplasm 7.2% 12.5% 16.6% 19.7% 15.9% 9.0% 9.5% 9.7% 100.0% 
Septicaemia, Sepsis, Systemic 
Inflammatory Response 
Syndrome/Shock 
16.9% 22.7% 19.2% 12.3% 11.5% 4.6% 5.8% 6.9% 100.0% 
Fibrosis of Lung and Other 
Chronic Lung Disorders 
7.3% 8.9% 8.9% 13.4% 16.0% 12.1% 16.3% 17.1% 100.0% 
Subtotal by Condition 7.1% 12.6% 14.3% 16.3% 15.0% 8.0% 11.9% 14.7% 100.0% 
 
Table 5. 15 Distribution of Duration (days) from Hospice Admission to Death in 2016 
(Male) 
 
 In the next section, we will analyse the prescription data in our database.   
5.4.3 Hospice drug coverage 
The United States Congress created a Medicare hospice benefit, in 1982, for beneficiaries, 
certified as having a life expectancy of six months or less.  Medicare hospice providers are 
paid a per diem rate that is designed to cover all services necessary for the palliation and 
management of the terminal illness and related conditions, including the cost of 
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medications related to the terminal illness.  When Medicare beneficiaries elect the hospice 
benefit, they forego Medicare coverage for curative treatment related to their terminal 
illness, but are still eligible for Medicare coverage for all other covered care.  For example, 
if a Medicare beneficiary with liver cancer elects the hospice benefit, Medicare will no 
longer pay for treatment to cure the cancer, but it will continue to pay for care related to 
other illnesses, like diabetes and hypertension.  
 Federal regulations at 42 CFR § 418.202(f) stipulate that the Medicare Hospice 
Benefit must cover all medications and biologicals used primarily for the relief of pain and 
symptom control for the terminal illness and related conditions.  This includes both 
prescription and over-the-counter drugs, as defined in §1861(t) of the Social Security Act.  
There is widespread agreement in the clinical literature about the classes of palliative drugs 
appropriate and necessary for patients at end of life [36-38].  In 2014, CMS [39] issued 
guidance on coverage of prescription drugs for patients in hospice, reiterating that drugs 
and biologicals, covered under the Medicare Part A per diem payments to a Medicare 
hospice program, are excluded from coverage under Medicare Part D17.  This guidance 
states that CMS “expects that Medicare hospice providers will continue to provide all of the 
medications that are reasonable and necessary for the palliation and management of a 
beneficiary’s terminal illness and related conditions.  We expect that this will routinely 
include, but is not limited to, the drugs in the four categories highlighted by the OIG18: 
1. Analgesics (opioids and non-opioid pain medications) 
2. Anti-nauseants (anti-emetics) 
3. Anti-cholinergic (laxatives and drugs prescribed for dizziness, vertigo, 
nausea, vomiting, diarrhoea, and symptoms of anti-psychotic medications).    
4. Anxiolytics (anti-anxiety drugs). 
                                                           
17 Medicare Part D: the component of Medicare coverage introduced in 2006 to cover outpatient drugs 
(infusion and other specialty drugs were already covered under Part B of Medicare).  The benefit is insured 
and administered by insurers, separately from Parts A and B (hospital and major medical) coverage, unless 
the member is part of a Medicare Part C (Medicare Advantage) plan (which covers all services, including 
outpatient drugs).  However, on entry to hospice, Medicare Advantage members revert to Parts A/B 
traditional Medicare.   
18 OIG:  Office of the Inspector General, or the Medicare Program Auditor-General, responsible for ensuring 
the financial integrity of the program.   
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 Hospices must complete a prior authorization form if they determine that a 
medication from these four classes is for a condition unrelated to the terminal illness or 
related conditions.  CMS recognizes that many maintenance drugs, as well as drugs to treat 
or cure a condition, are typically discontinued, as the focus of care shifts to palliation.  
Maintenance drugs, beyond the four classes noted above, that are appropriate to continue, 
as they may offer symptom relief, should be covered under the hospice benefit.   
5.4.3.1 Analysis of drug prevalence    
Table 5.16 shows the distribution of the four CMS drug classes, by patient, in 2015, and 
table 5.17 shows the distribution of the four CMS drug classes, by patient, in 2016.  
 
Analgesics Laxatives 
Anti-
nauseants 
Anxiolytics Total 
69,335 54,984 25,971 59,669 209,959 
Number of patients with at least one of 4 drug types 73,068 
Number of patients without any of 4 drug types (1.63%) 1,207 
      Total 74,275 
93.4% 74.0% 35.0% 80.3% 282.7% 
 
Table 5. 16 Prevalence of Four (CMS) Drug Classes: 2015 Admissions 
 
Analgesics Laxatives 
Anti-
nauseants 
Anxiolytics Total 
103,911 79,688 35,614 88,972 308,185 
Number of patients with at least one of 4 drug types 110,476 
Number of patients without any of 4 drug types (1.91%) 2,153 
      Total 112,629 
92.3% 70.8% 31.6% 79.0% 273.6% 
 
Table 5. 17 Prevalence of Four (CMS) Drug Classes: 2016 Admissions 
 
Of CMS’s four major drug classes (analgesics, laxatives, anti-nausea, and anxiolytic 
drugs), most patients have prescriptions for at least one drug class.  Most patients have 
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prescriptions for multiple drug types; only 2.6% of 2015 admissions and 3.2% of 2016 
admissions do not have at least one of the four drug classes.  The most frequently 
prescribed drug class is analgesics (93.4% in 2015 and 92.3% in 2016), with other drug 
classes having lower incidence.  On average, each patient with one or more prescriptions 
has a prescription for 2.8 (2015) and 2.7 (2016) drugs of the four drug types. 
Tables 5.18 and 5.19 show the prevalence of different combinations of the four drug 
types by patient; frequencies of combinations are roughly, uniformly, distributed, with 
approximately one-quarter of patients having one, two, three, or four of the different drug 
types.  These two tables do not distinguish the timing of the prescription, nor the strength or 
dosage, and simply present the frequencies of different combinations, at some time during 
hospice stay.  It is frequently possible that a patient will have simultaneous prescriptions of 
more than one drug from a class.  This observation has implications for other analysis, as 
we shall see shortly.   
 
Tables 5.18 and 5.19 show the distribution of different drug classes.  Ninety percent of 
patients have two or more classes of drugs.   
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All possible combinations of four drug 
classes 
Female Male 
Number 
of patients 
Group 
% of 
Total 
Analgesics 2,882 1,900 4,782  
Laxatives 513 385 898  
Anti-nauseants 146 76 222  
Anxiolytics 693 615 1,308 9.9 
Analgesics & Laxatives 2,847 2,166 5,013  
Analgesics & Anti-nauseants 430 246 676  
Anti-nauseants & Anxiolytics 4,974 3,685 8,659  
Analgesics & Anxiolytics 61 35 96  
Laxatives & Anti-nauseants 456 405 861  
Laxatives & Anxiolytics 1,046 666 1,712 23.3 
Analgesics & Laxatives & Anti-nauseants 14,237 11,339 25,576  
Analgesic & Laxatives & Anxiolytic 1,429 865 2,294  
Analgesic & Anti-nausea & Anxiolytics 130 75 205  
Laxatives & Anti-nauseants & Anxiolytics 12,225 8,398 20,623 66.7 
Analgesics & Laxatives & Anxiolytics & 
Anti-nauseants 
90 53 143 0.2 
Total 42,159 30,909 73,068 100.0 
 
Table 5. 18 Frequency of Drug Classes: 2015 Admissions 
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All possible combinations of four drug 
classes 
Female Male 
Number 
of 
patients 
Group 
% of 
Total 
Analgesics 4,588 3,067 7,655 
 
Laxatives 1,067 662 1,729 
 
Anti-nauseants 213 123 336 
 
Anxiolytics 1,312 992 2,304 10.9% 
Analgesics & Laxatives 4,820 3,350 8,170 
 
Analgesics & Anti-nauseants 694 370 1,064 
 
Anti-nauseants & Anxiolytics 9,140 6,285 15,425 
 
Analgesics & Anxiolytics 118 71 189 
 
Laxatives & Anti-nauseants 809 622 1,431 
 
Laxatives & Anxiolytics 1,436 925 2,361 25.9% 
Analgesics & Laxatives & Anti-nauseants 22,146 16,002 38,148 
 
Analgesisc & Laxatives & Anxiolytic 2,337 1,408 3,745 
 
Analgesic & Antinausea & Anxiolytics 198 119 317 
 
Laxatives & Anti-nauseants & Anxiolytics 16,704 10,639 27,343 63.0% 
Analgesics & Laxatives & Anxiolytics & 
Anti-nauseants 153 106 259 0.2% 
Total 65,735 44,741 110,476 100.0% 
 
Table 5. 19 Frequency of Drug Classes: 2016 Admissions 
 
5.4.3.2 Mapping drug class, strength, form, and dosage 
5.4.3.2.1 Drug Classes   
Within the four major drug classes, we group individual drugs into sub-classes.  In the 
United States, individual drugs are coded with a National Drug Code (NDC).  The NDC is 
a 10 or 11-digit code that provides information about the drug, manufacturer, form 
(capsule, pill, or liquid), formulation (active ingredient), and packaging (package size and 
type).  The NDC code allows grouping by manufacturer or packager.  For therapeutic 
studies, we need a classification by function.  Our data did not contain NDC codes for 
individual drugs.  Instead, the data consists of GCN codes, or generic code numbers, a 
numbering system developed by the First Data Bank Company.  The GCN is a five-digit 
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code representing a clinical formulation.  It is specific to active ingredient, strength, form, 
and route of administration.  Most importantly, it is constant across manufacturers and/or 
package size, allowing the grouping of pharmaceutically equivalent products.  Every drug 
has a hierarchical ingredient code (“HIC”).  Because the coding is hierarchical, the codes 
may be used to group different drugs into therapeutic classes and sub-classes.  This 
grouping of NDC codes into hierarchical ingredient codes is analogous to the condition 
grouping that is performed by the hierarchical condition categories for diagnosis codes, and 
greatly simplifies analysis of multiple drugs.  Table 5.20 provides an example of the coding 
and mapping.  
 
Characters Information Example 
1 Organ system nervous system 
2 Pharmacological class analgesics 
3 Therapeutic class narcotic analgesics 
4 Ingredient (base) morphine 
5-6 Ingredient (specific); characters 5-6 indicate the 
salt or ester when applicable and are blank 
otherwise 
morphine sulfate 
 
Table 5. 20 Example of HIC Coding 
 
First DataBank’s specific therapeutic class consists of the first three digits of the 
hierarchical ingredient code, and, therefore, is referred to as HIC-3.  For our study, we used 
the HIC-3 code to map drugs to the therapeutic class.  The GTC description is also listed in 
the database and provides a plain-language description of the drug class.  It is not used in 
the study.   
An important part of data preparation is the creation, from raw drug data, of a 
number of derived variables.  These include drug strength, form, and dosage.  These 
variables, and particularly changes in them, will form the time-dependent covariates in later 
analysis.  An example of the drug class coding is provided in table 5.21.   
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GCN Sequence 
Number 
Generic Name Label Name HIC3_DESC GTC_DESC Class 
3767 Diazepam 
Diazepam 2 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3767 Diazepam 
Diazepam 2 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3768 Diazepam 
Diazepam 5 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3766 Diazepam 
Diazepam 10 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3766 Diazepam 
Diazepam 10 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3736 
Chlordiazepoxide 
HCL 
Librium 5 mg 
capsule 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3767 Diazepam 
Diazepam 2 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
3766 Diazepam 
Diazepam 10 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
4732 Meclizine HCL  
Antivert 25 mg 
tablet 
Antiemetic/ 
Antivertigo agents 
Gastrointestinal  Anti-nauseants 
3746 
Clorazepate 
Dipotassium  
Clorazepate 7.5 mg 
tablet 
Anti-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
4682 
Trimethobenzamide 
HCL/B-Caine  
Trimethobenzamide 
100MG 
Antiemetic/ 
Antivertigo agents 
Gastrointestinal Anti-nauseants 
4731 Meclizine HCL 
Antivert 12.5 mg 
tablet 
Antiemetic/ 
Antivertigo agents 
Gastrointestinal Anti-nauseants 
4731 Meclizine HCL 
Meclizine 12.5 mg 
tablet 
Antiemetic/ 
Antivertigo agents 
Gastrointestinal Anti-nauseants 
4683 
Trimethobenzamide 
HCL/B-Caine 
Trimethobenzamide 
200MG 
Antiemetic/ 
Antivertigo agents 
Gastrointestinal Anti-nauseants 
3767 Diazepam 
Diazepam 2 mg 
tablet 
Anit-anxiety drugs 
Psychotherapeutic 
Drugs 
Anxiolytics 
 
Table 5. 21 Example of Drug Class Coding 
 
5.4.3.3 Coding drug strength 
An important requirement of this study is the need to reduce the multiplicity of different 
drugs, drug strengths, dosage, and route of administration, in such a way that they may be 
incorporated as variables into a model.  We do this by mapping drugs to relative strengths.  
For analgesics, this is largely straightforward because there is a clinical conversion of 
analgesics of the opioid type to equivalent units of morphine.  For other drug classes, 
instead of strength and dosage, we record whether the patient had a prescription for the 
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drug at a particular point in time, and (cumulatively) the number of prescriptions that the 
patient has had within the class during the stay.    
Table 5.22 shows examples of mappings of opioid (analgesic) drugs.  Opioids are 
mapped to their equivalent, in terms of oral morphine using their morphine conversion 
factor.  Intravenous hydromorphone is the strongest opioid drug; all other drug strengths are 
expressed as a percentage of hydromorphone’s (maximum) strength.  For example, 
morphine, OxyContin, and oxymorphone all have equivalent strengths, in terms of 
morphine equivalence, although tablet strengths are 60, 40, and 30 mg, respectively.    
 
Form Drug Strength Unit 
Oral 
morphine 
equivalent 
per dose 
Relative 
Strength 
Capsule Morphine Sulfate 60 MG 60 18% 
Tablet Morphine LA 60 MG 60 18% 
Tablet OxyContin CR 40 MG 60 18% 
Tablet Oxymorphone HCL 30 MG 60 18% 
Tablet Hydromorphone 16 MG 64 19% 
Capsule Morphine Sulfate 80 MG 80 24% 
Capsule Morphine Sulfate 90 MG 90 27% 
Tablet OxyContin CR 60 MG 90 27% 
Capsule Morphine Sulfate 100 MG 100 30% 
Liquid Morphine Sulfate 100 MG/5ML 100 30% 
Tablet Morphine LA  100 MG 100 30% 
Tablet OxyContin CR 80 MG 120 36% 
Tablet Morphine LA  200 MG 200 60% 
Intravenous Hydromorphone 10 MG/ML 333.33 100% 
 
Table 5. 22 Example of Strength Coding – Analgesic drugs 
 
An important consideration, which will become apparent below, is that it is possible 
for a patient to have a drug dosage that exceeds 100%, or more than one prescription at a 
time (non-analgesic drugs).  This phenomenon occurs when a patient has overlapping 
prescriptions within the same drug class.  For example, it is possible for a patient to be 
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prescribed two different analgesics of maximum strength at the same time.  The U.S. 
Centers for Disease Control and Prevention (CDC), the body that makes recommendations 
for drug use, recommends a daily dosage of no more than 90 milligrams of morphine 
equivalent (MME).  Patients in hospice regularly exceed this dosage, often by multiples.  
Analysis of a sample of 152,094 deceased patients from our database indicates that 98,204 
had at least one prescription day in excess of 90 mg; 60% of deceased patients had a 
prescription in excess of two times the CDC’s recommended daily dose (slightly fewer than 
40% of all deceased patients).  Table 5.23 shows the number and percentage of patients 
who had at least one day of opioid prescription, in excess of the recommended daily dose; 
table 5.24 shows the use of opioids for the number of days, continuously, prior to death.  
For example, 37% of deceased patients, with prescriptions in excess of 90 mg morphine 
equivalent, used at least twice the recommended dose of opioids for between one and seven 
days prior to death.   
 
MME ≥ 90 mg Patients % ≥ 90 mg* 
% all 
patients 
90 – 150 mg 33,363 34.0% 21.9% 
150+ - 180 mg 5,637 5.7% 3.7% 
180 mg + 59,204 60.3% 38.9% 
Total Patients 98,204 100.0% 64.6% 
* Patients are classified in the highest dosage category during their stay 
 
Table 5. 23 Patients with Prescriptions in Excess of the Recommended Maximum                   
Daily Dose of Opioids. 
 
While many drugs are titrated by body mass, opioids are not.  The dosage of opioids  
depends instead on pain level.  Patients (particularly cancer patients) lose so much weight 
during treatment that dosage would not vary much.  The authoritative source for Cancer 
Treatment in the US is National Comprehensive Cancer Network, which provides dosage 
instructions for pain control and side effect limitation, with no relation to patient 
weight. See for example [40].   
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MME ≥ 90 
mg 
1 - 7 days 
(%) 
8 - 30 days 
(%) 
31 - 90 days 
(%) 
90+ days 
(%) 
Subtotal Total 
90 – 150 mg 15,523 (47%) 670 (2%) 1 (0%) 0 (0%) 16,194 (49%) 33,363 
150 mg+ - 
180 mg 
2,413 (43%) 97 (2%) 0 (0%) 0 (0%) 2,510 (45%) 5,637 
180 mg+ 21,872 (37%) 2,625 (4%) 338 (1%) 45 (0%) 24,880 (42%) 59,204 
Total 39,808 (41%) 3,392 (3%) 339 (0%) 45 (0%) 43,584 (44%) 98,204 
 
Table 5. 24 Patients with Continuous Prescriptions in Excess of the Recommended 
Maximum Daily Dose of Opioids for Days until Death 
 
5.4.3.4 Treatment of ComfortPak drugs 
ComfortPaks are packages that contain small supplies of all four classes of drugs.  They are 
provided for use by the patient in an emergency, for example, when a supply of a specific 
drug has been used up, and the patient is waiting for the delivery of a new prescription.  
Use of drugs from the package is not recorded; therefore, we developed an algorithm to 
proxy the use of these drugs from the packs.    
ComfortPak (CP) drugs are included in the study, subject to the rules illustrated in 
figure 5.3.  Certain CP drug records contain no date; these records are ignored because a 
blank date implies that the ComfortPak prescription was never dispensed.  A prescription 
record for a regular drug is always included in the analysis. 
 
 
Figure 5. 3 Treatment of ComfortPak Drugs 
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ComfortPak drugs are excluded from the analysis if there is a single occurrence of a 
ComfortPak for that patient during the stay, assuming that the absence of a second 
ComfortPak prescription implies that the first pack was not exhausted.  (This assumption  
potentially undercounts ComfortPak drugs by ignoring ComfortPak drugs used from the 
first pack when a second pack may not have been ordered.  However, the ComfortPak 
contains only a two-day supply of the drug, implying that even if the drug is included or 
excluded erroneously, the potential error is minor.)  Only in the case of multiple 
ComfortPak prescriptions is the drug included in analysis; only prescriptions up to, and 
including, the penultimate CP supply are included (because with no further CP prescription, 
there is no indication that earlier ComfortPaks were used).  All drugs in the ComfortPak are 
included in the analysis, where the ComfortPak is deemed to have been used.   
5.4.3.5 Investigation of drug dosage 
An important aspect of this thesis is the predictive value of time-dependent variables, such 
as number of prescriptions and drug strength.  In this section, we discuss prescribing 
patterns of the four palliative drug classes.   
We investigated the prescribing pattern, particularly the dosage of analgesic drugs, 
and of the number of prescriptions of the other three drug classes, toward the end of life.  
The scale of relative dosage graphs is 0-1 (0% to 100% of the maximum dosage of oral 
equivalent morphine; refer to Table 5.22 for an example of the coding of relative strength 
of different drugs).  The measure in the analgesic charts is the average and median 
cumulative dosage of morphine equivalent.  The average cumulative drug dosage is 
calculated as 1ˆ 

T
t
t
d
d
T
, where td  is the daily analgesic dose (calculated as the strength per 
pill, multiplied by the number of pills per day, or equivalent when the drug form is not 
pills) and T is the number of days over which the dose is averaged.  Because a patient may 
be prescribed more than one opioid at a time, it is possible for a patient to have a total 
morphine equivalent dose that exceeds 100% (> 1.0 in Figure 5.4). Tables 5.23 and 5.24 
indicate that this is possible because of the number of patients whose prescriptions exceed 
the recommended maximum daily dosage.  Figure 5.4 shows the progression of the 
cumulative average and median dosage of analgesic drugs from admission to death.   
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Figure 5. 4 Cumulative Dosage of Analgesic Drugs at End of Life 
 
Prescription strength is highly variable by patient, as the difference between average 
and median drug strength in figure 5.4 shows.  Both median and average doses of 
analgesics increase exponentially over the length of stay in hospice.  For the remaining 
drug categories (anti-nausea, laxatives, and anxiolytics), we report the average and median 
number of prescriptions, per patient, at different times during the hospice stay.  
 
 
Figure 5. 5 Number of Laxative Prescriptions at End of Life 
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For non-analgesic drugs, on advice of a clinical pharmacist, we record the number 
of prescriptions, rather than the dose, because (unlike in the case of analgesics) there is no 
common measure to which to reduce all drugs within a class.  For example, figure 5.5 
shows the average and median number of laxative prescriptions, per patient, at different 
times in the patient’s stay.  On average, patients have 0.8 prescriptions early in the stay, 
increasing to an average of 1.0 prior to death, with a reduction in the average number of 
prescriptions in the last three days.  The number of patients who die shortly after admission 
contributes to the downturn in the average number of prescriptions.  The median number of 
prescriptions is roughly level throughout the stay at about 0.5, implying that one in two 
patients have a laxative prescription throughout the stay.  
“Anti-cholinergic burden” is defined as the cumulative effect of taking one or more 
drugs that are capable of developing anti-cholinergic adverse effects.  Peripheral 
manifestations may occur such as urinary retention, constipation, decreased secretions, 
amongst others and central manifestations, such as delirium, cognitive, and functional 
disorders.  Anti-cholinergic burden is associated with loss of function and prognosis [41].  
More work is required to understand the role of multiple medications in contributing to the 
anticholinergic burden, vs. the use of anticholinergic drugs.  
 
Figure 5. 6 Number of Anxiolytic Prescriptions at End of Life 
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Anxiolytic drugs are often prescribed together with analgesics, as tables 5.16 and 
5.17 indicate.  Both the mean and median numbers of anxiolytic prescriptions increase 
during the hospice stay, again with a small decline in the last seven days (figure 5.6). 
 
Figure 5. 7 Number of Anti-Nausea Prescriptions at End of Life 
 
On average, few patients have a prescription for an anti-nausea drug, although there 
is some increase in the average number of prescriptions during the stay, with a decline in 
the last few days of life, possibly because patients’ method of nutrition changes from solid 
to liquid form (see figure 5.7).  
5.4.3.6 Relationship of drug strength and diagnosis  
Figures 5.8 through 5.11 are similar to figures 5.4 through 5.7, except that here we show 
the pattern of prescribing by diagnostic group.  We compare drug strength and prescription 
prevalence during the patient’s stay with diagnosis, grouping the top ten admitting 
diagnoses into five categories as follows: 
1. Cancer: Metastatic cancer and acute leukemia, lung and other severe cancers, 
colorectal, bladder, and other cancers, and breast, prostate, and other cancers and 
tumours (Sum of the HCC categories HCC 8-12).  
2. Heart: Congestive heart failure, acute myocardial infarction, unstable angina and acute 
ischemic heart disease, and specified heart arrhythmias (HCCs 85-88 and 96).  
3. Kidney: Dialysis, acute renal disease, and chronic kidney disease (HCC 134-141). 
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4. Lung: COPD (HCC 82-84). 
5. Dementia and Psych conditions, such as drug/alcohol psychosis, schizophrenia, and 
major depressive, bipolar, and paranoid disorders (HCC 51-58). 
 
Figure 5. 8 Cumulative Analgesic Dose at End of Life by Diagnostic Category 
 
Figure 5. 9 Number of Laxative Prescriptions at End of Life by Diagnostic Category 
 
There is clear separation between cancer and lung diagnoses and other diagnoses, in 
terms of the analgesic prescription dosage throughout the patient’s hospice stay (figure 5.8).  
Average dosages of analgesics for cancer patients increase from 0.4 initially, to an amount 
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in excess of 100% (reflecting the prescriptions of multiple analgesic drugs).  The average 
dosage of dementia patients is conversely low, but not non-zero.  All diagnoses, however, 
experience sharp increases in drug strength in the last 30 days of life.   
Cancer patients experience the highest frequency of laxative prescriptions 
throughout their stays (figure 5.9), with lung (COPD) patients and heart patients 
experiencing lower, but similar, patterns of prescription frequency.  Although dementia and 
kidney patients experience relatively lower prescription frequency, the frequency within 
these diagnoses remains high.  Patients with all diagnoses, except cancer, experience 
reductions in laxative prescriptions in their last few days.  
 
 
Figure 5. 10 Number of Anxiolytic Prescriptions at End of Life by Diagnostic Category 
 
Figure 5.11 shows that the average frequency of anti-nausea drugs is relatively low 
(compared with other drug classes) throughout the hospice stay.  The frequency increases 
modestly during the stay, with a decline in the last few days of life.   
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Figure 5. 11 Anti-nausea Prescriptions at End of Life by Diagnostic Category 
 
 
As the analysis in this section shows, the prescribing patterns of different drugs vary 
during a patient’s hospice stay, both over time and by diagnosis, providing potential 
information for estimating a patient’s survival as prescriptions change.   
5.4.3.7 Relationship of drug strength and other variables 
Drug strength and number of prescriptions vary by a number of variables, implying that we 
will need to account for this variation in any time-dependent survival model.  In addition to 
time, age at admission has a significant effect on prescription strength.  Specifically, drug 
strength first increases and then decreases, with an increase in age at admission.  Figure 
5.12 shows the distribution of strength within each age group.  We first observe the 
increasing trend (moving from age group one and two to other groups) and then the 
decreasing trend (from group three towards the end).  However, the percentage of hospice 
in these two young-age groups is low and we can omit the initial increasing trend and focus 
only on the decreasing trend.  It may appear counter-intuitive that drug strength decreases 
with patient age at admission.  However, this finding is consistent with the clinical 
observation that older patients have a higher pain threshold and tolerance for pain than 
younger patients.  
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Figure 5. 12 Decreasing Trend in Analgesic Dose as Age Increases 
 
Figure 5.13 shows that males have, on average, a higher dose of analgesic drugs 
than females.  This is due, in part, to the difference in primary diagnoses.  As table 5.6 
shows, male hospice patients are more likely to suffer from cancer than females, while the 
prevalence of stroke and dementia is considerably higher in females.   
 
 
Figure 5. 13 Males Have a Higher Analgesic Dose on Average Compared to Females 
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Figure 5. 14 Home Care has Highest Analgesic Dose, on Average, Compared to Other 
Settings 
 
The drug strength variable constructed and analysed in this chapter will form an 
input variable in the survival models developed later.         
5.5 Summary 
This chapter covered the demographic, clinical, and drug data available in our database.  
Variables, particularly diagnostic and drug variables, have been developed that will be used 
as inputs to the survival models in succeeding chapters.   
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5.6 Appendix A: CMS’s Hierarchical Condition Categories (HCCs) 
HCCs are a very useful set of algorithms for mapping diagnoses to higher-level condition 
categories, enabling us to reduce the number of independent variables in an analysis.  The 
HCC system has the additional benefit that it was developed and is maintained by CMS.  
The (CMS) HCC system was developed in the late 1990s as a health risk adjuster for 
HMOs that enrol Medicare populations (now called Medicare Advantage).  Initially, the 
system focused only on inpatient diagnoses (PIP-DCG), but was later extended to all 
services.  The HCC system has been extensively evaluated and reported in the literature 
[42].  The fundamental concept of the HCC system is that diagnoses (approximately 15,000 
different ICD-9 codes and 80,000 ICD-10 codes) may be mapped to a set of condition 
categories (the HCCs).  The HCCs are, however, hierarchical; a patient with an 
uncomplicated diagnosis, as well as a diagnosis with complications, will trigger only one 
HCC, the highest severity within that condition category.   
 The HCC model is used for risk adjustment by assigning a weight to each HCC.  The 
weights are developed by a linear regression model, where the dependent variable is claims 
cost and independent variables include the HCCs, demographic variables and a few 
interaction terms.  Figure A5.1 shows the distribution of the CMS HCC risk scores of 
patients in this study.   
More information may be found in Duncan [35].   
 
 
Figure A5.1 Distribution of HCC Risk Scores for Hospice Population 
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5.7 Appendix B: Cancer diagnoses included in CMS’s Hierarchical Condition 
Categories  
The CMS HCCs group a number of different cancer diagnoses into categories denoted by 
Lung, Breast, Colorectal and Lymphatic cancers.  Within each of these groups are a number 
of other, less-prevalent cancers.  The following provides examples of the mapping of other 
cancers: 
Breast, Prostate and other cancers 
In addition to breast cancer this category includes cancer of the prostate, face, neck, 
genitals, etc. 
Lung and other severe cancers 
In addition to lung cancer, this category includes cancer of the esophagus, stomach, 
pancreas and leukemia.   
Colorectal, bladder and other cancers 
In addition to colorectal and bladder cancers, this category includes cancers of the mouth, 
tongue and kidneys.  
Lymphoma and other cancers 
In addition to cancers of the lymphatic system this category includes brain and ovarian 
cancers.   
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CHAPTER 6 – POLYPHARMACY, MEDICATION POSSESSION AND 
DEPRESCRIBING OF PREVENTATIVE DRUGS IN HOSPICE 
PATIENTS  
6.1 Background 
6.1.1 Introduction  
This chapter applies the principles of survival models to a problem frequently encountered 
in hospice: patients are prescribed drugs of limited efficacy that may also be potential 
sources of adverse drug events (ADEs).  We study the prevalence of drugs that are 
prescribed for preventive purposes, but which are no longer likely to be beneficial and 
could result in ADEs in a population with terminal illness, as well as the rate at which these 
drugs are withdrawn from patients (deprescribed).  
Patients receiving hospice and palliative care frequently have a number of co-
morbidities, in addition to the terminal illness that qualifies the patient for hospice.  
Because they often continue to require treatment for their underlying medical conditions, in 
addition to the medications prescribed for palliation, hospice patients frequently are at risk 
for polypharmacy.  Polypharmacy may be defined as the presence of five to nine different 
classes of medication; however, some definitions include taking a medication that lacks an 
indication, is ineffective, or duplicates treatment provided by another drug [43]. 
Polypharmacy is associated with multiple negative consequences, including an increased 
risk for adverse drug events, drug-drug and drug-disease interactions, reduced functional 
capacity, multiple geriatric syndromes, medication non-adherence, and increased mortality.  
Polypharmacy also contributes to increased health care costs for both the patient and the 
health care system [43].  
Deprescribing is defined as the systematic process of identifying and discontinuing 
drugs in instances in which existing or potential harms outweigh existing or potential 
benefits, within the context of an individual patient’s care goals, current level of 
functioning, life expectancy, values, and preferences [44].  After hospice election, many 
maintenance drugs, as well as drugs used to treat or cure a condition, should be considered 
for discontinuation, unless they are offering symptom relief.  
The Centers for Medicare and Medicaid Services (CMS, the administrator of the 
Medicare program for the elderly) pays hospices a per diem rate to include all medications, 
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services, and supplies related to the conditions affecting prognosis.  CMS expects that 
hospices provide “virtually all of the care needed by terminally ill individuals,” including 
related prescription drugs [45], p.2.  CMS requires hospices to cover the cost of these 
medications as part of the per diem payment.  In addition to the importance of 
deprescribing non-beneficial and over-used medications to decrease risk to patients, 
hospices should also take steps to deprescribe medications that are no longer needed by the 
patient, to avoid paying for treatment that is not medically necessary.  Studies of 
deprescribing in hospice patients are rare, and to our knowledge, this is the first study of 
medication possession and deprescribing rates in a large national database of hospice 
prescription drug data.   
6.2 Prior Studies 
As noted by Van Nordennen and colleagues [46], there is a lack of data regarding 
medication prescribing at the end of life.  Prior studies fall, generally, into three categories: 
principles of prescribing and consensus criteria [47, 48], reviews of the literature [49-54], 
or cohort studies of specific populations [37, 46, 55-60].  Although authors have studied 
institutionalized populations, studies of hospice patients are rare.  A frequent conclusion 
from review articles is that “patients with life-limiting illnesses are prescribed preventative 
medications considered inappropriate in the context of diminished life,” particularly lipid-
regulating drugs, antihypertensive, and antidiabetic medications ([53], abstract p.1).  Cohort 
studies reach similar conclusions.  For example, Currow and colleagues studied 260 
Australian end-of-life patients and concluded that “medications for co-morbid conditions 
especially for secondary prevention may be continued for longer than clinically 
indicated….there may be opportunities to prevent morbidity and even premature mortality 
in a person with a life-limiting illness, especially in older people, if medications for 
comorbid conditions are more actively managed” ([37], p. 593).  In a Dutch study, 
examining 155 patients with life expectancy of 3 months or less, Van Nordennen and 
colleagues observed that “all other [non-palliative] drug classes decreased between 
admission and date of death...including anti-coagulants, beta-blocking agents, drugs used in 
diabetes and lipid-modifying agents…. there are still patients dying with medication not 
used for symptom control” ([61], p.514)  Although several cohort studies report medication 
prevalence at admission and at death, ours is the first study that reports the observed rate at 
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which terminal patients are weaned from curative drugs, and the persistency of such drugs 
in the hospice population. 
6.3 Methods 
6.3.1 Design 
This is a historical cohort observational study that applies Cumulative Incidence Competing 
Risk survival models to our hospice database to estimate the rate of deprescribing of 
different drug classes.  Because patients survive in hospice for different durations, we also 
calculate patient medication possession ratios to estimate the percentage of a patient’s stay 
during which the patient had a prescription for each drug class.   
6.3.2 Potentially ineffective drug classes 
Our hospice population uses a wide range of drugs, classified by therapeutic class.  For this 
study, a professional pharmacist was consulted and has identified, for hospice patients at 
end of life, ten classes of potentially ineffective drugs.  The specific drugs that make up 
these classes number in the thousands; the actual drugs are available as supplementary 
material from the author.  Drug classes that consist of potentially ineffective drugs that 
show evidence of a high rate of prescribing within our database are antibiotics, anti-
hypertensives, proton pump inhibitors, inhalers, anti-coagulants, dementia medications, 
anti-virals, diabetes medications, statins and other lipid-lowering agents, appetite 
stimulants, and vitamins and supplements.   
6.4 Data 
In total, our data cover 186,904 patients admitted to hospice in 2015-2016, of whom 4,385 
remained alive at the date of extraction (May 2018).  See table 6.1.   
 
Year Female Male Total Subtotal 
 Alive Deceased Alive Deceased Alive Deceased By Year 
2015 140 42,730 55 31,350 195 74,080 74,275 
2016 3,041 63,949 1,149 44,490 4,190 108,439 112,629 
Subtotal by 
Year, Sex, and 
Status 
3,181 106,679 1,204 75,840 4,385 182,519 186,904 
 
Table 6. 1 Hospice Population by Age, Sex, Status, and Year of Admission 
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Study patients have a wide variety of primary conditions; for analysis, we grouped 
diagnoses using the Medicare hierarchical condition categories (HCCs) [35, 62].  We then 
aggregated Medicare HCCs into categories of conditions.  The aggregation of HCCs is 
described in Appendix 6.1.   
In table 6.2, we report patients by primary condition, grouped into seven primary 
condition categories.  In addition, for completeness (and because many published studies do 
not distinguish between palliative and therapeutic drug classes), we report both palliative 
and therapeutic drugs.  Palliative drugs make up a high percentage of all prescriptions, 
although the data also show significant therapeutic drug prescribing.  In the analysis that 
follows, we focus on other therapeutic and potentially ineffective classes that are often 
prescribed for maintenance rather than palliative care and omit the four palliative drug 
classes, because these classes are considered required for hospice patients and not a target 
for deprescribing.   
Overall, in Table 6.2, aggregating patients over the two years, 2015-2016, 173,246 
or 92.7% of all patients have an analgesic prescription (Table 6.3).  In table 6.2, cancer 
patients represent 66,656, or 35.7% of patients, out of the total patient population of 
186,904.  These patients account for 36.2% of all analgesic prescriptions (table 6.3), 
indicating that analgesic drug use is widely distributed by diagnosis and is not confined to 
cancer patients.  Of all cancer patients (66,656), 62,690, or 94.1%, have an analgesic 
prescription (table 6.4).   
The remainder of this chapter focuses on therapeutic or potentially ineffective 
drugs.  Patients with an antibiotic prescription number 43,316, or 23.2% of all patients.  
Cancer patients with an antibiotic prescription number 11,474.  Cancer patients represent 
26.5% of all patients with an antibiotic prescription (table 6.3) and 17.2% of all cancer 
patients have an antibiotic prescription (table 6.4).  It is important to note that tables 6.2 and 
6.3 show drug possession numbers and percentages for different diagnoses at some point 
during the hospice stay; they do not indicate the possession of these drugs over time.  
Because therapeutic drugs may have been prescribed at entry to hospice, they could be 
deprescribed during the patient’s stay.  Some patients will not have therapeutic 
prescriptions at admission to hospice because they have unused supplies of drugs from 
prior to admission; drugs will, however, be prescribed once supplies are exhausted.  We 
will study possession of drugs over time later in this chapter.  
  
 
Drug Class Cancer Dementia Heart Lung 
Gastro-
intestinal 
Kidney Liver Other Row total 
All 
 patients within 
drug class 
Palliative Drugs 
Analgesics 
 
62,690 
 
23,565 
 
18,841 
 
14,829 
 
2,482 
 
2,161 
 
1,853 
 
1,891 
 
128,312 
 
173,246 
Anxiolytics 53,292 20,442 16,353 13,145 2,043 1,823 1,634 1,566 110,298 134,672 
Laxatives 49,030 18,044 14,629 11,568 1,781 1,543 1,497 1,383 99,475 148,641 
Anti-nauseants 27,090 6,188 6,323 4,710 806 767 818 584 47,286 61,585 
Sub-total 192,102 68,239 56,146 44,252 7,112 6,294 5,802 5,424 385,371 518,144 
Other Drugs                     
Antibiotics 11,474 6,922 5,245 5,196 612 360 349 408 30,566 43,316 
Antihypertensives 6,963 3,610 8,728 3,215 358 594 257 278 24,003 36,219 
Proton pump inhibitors 13,459 2,587 3,643 3,494 394 302 498 256 24,633 31,934 
Inhalers 5,019 524 1,681 4,413 68 91 115 68 11,979 14,136 
Anticoagulants 1,717 293 1,880 524 55 50 6 34 4,559 6,211 
Antifungals 1,649 599 484 527 60 41 42 62 3,464 4,720 
Diabetes medications 987 307 430 288 20 41 34 24 2,131 3,072 
Dementia medications 76 793 69 40 17 6 1 8 1,010 1,568 
Antivirals 394 147 104 102 12 4 8 23 794 1,109 
Statins and other lipid-lowering agents 68 40 140 42 1 3 2 - 296 532 
Appetite stimulant 5 2 1 1 1 - - - 10 12 
Vitamins & supplements 1 1 1 1 - - 1 - 5 8 
Sub-total 41,812 15,825 22,406 17,843 1,598 1,492 1,313 1,161 103,450 141,766 
Total prescriptions 1,008,888 508,091 350,217 364,447 39,531 24,984 25,699 13,397 2,335,254   
Total patients with primary diagnosis 66,656 25,861 20,522 15,870 2,710 2,371 2,045 2,040 138,075 186,904 
Prescriptions per patient 15.14 19.65 17.07 22.96 14.59 10.54 12.57 6.57 16.91   
Table 6. 2 Distribution of Patients by Drug Class and Primary Condition (2015-2016) 
1
2
6
 
  
 
Drug Class Cancer Dementia Heart Lung 
Gastro-
intestinal 
Kidney Liver Other Row total 
All patients 
within drug 
class 
Palliative Drugs 
Analgesics 
 
0.362 
 
0.136 
 
0.109 
 
0.086 
 
0.014 
 
0.012 
 
0.011 
 
0.011 
 
0.741 
 
0.927 
Anxiolytics 0.396 0.152 0.121 0.098 0.015 0.014 0.012 0.012 0.819 0.721 
Laxatives 0.330 0.121 0.098 0.078 0.012 0.010 0.010 0.009 0.669 0.795 
Anti-nauseants 0.440 0.100 0.103 0.076 0.013 0.012 0.013 0.009 0.768 0.330 
                      
Other Drugs                     
Antibiotics 0.265 0.160 0.121 0.120 0.014 0.008 0.008 0.009 0.706 0.232 
Antihypertensives 0.192 0.100 0.241 0.089 0.010 0.016 0.007 0.008 0.663 0.194 
Proton pump inhibitors 0.421 0.081 0.114 0.109 0.012 0.009 0.016 0.008 0.771 0.171 
Inhalers 0.355 0.037 0.119 0.312 0.005 0.006 0.008 0.005 0.847 0.076 
Anticoagulants 0.276 0.047 0.303 0.084 0.009 0.008 0.001 0.005 0.734 0.033 
Antifungals 0.349 0.127 0.103 0.112 0.013 0.009 0.009 0.013 0.734 0.025 
Diabetes medications 0.321 0.100 0.140 0.094 0.007 0.013 0.011 0.008 0.694 0.016 
Dementia medications 0.048 0.506 0.044 0.026 0.011 0.004 0.001 0.005 0.644 0.008 
Antivirals 0.355 0.133 0.094 0.092 0.011 0.004 0.007 0.021 0.716 0.006 
Statins and other lipid-lowering agents 0.128 0.075 0.263 0.079 0.002 0.006 0.004 - 0.556 0.003 
Appetite stimulant 0.417 0.167 0.083 0.083 0.083 - - - 0.833 0.000 
Vitamins & supplements 0.125 0.125 0.125 0.125 - - 0.125 - 0.625 0.000 
 
Table 6. 3 Distribution of Primary Condition within Drug Class (2015-2016) 
 
 
  
1
2
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Table 6.4 shows the prevalence of different classes of prescriptions within each condition 
category.  For example, 94.1% of cancer patients have a prescription for an analgesic.  
Columns in table 6.4 sum to more than 100% because patients may have prescriptions from 
a number of drug classes.  
 
Drug Class Cancer Dementia Heart Lung 
Gastro-
intestinal 
Kidney Liver Other 
% Patients 
within 
Drug Class 
Palliative Drugs 
Analgesics 
 
0.941 
 
0.911 
 
0.283 
 
0.934 
 
0.916 
 
0.911 
 
0.906 
 
0.927 
 
0.929 
Anxiolytics 0.800 0.790 0.245 0.828 0.754 0.769 0.799 0.768 0.799 
Laxatives 0.736 0.698 0.219 0.729 0.657 0.651 0.732 0.678 0.720 
Anti-nauseants 0.406 0.239 0.095 0.297 0.297 0.323 0.400 0.286 0.342 
                    
Other Drugs                   
Antibiotics 0.172 0.268 0.256 0.327 0.226 0.152 0.171 0.200 0.221 
Antihypertensives 0.104 0.140 0.425 0.203 0.132 0.251 0.126 0.136 0.174 
Proton pump 
inhibitors 
0.202 0.100 0.178 0.220 0.145 0.127 0.244 0.125 0.178 
Inhalers 0.075 0.020 0.082 0.278 0.025 0.038 0.056 0.033 0.087 
Anticoagulants 0.026 0.011 0.092 0.033 0.02 0.021 0.003 0.017 0.033 
Antifungals 0.025 0.023 0.024 0.033 0.022 0.017 0.021 0.030 0.025 
Diabetes 
medications 
0.015 0.012 0.021 0.018 0.007 0.017 0.017 0.012 0.015 
Dementia 
medications 
0.001 0.031 0.003 0.003 0.006 0.003 0.000 0.004 0.007 
Antivirals 0.006 0.006 0.005 0.006 0.004 0.002 0.004 0.011 0.006 
Statins (HMG 
CoA Reductase 
Inhibitors) 
0.001 0.002 0.007 0.003 0.000 0.001 0.001 - 0.002 
Appetite stimulant 0.000 0.000 0.000 0.000 0.000 - - - 0.000 
Vitamins & 
supplements 
0.000 0.000 0.000 0.000 - - 0.000 - 0.000 
 
Table 6. 4 Prevalence of Drug Classes by Primary Condition (2015-2016) 
 
Tables 6.5 through 6.12 report the prevalence of potentially ineffective drugs by year, drug 
class, sex, and seven diagnosis categories.    
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Drug classes All diagnoses All diagnoses Row total 
 Female Male Female Male  
Antibiotics 9,545 6,620 28.9% 28.0% 16,165 
Antihypertensives 8,243 5,430 25.0% 23.0% 13,673 
Proton pump inhibitors 7,821 5,790 23.7% 24.5% 13,611 
Inhaler 3,544 2,996 10.7% 12.7% 6,540 
Anticoagulants 1,529 1,313 4.6% 5.6% 2,842 
Antifungals 1,342 592 4.1% 2.5% 1,934 
Diabetes medications 573 546 1.7% 2.3% 1,119 
Antivirals 259 189 0.8% 0.8% 448 
Statins (HMG CoA reductase inhibitors) 80 96 0.2% 0.4% 176 
Dementia medications 54 25 0.2% 0.1% 79 
Appetite stimulant 3 6 0.0% 0.0% 9 
Vitamins & supplements 4 1 0.0% 0.0% 5 
Total column 32,997 23,604 100.0% 100.0% 56,601 
Total patients 20,740 15,005    
Prescription per patient 1.59 1.57    
 
Table 6. 5 Number and Percentage of Patients with Potentially Ineffective Drugs (2015)   
 
Drug classes All diagnoses All diagnoses Row total 
 Female Male Female Male  
Antibiotics 16,872 10,279 32.5% 31.0% 27,151 
Antihypertensives 14,118 8,428 27.2% 25.4% 22,546 
Proton pump inhibitors 10,909 7,414 21.0% 22.3% 18,323 
Inhaler 4,208 3,388 8.1% 10.2% 7,596 
Anticoagulants 1,892 1,477 3.6% 4.5% 3,369 
Antifungals 2,064 722 4.0% 2.2% 2,786 
Diabetes medications 1,035 918 2.0% 2.8% 1,953 
Antivirals 414 247 0.8% 0.7% 661 
Dementia medications 275 143 0.5% 0.4% 418 
Statins (HMG CoA reductase inhibitors) 193 171 0.4% 0.5% 364 
Vitamins & supplements 3 - 0.0% 0.0% 3 
Appetite stimulant 1 2 0.0% 0.0% 3 
Total column 51,984 33,189 100.0% 100.0% 85,173 
Total patients 32,530 21,158    
Prescription per patient 1.60 1.57    
 
Table 6. 6 Number and Percentage of Patients with Potentially Ineffective Drugs (2016) 
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Drug classes Cancer Heart Lung Dementia Liver 
Gastro-
intestinal 
Kidney 
Antibiotics 4,861 1,718 1,936 2,089 165 181 87 
Antihypertensives 2,900 2,991 1,183 1,128 129 94 162 
Proton pump inhibitors 6,165 1,277 1,386 875 253 123 92 
Inhaler 2,473 687 1,802 225 73 25 25 
Anticoagulants 834 769 241 115 3 22 13 
Antifungals 747 191 191 191 20 17 13 
Diabetes medications 437 145 93 77 20 6 8 
Antivirals 168 32 32 49 3 1 2 
Statins (HMG CoA reductase inhibitors) 24 42 13 10 2 - - 
Dementia medications 4 2 1 48 - - - 
Appetite stimulant 5 1 1 1 - - - 
Vitamins & supplements 1 1 - 1 - - - 
Column total 18,619 7,856 6,879 4,809 668 469 402 
Total patients 12,612 4,326 3,714 3,384 437 340 262 
Prescription per class 1.48 1.82 1.85 1.42 1.53 1.38 1.53 
 
Table 6. 7 Relationship between Primary Condition and Potentially Ineffective Drugs 
(2015) 
 
Drug classes Cancer Heart Dementia Lung 
Gastro- 
intestinal 
Kidney Liver 
Antibiotics 6,613 3,527 4,833 3,260 431 273 184 
Antihypertensives 4,063 5,737 2,482 2,032 264 432 128 
Proton pump inhibitors 7,294 2,366 1,712 2,108 271 210 245 
Inhaler 2,546 994 299 2,611 43 66 42 
Anticoagulants 883 1,111 178 283 33 37 3 
Antifungals 902 293 408 336 43 28 22 
Diabetes medications 550 285 230 195 14 33 14 
Antivirals 226 72 98 70 11 2 5 
Dementia medications 23 16 205 13 6 - - 
Statins (HMG CoA reductase inhibitors) 44 96 30 28 1 3 - 
Vitamins & supplements - - - 1 - - 1 
Appetite stimulant - - 1 - 1 - - 
Column total 23,144 14,497 10,476 10,937 1,118 1,084 644 
Total patients 15,945 8,143 7,417 5,926 786 688 448 
Prescription per class 1.45 1.78 1.41 1.85 1.42 1.58 1.44 
 
Table 6. 8 Relationship between Primary Condition and Potentially Ineffective Drugs 
(2016) 
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Drug classes Cancer Heart Lung Dementia Liver 
Gastro- 
intestinal 
Kidney 
Antibiotics 38.5% 39.7% 52.1% 61.7% 37.8% 53.2% 33.2% 
Antihypertensives 23.0% 69.1% 31.9% 33.3% 29.5% 27.6% 61.8% 
Proton pump inhibitors 48.9% 29.5% 37.3% 25.9% 57.9% 36.2% 35.1% 
Inhaler 19.6% 15.9% 48.5% 6.6% 16.7% 7.4% 9.5% 
Anticoagulants 6.6% 17.8% 6.5% 3.4% 0.7% 6.5% 5.0% 
Antifungals 5.9% 4.4% 5.1% 5.6% 4.6% 5.0% 5.0% 
Diabetes medications 3.5% 3.4% 2.5% 2.3% 4.6% 1.8% 3.1% 
Antivirals 1.3% 0.7% 0.9% 1.4% 0.7% 0.3% 0.8% 
Statins (HMG CoA reductase inhibitors) 0.2% 1.0% 0.4% 0.3% 0.5% 0.0% 0.0% 
Dementia medications 0.0% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0% 
Appetite stimulant 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Vitamins & supplements 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Column total 18,619 7,856 6,879 4,809 668 469 402 
Total patients 12,612 4,326 3,714 3,384 437 340 262 
Prescription per class 1.48 1.82 1.85 1.42 1.53 1.38 1.53 
 
Table 6. 9 Frequency of Potentially Ineffective Drugs by Patient and Primary Condition 
(2015) 
 
 
Drug classes Cancer Heart Dementia Lung 
Gastro- 
intestinal 
Kidney Liver 
Antibiotics 41.5% 43.3% 65.2% 55.0% 54.8% 39.7% 41.1% 
Antihypertensives 25.5% 70.5% 33.5% 34.3% 33.6% 62.8% 28.6% 
Proton pump inhibitors 45.7% 29.1% 23.1% 35.6% 34.5% 30.5% 54.7% 
Inhaler 16.0% 12.2% 4.0% 44.1% 5.5% 9.6% 9.4% 
Anticoagulants 5.5% 13.6% 2.4% 4.8% 4.2% 5.4% 0.7% 
Antifungals 5.7% 3.6% 5.5% 5.7% 5.5% 4.1% 4.9% 
Diabetes medications 3.4% 3.5% 3.1% 3.3% 1.8% 4.8% 3.1% 
Antivirals 1.4% 0.9% 1.3% 1.2% 1.4% 0.3% 1.1% 
Dementia medications 0.1% 0.2% 2.8% 0.2% 0.8% 0.0% 0.0% 
Statins (HMG CoA reductase inhibitors) 0.3% 1.2% 0.4% 0.5% 0.1% 0.4% 0.0% 
Vitamins & supplements 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 
Appetite stimulant 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 
Column total 23,144 14,497 10,476 10,937 1,118 1,084 644 
Total patients 15,945 8,143 7,417 5,926 786 688 448 
Prescription per class 1.45 1.78 1.41 1.85 1.42 1.58 1.44 
 
Table 6. 10 Frequency of Potentially Ineffective Drugs by Patient and Primary Condition 
(2016) 
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Drug classes Cancer Heart Lung Dementia Liver 
Gastro-
intestinal 
Kidney 
Row  
total 
Antibiotics 44.0% 15.6% 17.5% 18.9% 1.5% 1.6% 0.8% 100.0% 
Antihypertensives 33.8% 34.8% 13.8% 13.1% 1.5% 1.1% 1.9% 100.0% 
Proton pump inhibitors 60.6% 12.6% 13.6% 8.6% 2.5% 1.2% 0.9% 100.0% 
Inhaler 46.6% 12.9% 33.9% 4.2% 1.4% 0.5% 0.5% 100.0% 
Anticoagulants 41.8% 38.5% 12.1% 5.8% 0.2% 1.1% 0.7% 100.0% 
Antifungals 54.5% 13.9% 13.9% 13.9% 1.5% 1.2% 0.9% 100.0% 
Diabetes medications 55.6% 18.4% 11.8% 9.8% 2.5% 0.8% 1.0% 100.0% 
Antivirals 58.5% 11.1% 11.1% 17.1% 1.0% 0.3% 0.7% 100.0% 
Statins (HMG CoA reductase 
inhibitors) 
26.4% 46.2% 14.3% 11.0% 2.2% 0.0% 0.0% 100.0% 
Dementia medications 7.3% 3.6% 1.8% 87.3% 0.0% 0.0% 0.0% 100.0% 
Appetite stimulant 62.5% 12.5% 12.5% 12.5% 0.0% 0.0% 0.0% 100.0% 
Vitamins & supplements 33.3% 33.3% 0.0% 33.3% 0.0% 0.0% 0.0% 100.0% 
 
Table 6. 11 Frequency of Potentially Ineffective Drugs Classes by Primary Condition 
(2015) 
 
Drug classes Cancer Heart Dementia Lung 
Gastro-
intestinal 
Kidney Liver 
Row 
total 
Antibiotics 34.6% 18.4% 25.3% 17.0% 2.3% 1.4% 1.0% 100.0% 
Antihypertensives 26.8% 37.9% 16.4% 13.4% 1.7% 2.9% 0.8% 100.0% 
Proton pump inhibitors 51.3% 16.7% 12.1% 14.8% 1.9% 1.5% 1.7% 100.0% 
Inhaler 38.6% 15.1% 4.5% 39.6% 0.7% 1.0% 0.6% 100.0% 
Anticoagulants 34.9% 43.9% 7.0% 11.2% 1.3% 1.5% 0.1% 100.0% 
Antifungals 44.4% 14.4% 20.1% 16.5% 2.1% 1.4% 1.1% 100.0% 
Diabetes medications 41.6% 21.6% 17.4% 14.8% 1.1% 2.5% 1.1% 100.0% 
Antivirals 46.7% 14.9% 20.2% 14.5% 2.3% 0.4% 1.0% 100.0% 
Dementia medications 8.7% 6.1% 77.9% 4.9% 2.3% 0.0% 0.0% 100.0% 
Statins (HMG CoA reductase 
inhibitors) 
21.8% 47.5% 14.9% 13.9% 0.5% 1.5% 0.0% 100.0% 
Vitamins & supplements 0.0% 0.0% 0.0% 50.0% 0.0% 0.0% 50.0% 100.0% 
6Appetite stimulant 0.0% 0.0% 50.0% 0.0% 50.0% 0.0% 0.0% 100.0% 
 
Table 6. 12 Frequency of Potentially Ineffective Drugs Classes by Primary Condition 
(2016) 
 
6.5 Results 
The analysis above shows information about drug prevalence but does not provide 
information about the duration of that possession or the rate at which drugs are withdrawn.  
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To understand the rate at which drugs are terminated or deprescribed we calculate the 
Cumulative Incidence Function (the complement of the survival function or crude 
incidence rate) often used in the analysis of competing risks.  Applying regular survival 
analysis in the presence of competing risks will lead to an overestimate of the true rate of 
the event of interest.   
 
6.5.1  Competing risks 
In our study of the termination of prescriptions, death is the competing risk event to 
prescription termination: the occurrence of death prevents the prescription from running for 
a full term (or being renewed) and is therefore a competing event to the prescription 
termination event.  “Competing risks are said to be present when a patient is at risk of more 
than one mutually exclusive event, such as death from different causes, and the occurrence 
of one of these will prevent any other event from ever happening” [63].  “When estimating 
the crude incidence of outcomes, analysts should use the cumulative incidence function, 
rather than the complement of the Kaplan-Meier survival function. The use of the Kaplan-
Meier survival function results in estimates of incidence that are biased upward, regardless 
of whether the competing events are independent of one another” [64]. 
 
Let ( )rxF t be the cumulative incidence function (CIF) for the event of interest; in our case, 
the termination of prescriptions within a drug class.  The CIF gives the proportion of 
patients whose prescriptions at time t  have terminated but who are still alive and at risk of 
death.  The CIF for prescription termination is calculated as follows:   
0
( ) Pr( , ) ( , ) ( )
t
rx rxF t T t D rx h u X S u du        (6.1) 
Where D  is the random variable denoting cause of failure, ( )rxh t is the cause-specific 
hazard function at time t (i.e. the instantaneous risk of prescriptions being terminated given 
that the patient still has prescriptions at time t , X is the vector of covariates and ( )S t is the 
overall survival function.   In this study, D is either “death” (coded as “1”) when death 
occurs prior to prescription termination, or “rx termination” (coded as “2”) when death 
occurs after termination of prescription. Censored events are coded as “0” (i.e. patients are 
alive with prescription end-point after the evaluation date).  
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In equation 6.3 calculation of the CIF is a two-step process: the first step is the application 
of the regular Kaplan-Meier approach to estimate the overall survival probability (the 
proportion of patients who have not experienced an end-point (death or prescription 
termination)).  The second step is to compute the conditional probabilities of the event of 
interest (cause-specific probability).   
 
6.5.2 Cumulative Incidence Function analysis of termination rates 
Initially, 100% of patients within a class have a prescription; over time, the  CIF curve 
represents the patient drug discontinuation within the class.  The CIF approach (figure 6.1) 
for competing risks estimates the duration of patients taking additional drugs while 
considering the patient’s future lifetime during hospice admission.  The y-axis shows the 
cumulative incidence rate; the x-axis shows the duration of drug prescription (days).  Anti-
fungal, anti-viral, and antibiotic medications are prescribed for the shortest period, with 
median prescription termination of seven, ten and twelve days, respectively.  Twenty-five 
percent of patients have an anti-fungal prescription terminated at three days or less; 
seventy-five percent of patients have their anti-fungal medication withdrawn within twenty-
two days.  Conversely, proton pump inhibitors (PPI) and anti-hypertensives are withdrawn 
more slowly with twenty-fifth quantile prescription terminations of 43 and 47 days.Note 
that the median and the seventy-fifth quantile prescription for some of these classes are 
‘missing’ (“NA” in Table 6.13) as the CIF curves never reach the levels of 0.5 and 0.75 on 
the y-axis. This suggests that there is limited deprescribing these prescriptions during 
patient’s stay in hospice; the prescriptions persist during the patient’s stay. In particular 
more than half of patients did not have their prescriptions terminated within a year.  
 Table 6.13 only reports duration quantiles; we also need to relate duration of the 
prescription to length of hospice stay, which we do using Medication Possession Ratios.  
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Drug classes 
                      CIF 
(death is the competing risk event) 
 Q25 Q50 Q75 
Antifungals 3 7 22 
Antivirals 7 10 304 
Antibiotics 7 12 240 
Vitamins & supplements  15 21 27 
Inhaler 5 23 183 
Statins and other lipid-lowering agents 15 93 NA 
Dementia medications 
Anticoagulants 
17 
21 
120 
146 
NA 
352 
Diabetes medications 17 197 NA 
Appetite stimulant 17 296 296 
Antihypertensives 47 NA NA 
Proton pump inhibitors 43 NA NA 
 
Table 6. 13 Quantile Survival Time of Drug Classes in Days 
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Figure 6. 1 Cumulative Incidence Function (CIF) Estimates of Termination of Preventive 
Drugs 
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6.5.3  Prescription Durations: Medication Possession Ratios 
The CIF approach shows the rate at which drug classes are withdrawn; it does not show the 
relationship of prescription duration and hospice length of stay.  Because patients have 
different durations on drugs, as well as different hospice length of stay, we need a way to 
relate the two. In addition to looking at the persistency of patient drug possession within 
each class we calculate a possession ratio at the individual patient level.  Possession Ratio 
is defined as the percentage of time that a patient has access to a medication, relative to the 
time that the patient could have had the medication.  On our context, the medication 
possession ratio for a patient is defined as: 
Days supply during hospice stay
Duration of hospice stay in days


 for each 
medication.   
Table 6.14 shows the distribution of Medication Possession Ratios for each drug.   
 
Drug Class Number of 
prescriptions Min Q25 Q50 Mean Q75 Max 
Antihypertensives 259,116 0.0000 0.7872 0.9299 0.8440 0.9834 1 
Proton pump inhibitors 142,123 0.0000 0.7143 0.9009 0.8096 0.9756 1 
Anticoagulants 33,675 0.0000 0.6410 0.8558 0.7659 0.9608 1 
Diabetes medications 13,585 0.0000 0.6077 0.8421 0.7478 0.9565 1 
Dementia medications 8,351 0.0061 0.6062 0.8377 0.7427 0.9400 1 
Appetite stimulant 18  0.1339 0.5089 0.8000 0.7147 0.9565 0.9184 
Statins and other lipid-
lowering agents 2,020  0.0126 0.5120 0.7564 0.6881 0.9164 1 
Inhalers 43,940 0.0000 0.4337 0.7551 0.6567 0.9241 1 
Vitamins and supplements 16  0.0281 0.1042 0.7778 0.5732 0.9184 1 
Antibiotics 91,691 0.0000 0.1911 0.5455 0.5223 0.8404 1 
Antivirals 1,755 0.0014 0.0893 0.4233 0.4618 0.8182 1 
Antifungals 6,578 0.0000 0.0411 0.1856 0.3237 0.5989 1 
 
Table 6. 14 Distribution of Medication Possession Ratios for potentially-inappropriate 
drugs 
In Table 6.14 the fractions indicate the proportion of their hospice stays that patients with 
the specific drug have a supply of the drug.  In the case of hypertensive medications, for 
example the 25th Quantile is 0.7872, implying that 75% of all patients have the drug in their 
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possession for almost 80% of their stays. Proton pump inhibitors (PPIs) are another drug 
with high possession ratios: 50% of all patients have a PPI for more than 90% of their 
hospice stay.  The conclusion from Table 6.14 is that, with the possible exception of 
antiviral and anti-fungal medications, patients have prescriptions for potentially-
inappropriate medications for a considerable portion of their stays in hospice.  
The variance in individual patients’ medication possession ratios can be considerable in the 
case of some drugs.  Figure 6.2 shows the mean and variance of each drug.  PPIs, which 
have a high mean possession ratio also have a narrow confidence interval, implying that 
patients with these drugs take them for a considerable portion of their hospice stays, and 
that there is relatively little variation by patient in terms of the proportion of hospice stay 
during which the patient has one of these drugs.  Antibiotics, anti-fungals and anti-viral 
medications have relatively low mean possession ratios, but also have relatively wide 
confidence intervals, implying that there is considerable variation in the length of the 
prescription by patient.   
 
 
Figure 6. 2  Mean and variance of Medication Possession Ratios by drug class.  
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Figure 6.3  Distribution of Medication Possession Ratios for Potentially-ineffective drugs 
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Figure 6.3 shows graphically the distribution of medication possession by drug class. Anti-
hypertensives, PPIs, anti-coagulants, diabetes medications and dementia medications are all 
heavily skewed toward possession for a high proportion of the hospice stay.  Appetite 
stimulants, inhalers, antibiotics, anti-viral medications and statins are more uniformly 
distributed, although in all cases some proportion of patients have prescriptions for their 
entire stay.  Anti-fungal medications are the exception with most patients having brief 
possession.  Antibiotics and anti-viral medications are more uniformly distributed with 
relatively low frequencies of patients having these drugs for a high percentage of their 
stays.  Other potentially-ineffective drugs, such as statins, continue to be prescribed: one 
patient in five has a statin for the entire hospice stay.  
  
6.6 Discussion 
Numerous studies point to the persistency of potentially ineffective drugs, leading 
to the possibility of polypharmacy in the hospice population.  Using a large database of 
hospice drug claims, we found, among hospice patients, there is a high prevalence of drugs 
that are frequently over-prescribed and potentially inappropriate.  The average patient has 
16.9 prescriptions during the hospice stay, representing 3.5 classes of medications.   
   
The median persistency of a drug class is shown in Table 6.13.  Our CIF  analysis 
shows that for several drug classes the median persistency is brief ( 7 days for anti-fungal 
medications and 10 days for antivirals).  Even drugs considered to be candidates for 
deprescribing, such as statins, have long persistency (a median persistency of 93 days  in 
the case of statins, implying that these drugs are deprescribed very slowly (if at all). For 
some drugs we are unable to calculate a median or higher quantile because prescriptions 
persist for these drugs well into the patient’s stay. 
 
Our data allows us to estimate the persistency of different drug classes within 
patients’ hospice stays, as measured by the Medication Possession Ratio.  Palliative drugs 
are prescribed with high frequency in the hospice population (with the exception of anti-
nauseants, the frequency ranges between 72% and 93% of all patients).  The incidence of 
most therapeutic drugs is low; with the exception of antibiotics, anti-hypertensives, and 
proton pump inhibitors (PPIs), no drug class is prescribed in more than 8% of the 
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population.  Antibiotics, anti-hypertensives, and PPIs are classes that are frequently 
mentioned in the literature as candidates for deprescribing; between 17% and 23% of the 
population has one or more of these drugs.  The sole exception to the low frequency of 
other drugs is inhalers, whose incidence is 28% among patients with a lung diagnosis.   
Analysis of Medication Possession Ratios is a relatively straightforward way to 
understand the deprescribing rate for different medications among hospice patients.  
Medication possession shows the proportion of the time when a patient has a prescription 
for a drug compared with the time that the patient could have the drug.  In our case the time 
when the patient could have the drug is the entirety of the patient’s hospice stay.  For most 
drugs Medication Possession ratios are high.  This is especially true of drugs such as Proton 
Pump Inhibitors for which the median possession ratio is 90%: more than half of all 
patients with a PPI prescription have the drug for more than 90% of their stay.  The only 
class of drugs with low possession ratios is anti-fungal, which is appropriate.   
 
6.7 Conclusion 
While the literature addresses principles of prescribing and desprescribing among patients 
of limited life expectancy (LLE), this is the first study, of which we are aware, that 
examines actual prescribing and medication possession rates among a large population of 
hospice patients.  Using a database of hospice drug claims, we found there is a relatively 
high prevalence, among hospice patients, of some classes of drugs that are considered by 
clinical consensus to be frequently over-prescribed and potentially inappropriate, although 
high prevalence of potentially inappropriate drugs is limited to PPIs, anti-hypertensives, 
and antibiotics.  In addition to high prevalence within the hospice population, these drugs 
are also prescribed for a high percentage of the patients’ average stay in hospice, suggesting 
that more should be done to examine patients’ medication regimens and deprescribe these 
drugs where appropriate.   
6.7.1 Limitations 
The drug classes examined in this study are potentially ineffective for patients at end of 
life; we did not examine patient charts that could indicate circumstances in which the 
prescriptions were appropriate.  Although this study is based on a large national database of 
hospice drug claims, it represents the experience of one PBM.  Our dataset consisted of 
demographic, prescription, and diagnosis data only and, therefore, does not include other 
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information about patient or prescriber-related factors that could affect prescribing 
behaviour.  
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6.8 Appendix A: Condition Categorization 
Cancer 
HCC8 = Metastatic Cancer and Acute Leukemia 
HCC9 = Lung and Other Severe Cancers 
HCC10 = Lymphoma and Other Cancers 
HCC11 = Colorectal, Bladder, and Other Cancers 
HCC12 = Breast, Prostate, and Other Cancers and Tumors 
Dementia 
HCC51 = Dementia With Complications 
HCC52 = Dementia Without Complication 
HCC54 = Drug/Alcohol Psychosis 
HCC55 = Drug/Alcohol Dependence 
HCC57 = Schizophrenia 
HCC58 = Major Depressive, Bipolar, and Paranoid Disorders 
Heart 
HCC85 = Congestive Heart Failure 
HCC86 = Acute Myocardial Infarction 
HCC87 = Unstable Angina and Other Acute Ischemic Heart Disease 
HCC88 = Angina Pectoris 
HCC96 = Specified Heart Arrhythmias 
 
Lung 
HCC82 = Respirator Dependence/Tracheostomy Status 
HCC83 = Respiratory Arrest  
HCC84 = Cardio-Respiratory Failure and Shock 
HCC111 = Chronic Obstructive Pulmonary Disease 
HCC112 = Fibrosis of Lung and Other Chronic Lung Disorders 
HCC114 = Aspiration and Specified Bacteria Pneumonias 
HCC115 = Pneumococcal Pneumonia, Empyema, Lung Abscess 
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Gastrointestinal 
HCC21 = Protein-Calorie Malnutrition 
HCC22 = Morbid Obesity 
HCC33 = Intestinal Obstruction/Perforation 
HCC34 = Chronic Pancreatitis 
HCC35 = Inflammatory Bowel Disease 
 
Liver  
HCC27 = End-Stage Liver Disease 
HCC28 = Cirrhosis of Liver 
HCC29 = Chronic Hepatitis 
Kidney  
HCC134 = Dialysis Status 
HCC135 = Acute Renal Failure 
HCC136 = Chronic Kidney Disease, Stage 5 
HCC137 = Chronic Kidney Disease, Severe (Stage 4) 
HCC138 = Chronic Kidney Disease, Moderate (Stage 3) 
HCC139 = Chronic Kidney Disease, Mild or Unspecified (Stages 1-2 or Unspec.) 
HCC140 = Unspecified Renal Failure 
HCC141 = Nephritis 
Other 
HCC2 = Septicemia, Sepsis, Systemic Inflammatory Response Syndrome/Shock 
HCC6 = Opportunistic Infections 
HCC17 = Diabetes with Acute Complications 
HCC18 = Diabetes with Chronic Complications 
HCC19 = Diabetes without Complication 
HCC122 = Proliferative Diabetic Retinopathy and Vitreous Hemorrhage 
 
HCC39 = Bone/Joint/Muscle Infections/Necrosis 
HCC40 = Rheumatoid Arthritis and Inflammatory Connective Tissue Disease 
HCC46 = Severe Hematological Disorders 
HCC166 = Severe Head Injury 
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HCC167 = Major Head Injury 
HCC169 = Vertebral Fractures without Spinal Cord Injury 
HCC170 = Hip Fracture/Dislocation 
HCC173 = Traumatic Amputations and Complications 
HCC176 = Complications of Specified Implanted Device or Graft 
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CHAPTER 7 – WHAT IS KNOWN ABOUT SURVIVAL OF HOSPICE 
PATIENTS: REVIEW OF THE LITERATURE19  
Much of the (considerable) literature on patient survival rates in hospice addresses the 
accuracy of physician prognosis.  Under Medicare rules, a patient must have a concurring 
prognosis from their own, and the hospice’s, physician that life expectancy is six months or 
less.  In 1996, Christakis and Escarce [65] analyzed a sample of Medicare data from 1990-
1993 and found that median survival in hospice was 36 days, with significant variance, 
depending on the admitting diagnosis.  About 15% of patients died within seven days and 
another 15% survived six months or longer.  In the 1990s, Christakis [66] recognized the 
advantages of hospice care, but also the barriers, which included referring physicians’ 
prognoses.  As a result, the stay of many patients in hospice was very short.    
There are two approaches to predicting survival of terminally-ill patients: clinical 
and statistical (actuarial).  Clinical estimation involves specifying the amount of time a 
patient will survive, based on a combination of subjective clinical experience and 
prognostic factors.  Physician assessment of prognosis, drawing on clinical experience, has 
been investigated in multiple studies and found to be largely unreliable [67].  In a study of 
over 1,500 cancer patients, Glare et al found that estimates were correct to within one week 
25% of the time; two weeks, 43% of the time and four weeks 61% of the time [68].  One 
study found that physicians over-estimated survival, by a factor of five [69].  Tools, such as 
the palliative performance scale (PPS), are used by physicians and hospices to aid in the 
estimation of life expectancy.   
7.1 Palliative Performance Scale to Estimate Length of Stay 
The palliative performance scale was introduced in 1996 as a tool to estimate life 
expectancy for patients being admitted to palliative care services.  This scale consists of 
five functional domains: ambulation, activity level and evidence of disease, self-care, oral 
intake, and level of consciousness.  Patients are scored in each domain on a scale of 0% to 
100%, by intervals of 10% (not a continuous scale).  Scores on this scale are subjective and 
researchers have questioned its reliability.  Nevertheless, the scale is widely used.  Some 
researchers argue that PPS should be split into three categories: the stable stage (scores 
                                                          
19 This literature review relates to the survival of patients in hospice, for which we develop models in the next 
chapter.   
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100% to 80%), the transitional stage (scores 70% to 40%), and the end-of-life stage (scores 
30% to 0%) [70].  
While certain patients may live longer than the six months, required by Medicare’s 
eligibility rules, and still be eligible for hospice, these patients are likely to undergo 
regulatory scrutiny and will require documentation from a physician to justify the need for 
hospice care.  In 2011, CMS began requiring hospices to conduct face-to-face visits to 
assess eligibility for hospice services when a patient is on service for 180 days [71].  
Because of these regulations, studies have assessed whether hospices are able to predict 
length of stay, and, in particular, the accuracy of the six months’ prediction.  Numerous 
studies have been performed to assess the reliability of the palliative performance scale, as 
a predictor of life expectancy.   
Harris et al. [72] looked at demographic variables, such as age, gender, race, and 
primary and secondary diagnoses of 126,620 patients in ten different hospices.  Patients 
diagnosed with debility, or dementia, were likely to live past six months (> 50% 
probability).  This study also found that patients who scored 60% or higher on the palliative 
performance scale were likely to live past six months (>50% probability).   
A similar study, by Rothenberg [73], looked at the common characteristics of 
patients who received face-to-face visits. The study also found that patients with a primary 
diagnosis of debility or dementia were more likely to live past six months and receive a 
face-to-face visit.  When compared to patients with a cancer diagnosis, debility, or 
dementia, patients were three times more likely to receive a face-to-face visit.  Singh [74] 
studied the PPS Score of 7,574 patients in a Pennsylvania hospice.  This study, 
unfortunately, does not report the numbers of patients who survive 180 days or more; 
however, Singh does report length of stay categories, by PPS score [63].  The data 
presented in table 7.1 are taken from this study. 
 
PPS 
Score  
Frequency LOS ≤ 7 
days 
LOS > 7 
days 
< 30 41% 82% 18% 
30 21% 44% 56% 
40 22% 27% 73% 
50 13% 16% 84% 
60+ 3% 7% 93% 
 
Table 7. 1 Relationship Between PPS and Survival 
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As these results show, the PPS score is reasonably successful at categorizing 
patients into two groups (those patients that survive for fewer than 7 days and those that 
survive more than 7 days) by survival percentages.  The number of “actuarial” or statistical, 
papers addressing survival is far fewer than the number of clinical papers, and we found 
few articles using prescribing data as covariates. 
7.2 Actuarial (Statistical) Studies Estimating Length of Stay 
Christakis and Escarce [65] applied Kaplan-Meier survival analysis and found significant 
differences, in terms of median survival, by admitting diagnosis (from 17 days for renal 
failure to 76.5 days for COPD) (p<0.001 using the Kruskal-Wallis test of difference in 
medians among diagnoses).  Of note is that the authors found that 15% of patients survived 
for 180 days or more.  These authors also model the influence of co-variates on length of 
stay: the number of recent hospitalizations, the type of hospice, and the risk profile of the 
patient all being significant factors.  Han et al [75] developed a multi-variate model based 
on a number of dimensions of self-reported data including: socio-demographics, co-
morbidities, health-related quality of life, activities of daily living (ADLs), and the medical 
outcomes study short form (SF-36).  This model out-performs the traditional PPS score, in 
terms of predicting six-month survival rates.  Some authors have addressed mathematical 
models of survival, for example Miladinovic and colleagues [76, 77] and Chiang and 
colleagues [78].  Chiang and colleages [78] developed a model for predicting death within 
seven days for cancer patients.  Their full model relies on demographic, laboratory, and 
clinical data and outperforms a model based on demographic and clinical (diagnostic) data 
only (ROC c-statistic of 82.3% vs. 77.8%).  Interestingly, Chiang et al point to a 
shortcoming of the statistical models: “..none of these methods can give us the full picture 
of the changes in survival probability for a given patient, over time, until death with the 
best available statistical accuracy.” [79].  Chiang and colleagues present a method for 
estimating individual Cox proportional hazards models for patients based on covariates, but 
the models are static (based on initial covariate values).  A different Chiang model uses 
time-dependent covariates [80], discussed below.  
Mladinovic et al [76] developed a predictive model, based on age, sex, diagnosis, and 
PPS score, but found that the addition of other variables, to PPS, while increasing the 
accuracy somewhat, did not result in a satisfactory accuracy.  This study used the Cox 
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proportional hazards models to estimate survival.  The same authors applied the Royston-
Parmar survival model [77] and found that the Royston-Parmar model fits the data 
significantly better than the Cox PH model.   
A considerable number of studies apply Kaplan-Meier or Cox proportional hazards 
models to survival data with different covariates  [81-89].  Significant covariates that are 
correlated with length of stay include age, marital status, secretions, performance scale 
(either PPS or Karnofsky performance scale, a similar index), and diagnosis. However, 
these studies are static.  The present study, using dynamic modelling of prescription drugs, 
provides the first possibility for addressing this shortcoming.   
7.3 Prescription Drug Use and Survival 
There is a body of (clinical) work researching the relationship between drug use, primarily 
opioids, but also sedatives, and survival.  Perhaps the best-known example of the role of 
opioids in hastening death, reported by Joseph Lelyveld in the New York Times in 1986, is 
that of his late Majesty, George V, whose doctor admitted to administering a lethal dose, in 
order that the King’s death could be announced in the The Times the following morning 
[90].  As stated by Sykes and Thorns [91] in 2003, “Opioids and sedative drugs are 
commonly used to control symptoms in patients with advanced cancer.  However, it is often 
assumed that the use of these drugs inevitably results in shortening of life.”   A review of 
selected studies, however, does not confirm this observation.  A survey of Dutch physicians 
in 2005, by Rurup et al [92] (following up on 1995 and 2001 surveys),  found some 
evidence of physicians prescribing opioids in order to hasten death.  However, the 
frequency had dropped with successive surveys, from 7% in 1995 to 3.1% in 2005.   The 
frequency with which physicians reported belief in the link between opioid use and earlier 
death also fell in successive surveys.   
In a 1999 study of hospice patients, Bercovitch et al [93] found that high-dosage 
morphine use did not affect survival.  In a later, 2004, study the same authors found similar 
results in a home hospice population: “very high doses of morphine … did not appear to 
affect the patients’ life expectancy adversely.” [94].  In another study of high-dosage 
OxyContin, Bercovitch and Adunsky [95] again found no relationship between dosage and 
shorter survival times.  Azoulay et al [96] studied whether opioids help or hinder survival 
of advanced cancer patients in hospice.  The authors conclude that opioid usage, even at 
high dosages, has no effect on survival.  Sykes and Thorns [91] reviewed 17 studies of the 
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use of opoids at the end of life.  The mean dose at admission varied significantly in six 
reported studies; however, the unweighted average increase in dosage in these studies 
between admission and death was 67%. The authors report five studies that examined the 
relationship between opioid use and survival (including the study by Bercovitch et al in 
1999 [93]) and found no studies that showed that opioid use shortened life.  Portenoy et al 
[97] studied 1,306 hospice patients and compared patients who received maximum doses 
with those who received usual doses of opioids. The authors found that in a multivariate 
regression study, while there was association between opioid dosage and shorter survival 
times, the model explained less than 10% of the overall variance in survival times.  With 
the exception of Portenoy’s study [97], most studies stratified the population by opioid dose 
into normal, high, or very high categories and compared the outcomes.  In some cases, 
further analysis was conducted, according to different covariates such as age, sex, or 
admitting diagnosis.  An example of such studies is a Spanish study of 223 patients by 
Bengoechea et al [98].  The authors stratify doses into two categories: regular (maximum 
dose less than 120 mg morphine) and high (maximum dose greater than 120 mg 
morphine)20.  The authors find that those administered higher doses survive longer; 
however, adjusting for covariates, most of this survival difference disappears except in 
patients with maximum dose greater than twice their initial dose at admission.   
Sykes and Thorns’ study [91] also surveyed 17 studies that address the use of 
sedatives at the end of life.  While analysis of sedation is more difficult than analysis of 
opioids, they conclude that “patients who received sedatives for over a week before death 
had better survival than those who did not receive sedation; patients who only had two or 
three days of sedatives had the same survival as those who never received sedation.”  The 
same authors [99] studied 237 hospice patients administered sedation and concluded 
“Sedation was given to 48% of patients. Of these, 13% received sedatives for seven days or 
more, while 56% commenced sedative use only in the last 48 hours of life.  The groups 
receiving no sedation or sedation for less than 48 hours had the shortest survival from 
admission (mean, 14.3 and 14.2 days), whereas the seven-day sedation group survived for a 
mean of 36.6 days (P <. 001).  Sedative use and dose increased toward the end of life.”  A 
                                                          
20 It should be noted that this opioid dosage is higher than that recommended in the U.S. by the CDC (90 mg. 
morphine-equivalent per day); although, as our data show, it is more representative of the average daily dose 
for hospice patients.  
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Dutch study by Rietjens et al [100], looked specifically at sedative use and found slightly 
longer, but not statistically-significant, survival after admission (eight days vs. seven days), 
among sedated patients compared with those that did not receive sedation.  Boland and 
colleagues, in a 2015 study [101], found little supporting evidence, in 20 studies reviewed, 
of shorter lifespans associated with opioid use, although this conclusion was largely due to 
short, poorly-constructed studies. 
7.4 Studies of the Effect of Varying Dosage on Survival 
There are few studies of the effect of variation in dosage. Chiang and Kao [80] report a 
Taiwanese study employing time-dependent Cox models to predict death.  The authors’ 
model finds that a three-day negative trend in morphine dosage is associated with death 
within one day. Other independent variables are also predictive, but none are related to 
opioid dosage.  The Chiang and Kao study appears to be the only one of its type (using 
time-dependent covariates).  In summary, most studies appear to show no, or a limited, 
relationship between opioid or sedative dosage and survival.  However, there are 
indications that a more rigorous multivariate analysis may show different results, as we 
shall examine in the next chapter.  
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CHAPTER 8 - RESULTS 
Introduction 
In this chapter we attempt to fit both semi-parametric and non-parametric survival models 
to the same data.  Cox regression requires no distributional assumption prior to fitting the 
model but it does require additional tools to predict life expectancy in hospice for new 
patients. Parametric models are chosen after we examine the distributional assumptions for 
the survival random variables. The estimation of future life expectancy in hospice for new 
patients is straightforward via parametric models. 
 
8.1 Exploratory Data Analysis:  Kaplan-Meier 
 
Kaplan-Meier estimation provides a visual way to determine the shape of the underlying 
distribution of the baseline hazard function and the survival function.  Earlier, we defined.       
1 1 2 2 0( ) exp( ... ) ( )i i i p pih t x x x h t       = 
'
0exp( ) ( )h t                                             (8.1) 
Integrating: 
'
0
0 0
( ) exp( ) ( )
t t
ih u du h u du                                                                    (8.2) 
and defining  '
0( ) exp( ) ( )iH t H t                                                                                (8.3) 
'
0ln ( ) ( ) ln ( )iH t X H t                                                                                                 (8.4) 
or the log-cumulative hazard function.  The plot of the log-cumulative hazard function, 
after converting data to a categorical basis, against the log of t, is a diagnostic for assessing 
the validity of the proportional hazards assumption.  
 
     
Number of 
observations 
Deaths 
Median 
survival 
time 
0.95 lower 
bound 
0.95 upper 
bound 
499,264 478,397 27 27 28 
Median Survival Time:  27 days.  
* 21,002 patients with observed survival exceeding 365 days have been excluded.  
 
Table 8. 1 Kaplan-Meier Estimation of Survival 
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Figure 8. 1 Kaplan-Meier estimate of Survival and Hazard Functions (Full Population) 
 
8.1.1 Kaplan-Meier estimation of survival by sex 
 
 
 
Figure 8. 2 Kaplan-Meier Estimate of Survival and Hazard Functions by Sex 
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Groups 
Number of 
observations 
Deaths 
Median 
survival 
time 
0.95 lower 
bound 
0.95 upper 
bound 
Females 289,376 274,621 43 31 32 
Males 209,888 203,776 26 23 23 
Total 499,264     
 
Table 8. 2 Kaplan-Meier Estimation of Survival by Sex 
 
Female survival is longer than that of males; median female survival is 43 days, 
while for males it is 26 days.  
 
8.1.2 Kaplan-Meier estimation of survival by site of care 
 
Figure 8. 3 Kaplan-Meier estimate of Survival and Cumulative Hazard Functions by Setting 
of Care (with confidence intervals) 
Key to Figure 8.3 
 IPU: Inpatient Facility 
 HC: Home Care 
 LTC: Long-term Care Facility 
 ALF: Assisted-living Facility 
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Groups 
Number of 
observations 
Deaths 
Median 
survival 
time 
0.95 lower 
bound 
0.95 upper 
bound 
ALF 15,310 11,285 69 66 72 
HC 327,812 316,294 27 27 27 
IPU 143,483 135,541 7 7 7 
LTC 12,608 11,285 33 33 34 
Total 449,213 
    
Note: IPU = Inpatient Facility; HC = Home Care; LTC = Long-term Care Facility; ALF = Assisted-living 
Facility 
 
Table 8. 3 K-M Estimation of Survival by Setting of Care 
 
Survival varies significantly by setting of care, with inpatient facilities having the 
lowest median survival and assisted living facility the highest.  However, both of these 
facilities have low numbers of patients.  In the case of assisted-living facilities, there is high 
variability in observed survival time.   
8.1.3 Survival and cumulative hazard functions for key primary diagnoses 
Figure 8.4 shows the estimated survival time and hazard function for principal (admitting) 
diagnoses.  In this figure, certain of the top 10 diagnoses, covered in Chapter 6 have been 
grouped, as follows:  
 Cancer: sum of lung, breast, prostate, colorectal, bladder, lymphoma and other 
severe cancers, and tumours.  
 Heart: congestive heart failure and heart disease 
 CVA: ischaemic, or unspecified stroke, and cerebrovascular disease 
 Lung: COPD 
 Dementia: dementia without complications. 
Cancer patients have the shortest survival time and dementia patients the longest.   
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Figure 8. 4 Kaplan-Meier estimate of Survival and Cumulative Hazard Functions by 
Admitting Diagnosis 
 
Key to Figure 8.4 
 Heart 
 Cancer 
 Lung 
 Dementia 
 CVA (cardio-vascular) 
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Groups 
Number of 
observations 
Events 
Median 
survival 
time 
0.95 lower 
bound 
0.95 upper 
bound 
Cancer 172,185 170,004 21 21 22 
Heart 64,544 61,479 31 31 32 
Lung 33,062 31,336 38 37 39 
CVA 41,849 38,436 40 39 41 
Dementia 72,038 66,119 53 52 54 
All 383,678 367,374    
 
Table 8. 4 Kaplan-Meier estimate of Survival and Hazard Functions by Admitting 
Diagnosis  
 
8.2 Cox Regression Models 
Recall the form of the Cox regression model is such that: 
'( )
0( | ) ( )
X
ih t X h t e
    or 
'( )exp
0( | ) [ ( )]
X
TS t X S t

 .  As the equation shows, the Cox model assumes that the covariates 
(X) have constant values over time.  The hazard function, at time t, for a particular 
observation has a multiplicative effect, between the baseline hazard (where all values of 
covariates are equal to 0) and the functional form, which is a linear combination of the 
predictors.  Cox regression is widely popular and used in many studies, due to few 
assumptions about the underlying distribution.  We do not specify a form of distribution for 
the baseline hazard function 0 ( )h t  or the baseline survival function 0 ( )S t .  However, 
because of the lack of a distribution assumption, Cox regression is less consistent with the 
theoretical survival function.  The estimation of the parameter vector   can be performed 
using the partial likelihood method, which causes a challenge to re-construct and predict the 
survival function for future observations.  At the same time, to apply the Cox model 
appropriately, one must carefully examine the PH assumption, as well as the functional 
form, as a linear combination of the covariates.   
One of the crucial assumptions of the Cox model is the constant relative risk.  
However, in practice, we are interested in examining the effect of covariates, whose values 
change over time.  In other words, if such covariates were added into a regular Cox model, 
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the proportional hazards assumption would no longer be true.  An extension of the Cox 
model, to incorporate time-dependent covariates, is possible; however, assumptions, 
regarding the type of time-dependent covariates, must be met.   
8.2.1 Cox regression models: results 
The output of the final Cox regression model is presented in table 8.5.  Variable selection 
procedures are performed using chi-squared tests.  This model, without time-dependent 
covariates, is presented to demonstrate the insufficiency of the simple Cox model without 
time dependent covariates, indicating that the model violates the PH assumption (see Table 
8.6).  We further examine the PH assumption and assess the overall fit of the model.  
To test the adequacy of the PH assumption, we perform the hypothesis test of 
Grambsch and Therneau [17] for each parameter in the model. Under this test, the null 
hypothesis is that the log hazard ratio function is constant over time.  From table 8.6, the 
Grambsch-Therneau test indicates non-proportionality of hazards for several predictors (p 
< 0.05).  This violation of the PH assumption can cause inaccurate interpretation for the 
estimated parameters.  A potential solution is the addition of time-varying covariates into 
the model.   
To study the overall fit of the Cox model, the standard approach for testing 
goodness-of-fit is the comparison of Cox-Snell residuals 
'( )
0
ˆ ( ) Xi ir H T e
  with the 
cumulative hazard function.  If the model is correct, the residual plot of the cumulative 
hazard rate ˆ ( ) vs. i iH r r  should follow a straight line through the origin.  Figure 8.5 indicates 
significant departure of the cumulative hazard rate from the straight line, indicating that the 
Cox model is a poor fit to the data.  As we shall see later the log-normal model fits the data 
better than the Cox model.  
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Figure 8. 5 Cox-Snell Residuals for the Cox model  
 
Table 8.5 shows the coefficients calculated for the fitted Cox model, and table 8.6 
shows the results of the hypothesis test for the PH assumption.  As discussed in Chapter 2, 
the coefficients in the Cox model act on the hazard rate.  Thus, a positive coefficient 
implies an exponentiated coefficient greater than 1.0 and, in turn, an increased hazard of 
death.  For example, being male (compared with female) has an exponentiated coefficient 
of 1.125, implying that males have about a one-eighth shorter expected survival duration 
than females.  All covariates in the Cox model are significant (p values equal to or close to 
zero), although we should be cautious about reading too much into this result because of the 
large sample size.   
We note that cancer and kidney disease diagnoses have shorter expected survival 
duration, while dementia and other psychological disorders have longer expected durations.  
The impact of the risk factor is somewhat minor (about a 4.4% shorter expected duration 
for a 1% increase in risk score).  However, because the diagnoses are covariates in the 
model, their effect enters the model directly.   
 
  
 157 
 
Covariates βˆ  e
βˆ (HR) P-value Lower 
.95 % (of 
HR) 
Upper 
.95% (of 
HR) 
GenderMale 0.117 1.125 0 1.117 1.133 
LevelOfCareHC (Home Care) 0.324 1.383 0 1.351 1.416 
LevelOfCareIPU (In-Patient Unit) 1.401 4.060 0 3.939 4.184 
LevelOfCareLTC (Long-Term Care) 0.349 1.418 0 1.385 1.452 
Age -0.004 0.996 0 0.996 0.997 
hcc2 (Sepsis) 0.298 1.348 0 1.307 1.390 
hcc8 (Metastatic Cancer and Acute Leukemia) 0.224 1.252 0 1.203 1.302 
hcc9 (Lung Cancer) 0.242 1.273 0 1.250 1.297 
hcc10 (Lymphoma Cancer) 0.190 1.209 0 1.185 1.233 
hcc11 (Colorectal, Bladder Cancer) 0.138 1.149 0 1.129 1.168 
hcc12 (Breast and Prostate Cancer) 0.132 1.141 0 1.122 1.160 
hcc18 (Diabetes with Chronic Complications) 0.030 1.030 0.004 1.009 1.052 
hcc21 (Protein-Calorie Malnutrition) -0.086 0.918 0 0.898 0.939 
hcc22 (Morbid Obesity) -0.097 0.908 0.066 0.819 1.007 
hcc23 (Metabolic Disorder) -0.079 0.924 0.024 0.863 0.989 
hcc27 (End-Stage Liver Disease) 0.252 1.287 0 1.215 1.363 
hcc28 (Cirrhosis of Liver) 0.199 1.220 0 1.184 1.257 
hcc33 (Intestinal Obstruction) 0.236 1.266 0 1.198 1.338 
hcc46 (Severe Hematological Disorder) 0.217 1.242 0 1.181 1.306 
hcc48 (Coagulation Defects and Other 
Specified Hematological Disorders) 
0.036 1.036 0.024 1.005 1.069 
hcc51 (Dementia with Complications) -0.254 0.776 0 0.752 0.801 
hcc52 (Dementia without Complications) -0.229 0.795 0 0.787 0.804 
hcc54 (Drug/Alcohol Psychosis) -0.259 0.772 0.00001 0.689 0.864 
hcc55 (Drug/Alcohol dependence) -0.133 0.875 0.074 0.756 1.013 
hcc57 (Schizophrenia) -0.296 0.744 0 0.693 0.799 
hcc58 (Major Depressive, Bipolar, and 
Paranoid Disorders) 
-0.162 0.850 0 0.831 0.870 
hcc70 (Quadriplegia) -0.224 0.799 0.016 0.666 0.959 
hcc71 (Paraplegia) -0.161 0.851 0.079 0.711 1.019 
hcc72 (Spinal Cord Disorders) -0.208 0.813 0.00000 0.746 0.885 
hcc73 (Amyotrophic Lateral Sclerosis) -0.321 0.726 0 0.690 0.763 
hcc74 (Cerebral Palsy) -0.328 0.720 0 0.643 0.806 
hcc75 (Polyneuropathy) -0.140 0.869 0 0.829 0.911 
hcc76 (Muscular Dystrophy) -0.434 0.648 0.00000 0.551 0.763 
hcc77 (Multiple Sclerosis) -0.366 0.694 0 0.652 0.738 
hcc78 (Parkinson’s and Huntington’s Diseases) -0.254 0.776 0 0.760 0.792 
hcc79 (Seizure Disorders and Convulsions) -0.129 0.879 0 0.854 0.905 
hcc84 (Cardio-Respiratory Failure and Shock) 0.098 1.103 0 1.076 1.131 
hcc86 (Acute Myocardial Infarction) 0.080 1.083 0.013 1.017 1.154 
hcc87 (Unstable Angina) -0.058 0.944 0.043 0.892 0.998 
hcc88 (Angina Pectoris) -0.119 0.888 0.001 0.825 0.955 
hcc96 (Specified Heart Arrhythmias) 0.047 1.048 0 1.032 1.065 
hcc99 (Cerebral Hemorrhage) 0.337 1.400 0 1.327 1.478 
hcc100 (Ischemic or Unspecified Stroke) 0.039 1.040 0.00000 1.024 1.057 
hcc103 (Hemiplegia/Hemiparesis) -0.119 0.887 0.00003 0.839 0.939 
hcc106 (Gangrene) 0.271 1.312 0.00000 1.180 1.458 
hcc111 (COPD) -0.113 0.893 0 0.881 0.905 
hcc112 (Chronic Lung Disorders) -0.125 0.882 0 0.849 0.917 
hcc114 (Bacterial Pneumonias) 0.203 1.225 0 1.171 1.282 
hcc115 (Pneumococcal Pneumonia) 0.126 1.134 0.048 1.001 1.285 
hcc134 (Dialysis Status) 0.322 1.380 0.002 1.130 1.686 
hcc135 (Acute Renal Failure) 0.297 1.346 0 1.285 1.410 
hcc136 (CKD-Stage 5) 0.410 1.506 0 1.460 1.554 
hcc137 (CKD-Severe) 0.090 1.095 0.001 1.039 1.153 
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hcc138 (CKD-Moderate) 0.070 1.072 0.0003 1.033 1.113 
hcc139 (CKD-Mild) 0.082 1.085 0 1.056 1.116 
hcc141 (Nephritis) 0.109 1.115 0.00000 1.073 1.159 
hcc157 (Pressure Ulcer of Skin) 0.318 1.375 0.105 0.935 2.021 
hcc166 (Severe Head Injury) 0.505 1.658 0.050 0.999 2.751 
hcc167 (Major Head Injury) 0.222 1.249 0.0002 1.112 1.403 
hcc170 (Hip Fracture) 0.142 1.153 0.001 1.063 1.249 
Neoplasm (Non-Chronic) 0.073 1.076 0.00001 1.042 1.111 
Heart (Non-Chronic) -0.069 0.933 0 0.921 0.945 
Digestive (Non-Chronic) 0.030 1.030 0.008 1.008 1.053 
Other -0.012 0.988 0.003 0.980 0.996 
Cerebrovascular (Non-Chronic) -0.292 0.746 0 0.735 0.758 
Gastrointestinal (Non-Chronic) 0.081 1.084 0.0003 1.038 1.133 
Lung (Non-Chronic) 0.129 1.138 0 1.105 1.171 
Pneumonia (Non-Chronic) 0.164 1.179 0 1.151 1.207 
Unknown.Causes (Non-Chronic) -0.056 0.945 0.00001 0.922 0.969 
Risk Score 0.044 1.044 0.00000 1.028 1.061 
 
Table 8. 5 Coefficients of the Cox PH Model  
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Variable Rho Chi-squared p 
GenderMale -0.017 91.848 0 
LevelOfCare HC (Home Care) -0.008 19.426 0 
LevelOfCare IPU (In-Patient Unit) -0.023 171.033 0 
LevelOfCare LTC (Long-Term care) -0.010 35.287 0 
Age 0.002 1.079 0.299 
hcc2 -0.023 184.760 0 
hcc8 0.009 24.621 0 
hcc9 0.027 246.741 0 
hcc10 0.029 280.675 0 
hcc11 0.037 445.239 0 
hcc12 0.034 380.750 0 
hcc18 -0.008 20.948 0 
hcc21 0.002 2.022 0.155 
hcc22 0.001 0.088 0.766 
hcc23 0.003 2.180 0.140 
hcc27 -0.004 6.153 0.013 
hcc28 0.000 0.002 0.961 
hcc33 -0.007 15.339 0 
hcc46 -0.002 1.736 0.188 
hcc48 0.003 2.340 0.126 
hcc51 0.005 9.243 0.002 
hcc52 0.028 266.672 0 
hcc54 0.001 0.272 0.602 
hcc55 -0.003 2.815 0.093 
hcc57 0.005 9.216 0.002 
hcc58 0.005 8.317 0.004 
hcc70 0.002 0.749 0.387 
hcc71 0.004 5.485 0.019 
hcc72 0.002 1.075 0.300 
hcc73 0.015 75.677 0 
hcc74 0.002 1.806 0.179 
hcc75 0.004 6.603 0.010 
hcc76 -0.002 1.971 0.160 
hcc77 0.006 10.206 0.001 
hcc78 0.018 103.109 0 
hcc79 0.007 14.971 0 
hcc84 -0.030 311.470 0 
hcc86 -0.007 16.234 0 
hcc87 0.003 2.198 0.138 
hcc88 0.003 3.379 0.066 
hcc96 -0.002 1.670 0.196 
hcc99 -0.022 160.251 0 
hcc100 -0.019 122.066 0 
hcc103 0.002 0.822 0.365 
hcc106 0.003 2.097 0.148 
hcc111 0.004 5.231 0.022 
hcc112 0.013 53.559 0 
hcc114 -0.014 62.602 0 
hcc115 -0.001 0.126 0.722 
hcc134 -0.003 2.930 0.087 
hcc135 -0.015 72.446 0 
hcc136 -0.023 174.505 0 
hcc137 -0.001 0.206 0.650 
hcc138 -0.004 4.269 0.039 
hcc139 -0.004 4.664 0.031 
hcc141 0.006 13.190 0 
hcc157 0.000 0.055 0.814 
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hcc166 0.000 0.064 0.800 
hcc167 -0.002 1.220 0.269 
hcc170 -0.004 4.412 0.036 
Neoplasm 0.016 82.096 0 
Heart 0.012 50.217 0 
Digestive -0.003 4.050 0.044 
Other 0.012 46.218 0 
Cerebrovascular 0.008 20.261 0 
Gastrointestinal -0.004 5.710 0.017 
Lung -0.007 15.560 0 
Pneumonia -0.014 70.052 0 
Unknown.Causes 0.005 7.012 0.008 
Risk Score 0.015 73.215 0 
  
Table 8. 6 Hypothesis Test for PH Assumption 
 
8.3 Accelerated Failure Time Models 
8.3.1 Checking the applicability of the log-normal AFT model 
A probability plot is applied to assess whether or not the data follow a log-normal 
distribution.  Figure 8.6 shows some departure from the log-normal distribution, but in the 
tail, starting at the 99th percentile.  Outliers of the extent of this quantile are rare in hospice, 
given that patients are not admitted with a life expectancy greater than six months (180 
days).   
 
Figure 8. 6 Log-Normal Probability Plot 
 
 
The image part with  
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The log-normal distribution does appear to be a good fit for the majority of the data, 
and out-performs the Cox model.  
 
Another tool to assess whether the log-normal AFT model fits our data is the 
Kaplan-Meier survival curve, stratified by different levels, within key predictors.  For 
selected predictors, we plot the inverse normal transformation of K-M survival estimates 
against log( )t .  Parallel and linear patterns indicate an appropriate fit.  Figure 8.8 shows 
two different examples, for two predictors (care setting and sex).  There are signs of non-
linearity in the tails, but, overall, the figures show adequate linearity.   
 
 
 
 
Figure 8. 7 Assessment of Log-Normal Assumption for Care Setting and Sex 
 
8.3.2 AFT model residuals 
The standardized residual for the i th  observation, in the log-normal AFT model, is 
defined as
ˆlog( )
ˆ
ˆ
i
t
t
s



  where 
i
t  is the observed survival time for the i th  observation, 
  is the estimated scale parameter, and ˆ  is the estimated location parameter, which can 
be expressed as a linear combination of predictors.  If the model is correctly specified, then 
the set ( , ), 1, 2..
i i
s i n    should behave like a censored sample from a log-normal 
distribution.  i  is the censored status of the i th observation.  In figure 8.8, we compute 
the Kaplan-Meier survival curve for the standardized residuals (computed from the model, 
in table 8.5).  The Kaplan-Meier curve of residuals is compared with the survival curve, 
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using the log-normal function.  Good concurrence indicates that the log-normal is an 
appropriate function to fit the data.  
 
 
Figure 8. 8 Comparison Between K-M Survival and Log-Normal Residuals 
 
8.3.3 Results of the log-normal AFT model 
The estimated parameter coefficients and acceleration factors for the log-normal AFT 
model show the direct impact of predictors on the rate of survival in hospice.  The final log-
normal AFT model includes 63 significant predictors (out of 101 predictors, in total) and is 
chosen using model selection criteria AIC and chi-squared tests.  For the AFT model, the 
Cox-Snell residual for the i th  observation is defined as 
 
ˆlog( )
ˆ log 1 ii
t
r


      
  
Φ ,                                                                                           (8.8) 
where Φ is the cumulative distribution of the standard normal distribution.  If the model is 
correctly specified, the set ˆ( , ), 1,2...
i i
r i n   behaves similarly to a censored sample of unit 
exponentially-distributed variables.  In figure 8.9, we show Cox-Snell residuals for the log-
normal AFT model (the residuals of the Cox model were shown previously, in figure 8.5) 
and plot them against the cumulative hazard rates.  The plots indicate that the Cox model 
does not fit the data as well as the log-normal AFT model.    
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Figure 8. 9 Cox-Snell Residuals, Log-normal AFT Model 
 
As discussed in Chapter 2, the coefficients of the AFT model act on survival, 
directly.  Hence, a negative coefficient, when exponentiated, becomes a value less than 1.0, 
implying a shorter expected survival duration.   
Sex and care setting play an important role in speeding, or slowing, the rate of 
survival in hospice.  The coefficients are shown in table 8.7.  As an example, the 
acceleration factor for males is 0.834, compared to female patients, implying that male 
survival is only 83.4% of that of females.  Males will die, on average, 16.6% faster in 
hospice.  Survival also depends on the facility in which the hospice patient is confined.  The 
baseline facility is the assisted living facility (ALF).  Assisted living setting patients have 
the longest life expectancy.  Compared with ALF patients, patients in home care, inpatient, 
and long-term care settings die on average 39.0%, 82.6%, and 42.1% faster than those in 
assisted living.  The effect of different care facilities on the survival rate of patients in 
hospice, estimated by the log-normal AFT model, is consistent with the observed survival 
in the Kaplan-Meier curves (figure 8.10 and table 8.8).  
 
 
 
Covariates βˆ ᵞˆ= eβˆ 
(AF) 
p-value Lower 
.95%  
(of AF) 
Upper 
.95%  
(of AF) 
(Intercept) 3.607 36.846 0.000 35.060 38.723 
Gender (M) -0.182 0.834 0.000 0.825 0.842 
Level of care (Home Care) -0.494 0.610 0.000 0.591 0.630 
Level of care (In-Patient Unit) -1.750 0.174 0.000 0.166 0.181 
 164 
 
Level of care (Long-Term Care) -0.547 0.579 0.000 0.560 0.598 
Age 0.005 1.005 0.000 1.004 1.005 
HCC2 (Sepsis) -0.481 0.618 0.000 0.591 0.646 
HCC8 (Metastatic Cancer and Acute 
Leukemia) 
-0.172 0.842 0.000 0.795 0.892 
HCC9 (Lung Cancer) -0.219 0.803 0.000 0.782 0.825 
HCC10 (Lymphoma Cancer) -0.155 0.856 0.000 0.832 0.882 
HCC11 (Colorectal, Bladder Cancer) -0.089 0.915 0.000 0.893 0.938 
HCC12 (Breast and Prostate Cancer) -0.094 0.911 0.000 0.889 0.933 
HCC18 (Diabetes with Chronic 
Complications) 
-0.051 0.950 0.001 0.922 0.979 
HCC19 (Diabetes without 
Complication) 
0.037 1.037 0.009 1.009 1.066 
HCC21 (Protein-Calorie 
Malnutrition) 
0.144 1.154 0.000 1.117 1.192 
HCC23 (Metabolic Disorders) 0.109 1.115 0.031 1.010 1.231 
HCC27 (End-Stage Liver Disease) -0.325 0.723 0.000 0.665 0.786 
HCC28 (Cirrhosis of Liver) -0.252 0.777 0.000 0.744 0.812 
HCC33 (Intestinal Obstruction) -0.367 0.693 0.000 0.639 0.751 
HCC46 (Severe Hematological 
Disorder) 
-0.272 0.762 0.000 0.708 0.820 
HCC51 (Dementia with 
Complications) 
0.385 1.469 0.000 1.405 1.537 
HCC52 (Dementia without 
Complications) 
0.365 1.441 0.000 1.419 1.463 
HCC54 (Drug/Alcohol Psychosis) 0.342 1.408 0.000 1.198 1.655 
HCC57 (Schizophrenia) 0.451 1.569 0.000 1.416 1.739 
HCC58 (Bipolar and Paranoid 
Disorders) 
0.254 1.289 0.000 1.248 1.332 
HCC70 (Quadriplegia) .0351 1.421 0.008 1.097 1.840 
HCC71 (Paraplegia) 0.370 1.447 0.006 1.113 1.882 
HCC72 (Spinal Cord Disorders) 0.302 1.352 0.000 1.196 1.529 
HCC73 (Amyotrophic Lateral 
Sclerosis) 
0.574 1.775 0.000 1.652 1.907 
HCC74 (Cerebral Palsy) 0.453 1.574 0.000 1.340 1.848 
HCC75 (Polyneuropathy) 0.230 1.259 0.000 1.177 1.347 
HCC76 (Muscular Dystrophy) 0.464 1.590 0.000 1.262 2.003 
HCC 77 (Multiple Sclerosis) 0.559 1.749 0.000 1.603 1.909 
HCC78 (Parkinson’s and 
Huntington’s Disease) 
0.416 1.516 0.000 1.473 1.561 
HCC79 (Seisure Disorders) 0.204 1.226 0.000 1.176 1.279 
HCC84 (Cardio-Respiratory Failure) -0.244 0.783 0.000 0.756 0.811 
HCC86 (AMI) -0.164 0.849 0.000 0.776 0.929 
HCC87 (Unstable Angina) 0.099 1.104 0.017 1.018 1.197 
HCC88 (Angina Pectoris) 0.190 1.210 0.000 1.088 1.344 
HCC96 (Specified Heart 
Arrhythmias) 
-0.006 0.936 0.000 0.915 0.958 
HCC99 (Cerebral Hemorrhage) -0.608 0.544 0.000 0.503 0.589 
HCC100 (Stroke) -0.107 0.899 0.000 0.878 0.920 
HCC103 (Hemiplegia) 0.166 1.181 0.000 1.090 1.279 
HCC106 (Gangrene) -0.292 0.747 0.000 0.640 0.872 
HCC111 (COPD) 0.158 1.171 0.000 1.149 1.194 
HCC112 (Chronic Lung Disorders) 0.229 1.257 0.000 1.190 1.328 
HCC114 (Bacterial Pneumonias) -0.372 0.689 0.000 0.646 0.736 
HCC134 (Dialysis Status) -0.457 0.633 0.000 0.473 0.847 
HCC135 (Acute Renal Failure) -0.463 0.629 0.002 0.588 0.673 
HCC136 (CKD – Stage 5) -0.593 0.552 0.000 0.528 0.578 
HCC137 (CKD – Severe) -0.121 0.886 0.002 0.822 0.955 
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HCC138 (CKD – Moderate) -0.102 0.903 0.000 0.856 0.953 
HCC139 (CKD – Mild) -0.114 0.892 0.000 0.857 0.929 
HCC141 (Nephritis) -0.120 0.887 0.000 0.838 0.938 
HCC167 (Major Head Injury) -0.351 0.704 0.000 0.594 0.834 
HCC170 (Hip Fracture) -0.252 0.777 0.000 0.692 0.874 
Heart (Non-Chronic) -0.118 1.125 0.000 1.104 1.147 
Digestive (Non-Chronic) -0.063 0.939 0.000 0.910 0.969 
Other (Non-Chronic) 0.033 1.034 0.000 1.021 1.046 
Cerebrovascular (Non-Chronic) 0.413 1.512 0.000 1.479 1.545 
Gastrointestinal (Non-Chronic) -0.136 0.873 0.000 0.819 0.930 
Lung (Non-Chronic) -0.208 0.812 0.000 0.779 0.848 
Pneumonia (Non-Chronic) -0.283 0.753 0.000 0.728 0.780 
Unknown Causes (Non-Chronic) 0.085 1.089 0.000 1.051 1.129 
Weight Loss (Non-Chronic) 0.034 1.034 0.016 1.006 1.063 
Risk Score -0.055 0.947 0.000 0.925 0.969 
 
Table 8. 7 Coefficients of the Log-normal AFT Model with ˆ 1.4768   
 
The effect of care facilities on the survival rates, as estimated by the log-normal 
AFT model, is consistent with the observed Kaplan-Meier survival curves, stratified by care 
setting (figure 8.10 and table 8.8).   
 
Figure 8. 10 Stratified Kaplan-Meier Curves for Different Care Settings 
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Care Median Survival Lower .95 Upper .95 
ALF 68 64 72 
HC 27 27 27 
IPU 7 7 7 
LTC 33 33 34 
 
Table 8. 8 Summary Statistics for K-M Curves for Different Care Settings 
 
From table 8.7, significant covariates are setting of care and sex; age is also 
statistically significant.  While a one-year change in ageless significant  impact on the 
survival rate, life expectancy of an individual significantly older would be much lower than 
that of a younger individual.  Different diagnoses also have an effect on the survival rate.  
For example, patients with sepsis (0.618) and lung cancer (0.803) die approximately 40% 
and 20% faster than patients without these conditions.  Patients with some diagnoses can be 
expected to survive for a much longer time.   Patients with dementia and schizophrenia 
survive, respectively, 57% and 44% longer than other patients.  The Kaplan-Meier curves 
for dementia are illustrated in figure 8.11 and table 8.9.  Risk score (HCC) is a measure of 
relative risk of each patient and measures the severity of the patient’s illness.  With an 
acceleration factor of 0.947, the model indicates the correlation between risk score and 
survival: for a 1-unit increase in risk score, survival time is reduced by 5.3%21 (This value is 
consistent with that of the coefficient of risk score for the Kaplan-Meier estimator in 
section 8.1.2, above). 
                                                          
21 In the Appendix to Chapter 5 we noted that the average risk score is 0.87; risk score ranges from 0.0 to 
about 4.0.   
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Figure 8. 11 Kaplan-Meier Curves for Patients with Dementia (HCC 52) 
 
 Median Survival Lower .95 Upper .95 
Non-Dementia (hcc52 = 0) 24 24 24 
Dementia (hcc52 = 1) 47 46 48 
 
Table 8. 9 Summary Statistics for K-M Curves for Dementia (HCC 52) 
 
8.4 Prediction using the Log-normal Accelerated Failure Time Model 
8.4.1 Prediction and external validation using test set 
Our objective in developing survival models, and in particular the log-normal AFT model, 
is to be able to predict survival (remaining life expectancy) of patients admitted to hospice.  
The survival curve is a representation of the death hazard rate (force of mortality, μ in 
actuarial terms).  Future life expectancy is estimated as the integral of the survival function 
or the area under the survival curve:   
0 0
( ) ( ) Pr( )E T S t dt T t dt
 
    .                (8.9) 
From the model in table 8.10, we can derive predictions of life expectancy using the 
time-quantiles function:  
1 1
0
ˆ ˆˆ ˆ ˆlog( ) (1 ( )) ( ) (1 ( ))i it S t X S t    
           ,                                            (8.10) 
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where log( )t is the estimated survival duration; 
1  is the inverse cumulative function of 
the normal standard distribution, and we fix the survival rate S(t) = q.    
Figure 8.12 and table 8.10 show an example of a predicted survival curve for a new 
patient.  The area under the survival curve is 67.50, compared to the actual length of stay of 
65 days.   
 
Figure 8. 12 Survival Curve for a Newly Admitted Patient 
 
Gender Level of Care Age Diagnoses Score 
Male Home care 76 HCC11 – Colorectal and bladder cancer 1.225 
   HCC48 – Coagulation defects  
   HCC85 – Congestive heart failure  
   HCC96 – Specified heart arrhythmias  
   Non-chronic heart disease  
   Other disease  
 
Table 8. 10 Sample Patient Characteristics for Newly Admitted Patient 
 
Estimates of future life expectancy, obtained as the integral of the survival curve 
0 0
( ) ( ) Pr( )E T S t dt T t dt
 
     are not particularly accurate.  This is due, in part, to the 
number of outliers in the data; a small number of patients survive for durations that 
significantly exceed the six months duration that is expected of terminally ill hospice 
patients.  We, instead, modify the life expectancy function to be conditioned on T ≤ 180 to 
be consistent with the CMS definition of expected maximum duration of patients admitted 
to hospice.  
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0
1
( | 180) ( )
Pr( 180)
TE T T t f t dt
T
 
                                                                                (8.11) 
2
2
(log( ) )180
2
0
1 1
( | 180)
Pr( 180) 2
t
E T T e dt
T





 
   
                                                                      (8.12) 
We define the error from the prediction as the absolute difference between the 
actual and the predicted lengths of stay.  In the test (hold-out) set, we first exclude the 
censored patients and apply the long-normal AFT model to estimate the expectation of 
future lifetime and the conditional expected future lifetime, and then compare to the actual 
lengths of stay.  Figure 8.13 shows histograms of the errors for the basic model E(T) and 
the errors of the conditional model E(T).  The median error is 50.5 days (s.d. 68.3 days) 
when estimating the expectation using the basic model (figure 8.13 a) and 27 days (s.d. 
25.6) when estimating the conditional model (figure 8.13 b).   
 
 
Figure 8. 13 Frequency Distribution of Differences between Actual and Predicted Lengths 
of Stay 
 
In table 8.11, we aggregate the errors into five groupings  to assess the distribution 
of the errors. Quintile 1 contains all observations where the difference between the 
predicted and actual values of life expectancy is between 0 and 15 days. Quintile five 
contains all observations where the difference between predicted and actual duration to 
death is in excess of 90 days.  
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Quintile Range 
1 [0,15) 
2 [15,30) 
3 [30,60) 
4 [60,90) 
5 [90,∞) 
 
Table 8. 11 Error Groups 
 
We compare aggregated errors between the actual and predicted lengths of stay in 
the test set.  Table 8.12 compares error groups for the basic model and the conditional 
model.  
 
Actual – Expected 
LOS 
Group 1 Group 2 Group 3 Group 4 Group 5 
Basic Model 0.12 0.13 0.35 0.20 0.20 
Conditional Model 0.24 0.34 0.32 0.05 0.05 
  
Table 8. 12 Distribution of Errors by Group  
 
Predictions, using the conditional model, are reasonably accurate, with most errors 
falling with groups  1-3 (less than 60 days).  Only 10% of all errors, using the conditional 
model, exceed 60 days.   
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8.5 Time Dependent Models    
8.5.1 Time-dependent Cox model 
The main focus of this study is the examination of the effect of demographic information at 
the beginning of hospice admission (e.g. care setting, gender, age, risk score from CMS 
HCC model, and diagnosis), together with drug information during hospice admission for 
the terminal event.  We measure drug strength22 in dosage of analgesic and other 
medications throughout the medication prescription history for all patients.  In this case, 
strength is obviously a time-dependent covariate, whose values vary with time.   
Above, we observed that the proportional hazards assumption, necessary for fitting 
the Cox model, is violated.  We incorporated several variables, whose values vary with 
time, to relax the PH assumption.  Several time-dependent variables added to the model are 
the daily analgesic dose, number of anxiolytic prescriptions, number of laxative 
prescriptions, and number of anti-nausea prescriptions.  All of these time-dependent 
variables were obtained from the historical drug records available in our database.  Earlier, 
we found that a parametric model, assuming the log-normal distribution for the survival 
time, is better at representing the data.  Therefore, we fit both a time-dependent Cox model 
and a time-dependent parametric model and compare the goodness of fit of these models 
using AIC values.     
For this model, we fit both fixed and time-dependent covariates.  Fixed covariates in 
this model are care setting, sex, age at admission, risk score (from the CMS HCC 2013 
model), and the presence of non-palliative drugs.  In the case of non-palliative drugs, which 
enter the model as factors, the presence of the drug, at any time in the patient record, is 
counted as a positive value.  Our time-dependent variables are number of analgesic drug 
prescriptions and drug strength, both of which vary with time.   
 
 
 
                                                          
22 As a reminder (see Chapter 5), analgesic drug strength is measured relative to the strength of oral morphine, 
using an opioid converter.   
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8.5.2 Time-dependent log-normal AFT model 
Let ( ), ( ), ( ), ( )Lax Antinau Anxioi i i iD t N t N t N t     be the daily dose of analgesic, number of laxative 
prescriptions, number of anti-nausea prescriptions, and number of anxiolytic prescriptions, 
respectively, for patient i at time t.  The hazard function for the time-dependent Cox model 
is: 
1 1 2 2 3 3 4 4( ;{ ( ), [ , ], ( ), [ , ], ( ), [ , ], ( ), [ , ]})
Lax Antinau Anxio
i i i it D v v o t N v v o t N v v o t N v v o t          
( ) ( ) ( ) ( )
0( )
Lax Antinau Anxio
i i i iX D t N t N t N tt e
         ,                                                                (8.13) 
where 1 1 2 2 3 3 4 4( ), [ , ], ( ), [ , ], ( ), [ , ], ( ), [ , ]
Lax Antinau Anxio
i i i iD v v o t N v v o t N v v o t N v v o t        are the 
2log ( , )i iT N  ∼ covariate paths for the daily analgesic dose, number of laxative 
prescriptions, number of anti-nausea prescriptions, and number of anxiolytic prescriptions 
for patient i, from time of admission to time t.  , ,  and     are the overall mean effects of 
the daily analgesic dose, number of laxative prescriptions, number of anti-nausea 
prescriptions, and number of anxiolytic prescriptions, respectively, on the hazard function, 
across all time points at which the covariates are measured.  X is the fixed covariate matrix.   
Similarly, the log-normal AFT model allows us to estimate the overall effect of the 
number of prescriptions and daily dose on the survival function.   
Let iT be the future lifetime random variable for the i th observation.  We assume 
that 2( , )i iT N  ∼ , or that the future lifetime of patient i is from the log-normal 
distribution.  The mean parameters vary by observation while the variance is kept constant 
across all observations. i is modelled as a linear combination of the fixed and time-
dependent covariates.    Once again, let ( ), ( ), ( ), ( )Lax Antinau Anxioi i i iD t N t N t N t     be the daily 
dose of analgesic, number of laxative prescriptions, number of anti-nausea prescriptions, 
and number of anxiolytic prescriptions, respectively, for patient i at time t.   We have a 
historical path for for these time-dependent covariates up to time t : 
1 1 2 2 3 3 4 4( ), [0, ], ( ), [0, ], ( ), [0, ], ( ), [0, ]
Lax Antinau Anxio
i i i iD t N t N t N t                 .   
Thus: ( ) ( ) ( ) ( ) ( )Lax Antinaus Anxioi i i i it BX D t N t N t N t          
where , ,  and     are the overall mean effects of the daily analgesic dose and numbers of 
laxative, antinausea and anxiolytic prescriptions.   We are interested in predicting the 
survival time beyond t for the i th observation.  
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Pr( ) 1 Pr( ) 1 Pr(ln ln )i i iT t T t T t        
ln ( ) ln ( )
1 Pr i i i
T t t t 
 
     
 
= 
ln ( )
1 i
t t

  
 
       (8.14) 
 
Where  is the cumulative function of the standard normal distribution.  
                                
We make one change in the modelling at this point: instead of incorporating all 89 
HCCs individually, we aggregate the HCCs into diagnosis groups (e.g. cancer, kidney, 
diabetes, etc.) to reduce the dimensionality of the data.  In total, we have 18 fixed 
covariates and two time-dependent variables (number and daily dose of analgesic 
prescriptions, respectively).  Tables 8.13 and 8.14 show the results of the Cox regression 
and log-normal AFT models, respectively.   
 
 
Covariates Coefficient 
Exp(coeff)  
(Hazard ratio) 
P-value 
Lower 95 % 
(of HR) 
Upper 95% 
(of HR) 
Gender Male 0.117 1.124 0 1.117 1.132 
Level Of Care HC (Home Care) 0.265 1.303 0 1.273 1.334 
Level Of Care IPU (In-Patient 
Unit) 
1.454 4.28 0 4.152 4.411 
Level Of Care LTC (Long-
Term care) 
0.397 1.488 0 1.453 1.524 
Age 0.002 1.002 0 1.002 1.002 
Infection 0.323 1.381 0 1.342 1.421 
Cancer 0.23 1.259 0 1.246 1.272 
Diabetes -0.003 0.997 0.7 0.984 1.011 
Gastrointestinal -0.031 0.97 0.001 0.952 0.988 
Liver 0.249 1.283 0 1.251 1.316 
Musculoskeletal 0.07 1.073 0 1.045 1.101 
Psych -0.224 0.799 0 0.791 0.806 
Lung -0.073 0.93 0 0.921 0.939 
Heart 0.043 1.044 0 1.035 1.054 
Kidney 0.213 1.238 0 1.219 1.257 
Injury 0.199 1.221 0 1.096 1.359 
HCCs Risk Score 0.028 1.028 0 1.022 1.034 
Analgesic Dose (Time-
Dependent) 
0.068 1.07 0 1.07 1.071 
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Number of Laxative 
Prescriptions (Time-Dependent) 
0.002 1.002 0.008 1.001 1.004 
Number of Anti-Nausea 
Prescriptions (Time-Dependent) 
0.005 1.005 0.004 1.002 1.009 
Number of Anxiolytic (Time-
Dependent) 
0.116 1.123 0 1.122 1.125 
 
Table 8. 13 Time-Dependent Cox Model Coefficients 
Covariates Coefficient S.E 
Exp (coeff) 
(Aceeleration
Factor) 
Lower 95% 
(of AF) 
Upper 95% 
(of AF) 
Meanlog (Intercept) 4.375 0.026    
Sdlog () 1.466 0.002    
Gender Male -0.166 0.005 0.847 0.838 0.856 
Level Of Care HC (Home Care) -0.411 0.017 0.663 0.641 0.685 
Level Of Care IPU (In-Patient 
Unit) 
-1.854 0.022 0.157 0.150 0.164 
Level Of Care LTC (Long-
Term care) 
-0.607 0.017 0.545 0.527 0.563 
Age 0.001 0.000 1.001 1.000 1.001 
Infection -0.517 0.021 0.596 0.572 0.622 
Cancer -0.238 0.008 0.788 0.776 0.800 
Diabetes 0.026 0.010 1.026 1.006 1.046 
Gastrointestinal 0.048 0.014 1.049 1.021 1.078 
Liver -0.332 0.019 0.718 0.691 0.745 
Musculoskeletal -0.086 0.020 0.918 0.883 0.954 
Psych 0.358 0.007 1.430 1.411 1.450 
Lung 0.071 0.007 1.074 1.058 1.090 
Heart -0.049 0.007 0.952 0.939 0.965 
Kidney -0.314 0.011 0.731 0.715 0.747 
Injury -0.297 0.081 0.743 0.634 0.871 
HCCs Risk Score -0.020 0.005 0.980 0.972 0.989 
Analgesic Dose (Time-
Dependent) 
-0.098 0.001 0.907 0.906 0.908 
Number of Laxative 
Prescriptions (Time-Dependent) 
-0.004 0.001 0.996 0.993 0.999 
Number of Anti-Nausea 
Prescriptions (Time-Dependent) 
0.002 0.003 1.002 0.996 1.008 
Number of Anxiolytic (Time-
Dependent) 
-0.215 0.002 0.807 0.804 0.810 
 
Table 8. 14 Time-Dependent Log-Normal AFT Model Coefficients 
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 Both models agree on the significant impact of both the number of prescriptions in 
laxatives and anxiolytics and the daily analgesic dose on the hazard rate and survival time 
in hospice.  For the log-normal model, both the number of prescriptions and the daily 
analgesic dose reduce survival time: for each percentage increase, daily dose survival is 
reduced by 9.3%, on average, across all time points.  Similarly, the survival time is reduced 
by 0.4% and 19.3%, on average, across all time points (at which the number of 
prescriptions is recorded), for each additional laxative prescription and anxiolytic 
prescription respectively.  
 
In building Accelerated Failure Time models, a number of different AFT models were 
examined prior to selection of the log-normal model: Weibull, gamma, log-normal, log-
logistic and generalized gamma models.  Among these models, the log-normal distribution 
performed best, passed the diagnostic tests for distribution assumptions and had the 
smallest AIC.  At the same time the log-normal AFT model is relatively straightforward to 
implement and interpret.   
 
8.6 Prediction Using the Time-Dependent Log-Normal AFT Model 
Using the output of the time-dependent log-normal AFT model, we are able to predict the 
expected remaining lifetime of a patient at any time point t, given that the patient is still 
alive at time t.  Given that the criterion for admission to hospice is a life expectancy of less 
than six months, we exclude censored patients and all patients whose length of stay exceeds 
180 days in the test (hold-out) set.  For each individual in the test set, at any point in time t,  
we predict the conditional remaining expected lifetime, given that the patient is alive at 
time t and will die in the remaining (180 – t) days, E(T ǀ T ≥ t,T ≤ (180 – t)) and further 
compare with the actual remaining lifetime.  Estimated mean errors at each interval and 
their confidence intervals are shown in figure 8.14.   
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Figure 8. 14 Distribution of Mean Errors at Different Times 
 
In Figure 8.14 the errors in each time period before death diminish as death approaches, 
reaching a minimum 30-45 days before death.  The errors increase again closer to death, 
possibly because of the shape of the drug utilization distribution (see Figures 5.4 to 5.7 
above).   
 
8.7 Conclusion 
We set out to model the survival of patients in hospice, and in particular, to find ways to 
incorporate covariates into the model to improve accuracy of estimated future life 
expectancy.  The Cox regression model is widely used to study the effect of multiple 
predictors on time-to-event outcomes, due to its flexible assumptions regarding the survival 
distribution.  However, one assumption in the Cox model is that the effect of covariates on 
the hazard function is constant over time (Cox PH assumption).  In our analysis, we found 
that the Cox PH assumption is violated.  In addition to violating the Cox PH assumption, 
we found that the Cox-Snell residuals indicate that the Cox model is not a good choice of 
model.  
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Possible remedies for the PH assumption violation include stratifying the failing 
categorical variables, incorporating time-dependent covariates, and fitting separate Cox 
models for different time intervals.  Ultimately, however, the Cox model is rejected, based 
on the difficulty of calculating life expectancy.   
Our analysis shows that parametric survival models should be considered in place of 
the Cox model.  In particular, the log-normal AFT model outperforms the Cox model in 
fitting the dataset.  We test the goodness-of-fit of the log-normal AFT model to the training 
data (residuals vs. cumulative hazard function).  For out-of-sample testing we show the 
cross-validation errors on a test set (see Figure 8.14).   
A further test of the log-normal AFT model fit is to compare the Average Expected 
LOS to Average Actual (remaining) LOS.  Because of the dynamic nature of the model, we 
perform this test for different levels of t (actual survival time).   A perfect model would 
have a ratio of 1.0 (average expected remaining lifetime = average actual remaining 
lifetime).   
Figure 8.15 shows the ratio of 
Average Expected Future Lifetime
| Survival to 
Average Actual Future Lifetime
t .  In 
this figure, Length of Stay (LOS) is measured from time t . We test this ratio for 4 different 
survival groups: [0,5), [5,10), [10,30) and 30.t t t t     (Thus for example for group 
[10,30)t  we assume that the patient has survived for 10 days and we are estimating 
survival beyond day 10.)    
The ratio for the first survival group ( [0,5)t  is low, indicating that the model initially 
underestimates actual survival significantly.  Once the patient has survived for 10 days, 
however, the predictions become more accurate, with the initial prediction ratio for survival 
groups [10,30) and 30t t  close to 1.0.   
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Figure 8. 15 Comparison of Expected and Actual Survival times for patients surviving 
different durations 
 
In contrast to Cox regression, the log-normal AFT model provides the direct impact 
of many factors on survival outcomes, together with smooth estimates of survival and 
hazard functions.  Ultimately, the time-dependent log-normal AFT model provides 
satisfactory predictions of life expectancy for patients, conditioning on life expectancy of 
less than six months.  Implementing the model in an operational setting is another issue 
entirely.  
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8.8 Appendix A: Concurrence of Training and Test Datasets   
The fit of the K-M model is demonstrated by comparing the distribution of survival of the 
training and test (holdout) data.   
 
 
 
Figure A8.1a  Kaplan-Meier distribution of Training Set (70%; Median Survival Time 27 
days) 
 
 
 
 
Figure A8.1b  Kaplan-Meier distribution of Test Set (30%) 
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Number at risk 
Days 0 100 200 300 400 500 600 700 800 
Training Set (70%) 348,785  81,557  41,528  21,426  11,329  5,959  2,939  663  0  
 
100% 23% 12% 6% 3% 2% 1% 0% 0% 
Test Set (30%) 149,479 35,328 17,953 9,244 4,828 2,530 1,278 318 0 
 
100% 24% 12% 6% 3% 2% 1% 0% 0% 
 
Table A8.1 Kaplan-Meier Survival: Training vs. Test Sets 
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8.9 Appendix B: Sample predictions using the log-normal AFT model 
In this section, we show the relationship between analgesic dose and life expectancy for 
four sample patients.  Figures A8.2 – A8.5 show clearly the inverse relationship between 
changes in dosage and life expectancy.  Patient 2’s life expectancy increases at about 13 
days prior to death, but this is because an anxiolytic drug is temporarily discontinued (not 
shown in the figure, but clearly seen in table A8.1).  Patient 3’s life expectancy decreases 
significantly at day 4, prior to death, although the patient’s analgesic dose does not increase 
until day 3.  This is because an anxiolytic prescription was added one day prior to the 
increase in analgesic dosage.  
 
Cph 
PatientID t 
Analgesic 
Dose 
Lax- 
ative 
Anti- 
nausea 
Anxio- 
lytic 
Actual 
LOS 
Remaining 
expected 
life time 
Remaining 
LOS 
Absolute 
difference 
Patient 1: 
        
  
xxxx278 0 0.600 2 1 2 10 17.603 9.0 8.603 
xxxx278 1 0.683 2 1 2 10 17.473 8.0 9.473 
xxxx278 2 0.683 2 1 2 10 17.447 7.0 10.447 
xxxx278 3 21.240 1 0 2 10 3.036 6.0 2.964 
xxxx278 4 3.983 1 0 1 10 16.087 5.0 11.087 
xxxx278 5 4.223 1 0 0 10 18.487 4.0 14.487 
xxxx278 6 21.240 1 0 1 10 3.727 3.0 0.727 
xxxx278 7 21.240 1 0 1 10 3.726 2.0 1.726 
xxxx278 8 21.240 1 0 0 10 4.561 1.0 3.561 
xxxx278 9 21.240 1 0 0 10 4.559 0.0 4.559 
 
Table A8.2 Predicted and Actual Future Lifetime (Sample Patient 1) 
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Figure A8.2 Analgesic Drug Dosage vs. Predicted Days to Death (Sample Patient 1) 
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Cph 
PatientID t 
 
Analgesic 
Dose 
Lax- 
ative 
Anti- 
nausea 
Anxio- 
lytic 
Actual 
LOS 
Remaining 
expected 
life time 
Remaining 
LOS 
Absolute 
difference 
Patient 2:           
xxxx225 0 0.001 0 0 0 59 45.101 58.0 12.899 
xxxx225 1 0.001 0 0 0 59 44.962 57.0 12.038 
xxxx225 2 0.003 0 4 0 59 44.974 56.0 11.026 
xxxx225 3 0.003 0 4 0 59 44.833 55.0 10.167 
xxxx225 4 0.003 0 4 0 59 44.691 54.0 9.309 
xxxx225 5 0.003 0 4 0 59 44.549 53.0 8.451 
xxxx225 6 0.003 0 4 0 59 44.406 52.0 7.594 
xxxx225 7 0.003 0 4 0 59 44.262 51.0 6.738 
xxxx225 8 0.003 0 4 0 59 44.118 50.0 5.882 
xxxx225 9 0.003 0 4 0 59 43.973 49.0 5.027 
xxxx225 10 0.003 0 4 0 59 43.828 48.0 4.172 
xxxx225 11 0.003 0 4 0 59 43.682 47.0 3.318 
xxxx225 12 0.003 0 4 0 59 43.535 46.0 2.465 
xxxx225 13 0.003 0 4 0 59 43.388 45.0 1.612 
xxxx225 14 0.003 0 4 0 59 43.240 44.0 0.760 
xxxx225 15 0.003 0 4 0 59 43.091 43.0 0.091 
xxxx225 16 0.003 0 4 0 59 42.942 42.0 0.942 
xxxx225 17 0.003 0 4 0 59 42.792 41.0 1.792 
xxxx225 18 0.003 0 4 0 59 42.641 40.0 2.641 
xxxx225 19 0.450 0 4 2 59 34.093 39.0 4.907 
xxxx225 20 0.450 0 4 2 59 33.989 38.0 4.011 
xxxx225 21 0.450 0 4 2 59 33.883 37.0 3.117 
xxxx225 22 0.450 0 4 2 59 33.778 36.0 2.222 
xxxx225 23 0.450 0 4 2 59 33.672 35.0 1.328 
xxxx225 24 0.450 0 4 2 59 33.565 34.0 0.435 
xxxx225 25 0.450 0 4 2 59 33.457 33.0 0.457 
xxxx225 26 0.450 0 4 2 59 33.349 32.0 1.349 
xxxx225 27 0.450 0 4 2 59 33.240 31.0 2.240 
xxxx225 28 0.450 0 4 2 59 33.131 30.0 3.131 
xxxx225 29 0.450 0 4 2 59 33.021 29.0 4.021 
xxxx225 30 0.450 0 4 2 59 32.910 28.0 4.910 
xxxx225 31 0.450 0 4 2 59 32.799 27.0 5.799 
xxxx225 32 0.450 0 4 2 59 32.687 26.0 6.687 
xxxx225 33 0.453 0 4 2 59 32.570 25.0 7.570 
xxxx225 34 0.453 0 4 2 59 32.457 24.0 8.457 
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xxxx225 35 0.453 0 4 2 59 32.343 23.0 9.343 
xxxx225 36 0.453 0 4 2 59 32.228 22.0 10.228 
xxxx225 37 0.453 0 4 2 59 32.113 21.0 11.113 
xxxx225 38 0.453 0 4 2 59 31.998 20.0 11.998 
xxxx225 39 0.453 0 4 2 59 31.881 19.0 12.881 
xxxx225 40 0.453 0 4 2 59 31.764 18.0 13.764 
xxxx225 41 0.453 0 4 2 59 31.646 17.0 14.646 
xxxx225 42 0.453 0 4 2 59 31.528 16.0 15.528 
xxxx225 43 0.453 0 4 2 59 31.408 15.0 16.408 
xxxx225 44 0.453 0 4 2 59 31.288 14.0 17.288 
xxxx225 45 0.453 0 4 2 59 31.168 13.0 18.168 
xxxx225 46 0.453 0 4 2 59 31.046 12.0 19.046 
xxxx225 47 0.453 0 4 0 59 37.304 11.0 26.304 
xxxx225 48 0.453 0 4 0 59 37.136 10.0 27.136 
xxxx225 49 0.453 0 4 0 59 36.967 9.0 27.967 
xxxx225 50 0.453 0 4 0 59 36.798 8.0 28.798 
xxxx225 51 0.453 0 4 0 59 36.627 7.0 29.627 
xxxx225 52 0.453 0 4 0 59 36.455 6.0 30.455 
xxxx225 53 0.453 0 4 0 59 36.283 5.0 31.283 
xxxx225 54 0.453 0 4 2 59 30.048 4.0 26.048 
xxxx225 55 0.453 0 4 2 59 29.920 3.0 26.920 
xxxx225 56 0.453 0 4 2 59 29.791 2.0 27.791 
xxxx225 57 0.453 0 4 2 59 29.661 1.0 28.661 
xxxx225 58 0.453 0 4 2 59 29.531 0.0 29.531 
 
Table A8.3 Predicted and Actual Future Lifetime (Sample Patient 2) 
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Figure A8.3 Analgesic Drug Dosage vs. Predicted Days to Death (Sample Patient 2) 
 
Cph 
Patient 
ID t 
Analgesic 
Dose Laxative 
Anti-
nausea Anxiolytic 
Actual 
LOS 
Remaining 
expected 
life time 
Remainin
g LOS 
Absolute 
difference 
Patient 3: 
        
  
xxxx545 0 0.000 0 0 0 7 21.682 6.0 15.682 
xxxx545 1 0.000 0 0 0 7 21.643 5.0 16.643 
xxxx545 2 0.000 0 0 0 7 21.605 4.0 17.605 
xxxx545 3 0.000 0 0 8 7 5.296 3.0 2.296 
xxxx545 4 2.571 0 0 8 7 4.187 2.0 2.187 
xxxx545 5 2.571 0 0 8 7 4.186 1.0 3.186 
xxxx545 6 2.571 0 0 8 7 4.184 0.0 4.184 
 
Table A8.4 Predicted and Actual Future Lifetime (Sample Patient 3) 
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Figure A8.4 Analgesic Drug Dosage vs. Predicted Days to Death (Sample Patient 3) 
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Cph 
PatientID t 
Analgesic 
Dose Laxative 
Anti-
nausea Anxiolytic 
Actual 
LOS 
Remaining 
expected 
life time 
Remaining 
LOS 
Absolute 
difference 
Patient 4: 
        
  
xxxx133 0 0.000 0 0 0 22 46.819 21.0 25.819 
xxxx133 1 0.000 0 0 0 22 46.671 20.0 26.671 
xxxx133 2 1.080 0 0 2 22 36.090 19.0 17.090 
xxxx133 3 1.080 0 0 2 22 35.993 18.0 17.993 
xxxx133 4 1.080 0 0 2 22 35.895 17.0 18.895 
xxxx133 5 1.080 0 0 2 22 35.797 16.0 19.797 
xxxx133 6 1.080 0 0 2 22 35.698 15.0 20.698 
xxxx133 7 1.080 0 0 2 22 35.599 14.0 21.599 
xxxx133 8 1.080 0 0 2 22 35.500 13.0 22.500 
xxxx133 9 1.080 0 0 2 22 35.400 12.0 23.400 
xxxx133 10 1.080 0 0 2 22 35.299 11.0 24.299 
xxxx133 11 2.160 2 0 8 22 14.300 10.0 4.300 
xxxx133 12 2.160 2 0 8 22 14.280 9.0 5.280 
xxxx133 13 2.160 2 0 8 22 14.260 8.0 6.260 
xxxx133 14 2.160 2 0 8 22 14.241 7.0 7.241 
xxxx133 15 2.160 2 0 8 22 14.220 6.0 8.220 
xxxx133 16 2.220 2 0 8 22 14.137 5.0 9.137 
xxxx133 17 2.220 2 0 8 22 14.116 4.0 10.116 
xxxx133 18 2.220 2 0 8 22 14.096 3.0 11.096 
xxxx133 19 2.220 2 0 8 22 14.075 2.0 12.075 
xxxx133 20 2.220 2 0 8 22 14.054 1.0 13.054 
xxxx133 21 2.220 2 0 8 22 14.033 0.0 14.033 
 
Table A8.5 Predicted and Actual Future Lifetime (Sample Patient 4) 
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Figure A8.5 Analgesic Drug Dosage vs. Predicted Days to Death (Sample Patient 4) 
 
These sample patients show the potential usefulness of this model in an operational 
setting.  Hospice operators need to know, for planning and staffing purposes, the expected 
length of service of their patients.  The examples show that incorporation of the drug 
dosage and prescription data into the planning process can provide valuable information 
about life expectancy of hospice patients.   
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CHAPTER 9 – CONCLUSION AND FUTURE WORK 
The purpose of this study was to demonstrate the applicability and value of survival models 
in real-world health and health insurance situations of the type that a health actuary might 
encounter.  In our first example, we evaluated survival of permanently disabled workers 
with lifetime medical benefits under the workers’ compensation laws of California.  We 
fitted standard actuarial parametric models (Gompertz), as well as different polynomial 
functions.  Neither the actuarial functions nor the prescribed U.S. Life table fitted the 
empirical data well.  Among polynomial functions, a quadratic function fitted reasonably 
well to the underlying data, while higher-order functions appeared to over-fit the data.  
From a purely reserving perspective, a table of mortality rates, based on the quadratic 
function, would appear to provide more accurate reserve estimates.  However, we also 
fitted both stratified Kaplan-Meier and Cox Proportional Hazards models.  The Kaplan-
Meier estimator generates a survival model, while the Cox model allows us to estimate the 
effect of covariates on the hazard of claim termination.  The advantage of these models, for 
the management of the business, lies in their inclusion of covariates, which are not 
available in typical actuarial mortality models.  Estimates of coefficients, of different 
covariates, allow management to concentrate claims adjuster attention on claimants who are 
at highest-risk of persistency.  Typically, a reserve would provide management information 
about relative risk, and the claims adjuster could concentrate on managing, or negotiating, a 
settlement of high reserve claims.  In the case of California permanently disabled claimants, 
the reserve is potentially mis-leading in two respects.  Our analysis shows that survival is 
over-estimated, while, at the same time, failure to include a provision for medical claims 
inflation (in a medical environment where 5% to 6% annual increases are common) implies 
that the reserve is probably under-stated, particularly for those claimants with expected 
longer survival.   
Our other two examples pertain to hospice patients at the end of life.  Our hospice 
dataset contains observations of patients from admission to hospice until end of life (or 
censor date), including their prescription drug history.  To facilitate analysis of the dataset, 
we constructed a number of derived variables, including (for drugs in the four commonly-
prescribed classes at end of life) an index of relative drug strength, the cumulative strength 
over the course of hospice stay, and the number of prescriptions filled for each drug class. 
 190 
 
We also mapped patient diagnoses to the Medicare Hierarchical Condition Categories 
(HCCs) for ease of analysis at the diagnostic level.   
Access to prescription drug data allows us to develop two different survival models: 
the rate at which drugs from potentially ineffective classes are withdrawn, and the life 
expectancy of patients following admission to hospice.  Patients with limited life 
expectancy are at risk of polypharmacy and attendant adverse drug events.  In addition, 
cost, wastage, and diversion23 of drugs are problems that pharmacists can manage with 
models that predict which drugs and patient profiles are most subject to ineffective 
prescribing.  The first application requires the implementation of a competing risks model 
because patients are subject to two risks simultaneously: termination of the prescription and 
death.  We applied the Cumulative Incidence Function (CIF) approach to estimate the rate 
at which drugs are withdrawn from terminally-ill patients.  Because the termination rate 
takes no account of the patient’s length of hospice stay, we also calculated Medication 
Possession Ratios, relating the duration of the prescription to the patient’s length of hospice 
stay.  While a few drugs are withdrawn quickly most classes of drugs are prescribed for 
most of the patient’s hospice stay, risking polypharmacy and adverse drug reactions.     A 
version of this model is being implemented in a hospice pharmacy to identify combinations 
of drugs and patient variables that are likely to result in persistency of prescriptions that are 
potentially ineffective, so that these drugs may be withdrawn earlier.   
Our second application is a more typical actuarial application, estimating life 
expectancy of hospice patients.  Accurate estimates of expectancy are important for the 
management of hospice clinical resources, as well as drug prescriptions, because of the 
potential for wastage and cost of drugs in terminal patients.  Access to detailed prescription 
data, including dosage, allows us to apply time-dependent and accelerated failure time 
models to account, dynamically, for the effect on life expectancy of changes in 
prescriptions and dosage.   
Access to detailed prescription data allows us to analyse prescribing patterns over 
the duration of a patient’s hospice stay.  Generally, the dosage of analgesic and anxiolytic 
drugs increases during the stay, with anti-nausea and laxative drugs showing a more 
                                                          
23 A problem with drugs (particularly opioids which are addictive and for which there is “street” demand) is 
potential theft and re-sale by care-givers.   
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uniform pattern.  As may be expected, cancer patients experience the highest dosages of 
drugs, although the four palliative drug classes are found in all diagnostic groups.  The 
dosage patterns, over time and by diagnosis, provide us with the ability to incorporate these 
time-dependent covariates into models of survival.  We tested a number of different semi-
parametric and parametric models, with the time-dependent Cox model and accelerated 
failure time log-normal models providing the best fit to the data.  Finally, we illustrated the 
application of the models, within an operational environment, with four examples, drawn 
from the database.  Discussions are currently in progress with EP to implement the 
predictive model into their patient management system to give nurses and pharmacists real-
time warning of changes in patient life expectancy.  In conclusion, we set out to illustrate 
the potential usefulness of survival models for health actuarial practice.  Our examples have 
illustrated use of both typical (static covariate) models, as well as a type of model with 
which actuaries will be less familiar: time-dependent models.  Our workers’ compensation 
example shows the usefulness of covariate models as a management tool for managing a 
book of claimants.  However, as our hospice example shows, more useful information 
about patient status may be derived from covariates that change over time, leading to 
improved patient management.  
These are new tools for most health actuaries, but they provide both powerful 
insights, as well as opportunities for health actuaries to expand their practice into non-
traditional areas of medical management.   
Future work: the patient’s drug pathway unfolds as a stochastic process.  The 
incorporation of stochastic processes into the modelling opens a large subject, beyond our 
current scope.  Incorporation of stochastic and point processes is a potentially useful 
direction for future work.   
One last point, which is important to make about this thesis and health actuaries 
generally, is that health actuaries are, first and foremost, risk managers, serving business 
clients, and secondly statisticians.  This thesis is somewhat representative of the work of a 
health actuary, in that it required in-depth knowledge of a number of business topics 
specific to the application of the survival models.  From a statistical perspective, the models 
may be relatively straightforward; as the hospice examples show, the business context in 
which they are applied is not.  We could not have applied survival modelling to hospice 
patients without understanding the regulatory model within which hospices operate, as well 
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as the diagnostic and prescription drug information available.  Over time, actuarial 
modelling will, no doubt, become more sophisticated, but the health actuary of the future 
will be required to be part risk modeller, part epidemiologist, and part statistician.   
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